日本臨牀　別冊　循環器症候群（第3版）I

出版社： 日本臨牀社
発行日： 2019-09-20
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 循環器症候群（第3版）I―その他の循環器疾患を含めて―
電子書籍版： 2019-09-20 （第3版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

19,800 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

19,800 円(税込)

購入する

目次

  • 特集　循環器症候群（第3版）I
    　　　―その他の循環器疾患を含めて―

    I．心不全
    1．心不全の大規模レジストリ研究
    2．左室駆出率による心不全の分類
    3．急性心不全、慢性心不全の急性増悪
    4．末期心不全(心不全終末期）
    5．虚血性心不全
    6．高血圧性心不全
    7．心原性ショック
    8．高拍出性心不全
    　9．右心不全
    　10．心原性肺水腫
    　11．高齢者心不全
    　12．心不全の新たな治療薬
    　13．新規心原性ショックに対する経皮的循環補助装置
    　14．左室補助人工心臓
    　15．本邦における心臓移植
    　16．心不全の心臓リハビリテーション

    II．心筋疾患
    1．心筋疾患の分類(変遷と現状)
    2．家族性心筋症・サルコメア病
    3．肥大型心筋症
    4．拡張相肥大型心筋症
    5．閉塞性肥大型心筋症
    6．心尖部肥大型心筋症
    7．特発性拡張型心筋症
    8．遺伝性心筋疾患
    9．心臓サルコイドーシス
    　10．心アミロイドーシス
    　11．Fabry病
    　12．心ヘモクロマトーシス
    　13．頻拍誘発性心筋症
    　14．薬剤性心筋症（抗がん薬）
    　15．薬剤性心筋症（その他の薬剤）
    　16．栄養性心筋障害・脚気心
    　17．虚血性心筋症
    　18．高血圧性心筋症
    　19．周産期心筋症・産褥性心筋症
    　20．アルコール心筋症
    　21．心筋炎後心筋症
    　22．筋ジストロフィー心筋症
    　23．膠原病に伴う心筋症
    　24．甲状腺疾患に伴う心筋
    　25．先端巨大症性心筋症
    　26．褐色細胞種に伴う心筋症
    　27．たこつぼ症候群
    　28．不整脈原性右室心筋症
    　29．ミトコンドリア心筋症
    　30．代謝性心筋症の分類
    　31．糖尿病性心筋症
    　32．尿毒症性心筋症
    　33．放射線照射による心筋障害
    　34．ペーシング誘発性心筋症
    　35．拘束型心筋症
    　36．左室心筋緻密化障害
    　37．特発性心筋炎
    　38．感染性心筋炎・疫学
    　39．リンパ球性心筋炎
    　40．リウマチ性心炎（心膜炎・心筋炎・心内膜炎）
    　41．マイコプラズマ性心膜炎・心筋炎
    　42．スピロヘータ性心膜炎・心筋炎・血管炎
    　43．巨細胞性心筋炎
    　44．好酸球性心筋炎
    　45．劇症型心筋炎
    　46．慢性心筋炎
    　47．薬剤性心筋炎-メサラジンによる薬剤性心筋炎の小児例
    　48．免疫拒絶による心筋炎

    III．　弁膜症
    1．弁膜症の疫学と病因
    2．大動脈弁狭窄症
    3．大動脈弁閉鎖不全症
    4．大動脈二尖弁
    5．大動脈弁嚢胞変性 – 大動脈基部奇形と弁変性
    6．僧帽弁狭窄症
    7．機能性僧帽弁閉鎖不全
    8．器質性僧帽弁閉鎖不全
    9．心房性僧帽弁閉鎖不全
    　10．Barlow病
    　11．肺動脈弁狭窄・閉鎖不全
    　12．三尖弁閉鎖不全症,三尖弁狭窄症
    　13．リウマチ性連合弁膜症
    　14．僧帽弁輪石灰化と乾酪壊死
    　15．感染性心内膜炎、弁輪部膿瘍
    　16．弁置換術の適応と人工弁の選択
    　17．人工弁機能不全
    　18．人工弁心内膜炎
    　19．人工弁血栓弁
    　20．構造的心疾患:SHDとカテーテル治療
    　21．大動脈弁形成術の適応と術式
    　22．僧帽弁形成術の適応と術式
    　23．三尖弁形成術の適応と術式

    IV．心内膜疾患
    1．感染性心内膜炎の疫学と分類
    2．感染性心内膜炎の診断と予防
    3．感染性心内膜炎の薬物治療
    4．活動性感染性心内膜炎の外科治療
    5．デバイス感染に伴う感染性心内膜炎
    6．Lo¨ffler心内膜心筋炎
    7．非細菌性血栓性心内膜炎
    8．Libman-Sacks 心内膜炎
    9．心内膜心筋線維症
    　10．心内膜線維弾性症

    V．心膜疾患
    1．心膜炎の分類と疫学
    2．ウイルス性心膜炎
    3．細菌性心膜炎
    4．真菌性心膜炎
    5．原虫性・寄生虫性心膜炎
    6．膠原病・全身性血管炎での心膜炎
    7．悪性腫瘍に伴う心膜炎
    8．粘液水腫・心アミロイド―シスにおける心膜疾患
    9．尿毒症性心膜炎
    　10．薬物による心膜炎
    　11．心不全・肺高血圧に伴う心膜炎
    　12．心筋梗塞後の心膜炎
    　13．放射線照射による遅発性収縮性心外膜炎
    　14．慢性収縮性心膜炎
    　15．滲出性収縮性心膜炎
    　16．術後収縮性心膜炎
    　17．心膜切開後症候群
    　18．心タンポナーデ
    　19．乳び心膜症・コレステロール心膜炎
    　20．心臓周囲脂肪・血管周囲脂肪
    　21．心膜膿瘍(心嚢内膿瘍)
    　22．心膜嚢胞・心膜嚢腫・心膜憩室・心膜ヘルニア
    　23．出血性心膜炎・心膜血腫・心膜気腫

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 心不全

P.14 掲載の参考文献
1) Gheorghiade M, et al : Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 296 : 2217-2226, 2006.
PubMed
2) Adams KF, et al : Characteristics and outcomes of patients hospitalized for heart failure in the United States : rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149 : 209-216, 2005.
 
3) Nieminen MS, et al : EuroHeart Failure Survey II (EHFS II) : a survey on hospitalized acute heart failure patients : description of population. Eur Heart J 27 : 2725-2736, 2006.
 
4) Mentz RJ, et al : Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). Am J Cardiol 111 : 582-587, 2013.
PubMed
5) Fonarow GC, et al : An obesity paradox in acute heart failure : analysis of body mass index and inhospital mortality for 108,927 patients in the Acute Decompensated Heart Failure National Registry. Am Heart J 153 : 74-81, 2007.
 
6) Fonarow GC, et al : Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure : findings from the OPTIMIZE-HF program. J Am Coll Cardiol 52 : 190-199, 2008.
PubMed
7) Galvao M, et al : Gender differences in in-hospital management and outcomes in patients with decompensated heart failure : analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Card Fail 12 : 100-107, 2006.
 
8) Tsuchihashi M, et al : Clinical characteristics and prognosis of hospitalized patients with congestive heart failure-a study in Fukuoka, Japan. Jpn Circ J 64 : 953-959, 2000.
PubMed
9) Tsutsui H, et al : Mortality and readmission of hospitalized patients with congestive heart failure and preserved versus depressed systolic function. Am J Cardiol 88 : 530-533, 2001.
PubMed
10) Tsuchihashi M, et al : Medical and socioenvironmental predictors of hospital readmission in patients with congestive heart failure. Am Heart J 142 : E7, 2001.
PubMed
11) Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) : The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction : an individual patient data meta-analysis. Eur Heart J 33 : 1750-1757, 2012.
 
12) Tsutsui H, et al : Clinical characteristics and outcome of hospitalized patients with heart failure in Japan. Circ J 70 : 1617-1623, 2006.
PubMed
13) Tsuchihashi-Makaya M, et al : Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 73 : 1893-1900, 2009.
PubMed
14) Hamaguchi S, et al : Mode of death in patients with heart failure and reduced vs. preserved ejection fraction : report from the registry of hospitalized heart failure patients. Circ J 76 : 1662-1669, 2012.
PubMed
15) Sato N, et al : Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND Registry). Circ J 77 : 944-951, 2013.
PubMed
16) Shiba N, et al : Analysis of chronic heart failure registry in the Tohoku district : third year follow-up. Circ J 68 : 427-434, 2004.
PubMed
17) Shiba N, et al : Trend of westernization of etiology and clinical characteristics of heart failure patients in Japan-first report from the CHART-2 study. Circ J 75 : 823-833, 2011.
PubMed
18) Tsutsui H, et al : Characteristics and outcomes of patients with heart failure in general practices and hospitals. Circ J 71 : 449-454, 2007.
PubMed
19) Hamaguchi S, et al : Chronic kidney disease as an independent risk for long-term adverse outcomes in patients hospitalized with heart failure in Japan. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 73 : 1442-1447, 2009.
PubMed
20) Hamaguchi S, et al : Anemia is an independent predictor of long-term adverse outcomes in patients hospitalized with heart failure in Japan. A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 73 : 1901-1908, 2009.
PubMed
21) Hamaguchi S, et al : Hyperuricemia predicts adverse outcomes in patients with heart failure. Int J Cardiol 151 : 143-147, 2011.
PubMed
22) Hamaguchi S, et al : Effects of atrial fibrillation on long-term outcomes in patients hospitalized for heart failure in Japan : a report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 73 : 2084-2090, 2009.
PubMed
23) Hamaguchi S, et al : Body mass index is an independent predictor of long-term outcomes in patients hospitalized with heart failure in Japan. Circ J 74 : 2605-2611, 2010.
PubMed
24) Tsuchihashi-Makaya M, et al : Sex differences with respect to clinical characteristics, treatment, and long-term outcomes in patients with heart failure. Int J Cardiol 150 : 338-339, 2011.
PubMed
25) Hamaguchi S, et al : Predictors of long-term adverse outcomes in elderly patients over 80 years hospitalized with heart failure. -A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD) -. Circ J 75 : 2403-2410, 2011.
PubMed
26) Tsuchihashi-Makaya M, et al : Discharge use of angiotensin receptor blockers provides comparable effects with angiotensin-converting enzyme inhibitors on outcomes in patients hospitalized for heart failure. Hypertens Res 33 : 197-202, 2010.
PubMed
27) Tsuchihashi-Makaya M, et al : Beta-blocker use at discharge in patients hospitalized for heart failure is associated with improved survival. Circ J 74 : 1364-1371, 2010.
PubMed
28) Hamaguchi S, et al : Spironolactone use at discharge was associated with improved survival in hospitalized patients with systolic heart failure. Am Heart J 160 : 1156-1162, 2010.
PubMed
29) Hamaguchi S, et al : Loop diuretic use at discharge is associated with adverse outcomes in hospitalized patients with heart failure : a report from the Japanese cardiac registry of heart failure in cardiology (JCARE-CARD). Circ J 76 : 1920-1927, 2012.
PubMed
30) Goto D, et al : Clinical characteristics and outcomes of dilated phase of hypertrophic cardiomyopathy : report from the registry data in Japan. J Cardiol 61 : 65-70, 2013.
PubMed
31) Hamaguchi S, et al : Characteristics, management, and outcomes for patients during hospitalization due to worsening heart failure-A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). J Cardiol 62 : 95-101, 2013.
 
32) Hamaguchi S, et al : Hyponatremia is an independent predictor of adverse clinical outcomes in hospitalized patients due to worsening heart failure. J Cardiol 63 : 182-188, 2014.
PubMed
33) Hamaguchi S, et al : Weekend versus weekday hospital admission and outcomes during hospitalization for patients due to worsening heart failure : a report from Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Heart Vessels 29 : 328-335, 2014.
PubMed
P.21 掲載の参考文献
1) 日本循環器学会/日本心不全学会合同ガイドライン. 急性・慢性心不全診療ガイドライン (2017年改訂版), 2018.
 
2) 衣笠良治, 山本一博 : 重症心不全-なぜ, どのように分類するのか? 心エコー 19 : 806-811, 2018.
Medical*Online
3) Steinberg BA, et al : Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction : prevalence, therapies, and outcomes. Circulation 126 : 65-75, 2012.
PubMed
4) Tsuji K, et al : Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study. Eur J Heart Fail 19 : 1258-1269, 2017.
 
5) Tsutsui H, et al : Angiotensin Receptor Neprilysin Inhibitor in Japanese Patients With Heart Failure and Reduced Ejection Fraction-Baseline Characteristics and Treatment of PARALLEL-HF Trial. Circ J 82 : 2575-2583, 2018.
PubMed
6) Yusuf S, et al : Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction : the CHARM-Preserved Trial. Lancet 362 : 777-781, 2003.
PubMed
7) Anand IS. et al : Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction : findings from the I-PRESERVE trial. Circ Heart Fail 4 : 569-577, 2011.
PubMed
8) Pitt B, et al : Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370 : 1383-1392, 2014.
PubMed
9) Yamamoto K, et al : Effects of carvedilol on heart failure with preserved ejection fraction : the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail 15 : 110-118, 2013.
PubMed
10) Solomon SD, et al : The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction : a phase 2 double-blind randomised controlled trial. Lancet 380 : 1387-1395, 2012.
PubMed
11) Lund LH, et al : Heart failure with mid-range ejection fraction in CHARM : characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail 20 : 1230-1239, 2018.
PubMed
12) Solomon SD, et al : Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 37 : 455-462, 2016.
PubMed
13) Owan TE, et al : Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355 : 251-259, 2006.
PubMed
14) Tsuchihashi-Makaya M, et al : Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 73 : 1893-1900, 2009.
PubMed
15) Kinugasa Y, et al : Multidisciplinary intensive education in the hospital improves outcomes for hospitalized heart failure patients in a Japanese rural setting. BMC Health Serv Res 14 : 351, 2014.
 
P.26 掲載の参考文献
1) 日本循環器学会, ほか : 日本循環器学会/日本心不全学会合同ガイドライン. 急性・慢性心不全診療ガイドライン (2017年改訂版), 2018. [http://www.j-circ.or.j p/guideline/pdf/JCS2017_tsutsui_h.pdf] (2019年7月閲覧)
 
2) 日本循環器学会 : 循環器疾患診療実態調査報告書 (2018年度実施・公表) JROAD (The Japanese Registry Of All cardiac and vascular Diseases). [http://j-circ.or.jp/jittai_chosa/jittai_chosa2017web.pdf] (2019年7月閲覧)
 
3) Sato N, et al : Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND Registry). Circ J 77 : 944-951, 2013.
PubMed
4) Shiraishi Y, et al : 9-Year Trend in the Management of Acute Heart Failure in Japan : A Report From the National Consortium of Acute Heart Failure Registries. J Am Heart Assoc 7 : e008687, 2018.
PubMed
5) Mebazaa A, et al : Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med 36 : S129-139, 2008.
PubMed
6) Nohria A, et al : Evaluation and monitoring of patients with acute heart failure syndromes. Am J Cardiol 96 : 32G-40G, 2005.
PubMed
7) Kajimoto K, et al : Relationship between systolic blood pressure and preserved or reduced ejection fraction at admission in patients hospitalized for acute heart failure syndromes. Int J Cardiol 168 : 4790-4795, 2013.
PubMed
8) Cotter G, et al : Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 351 : 389-393, 1998.
PubMed
9) Cooper LB, et al : The Impact of Worsening Heart Failure in the United States. Heart Fail Clin 11 : 603-614, 2015.
PubMed
P.31 掲載の参考文献
1) Qaseem A, et al : Evidence-based interventions to improve the palliative care of pain, dyspnea, and depression at the end of life : a clinical practice guideline from the American College of Physicians. Ann Intern Med 148 : 141-146, 2008.
PubMed
2) Lynn J : Perspectives on care at the close of life. Serving Patients who may die soon and their families : the role of hospice and other services. JAMA 285 : 925-932, 2001.
PubMed
3) Yancy CW, et al : 2013 ACCF/AHA guideline for the management of heart failure : a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62 : e147-239, 2013.
 
4) Ponikowski P, et al : 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure : The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37 : 2129-2200, 2016.
 
5) 日本循環器学会, ほか : 循環器病の診断と治療に関するガイドライン. 循環器疾患における末期医療に関する提言, 2010. [http://www.j-circ.or.jp/guideline/pdf/JCS2010_nonogi_h.pdf] (2019年6月閲覧)
 
6) Hunt SA, et al : ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) : developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation : endorsed by the Heart Rhythm Society. Circulation 112 : e154-235, 2005.
 
7) Roger VL, et al : Heart disease and stroke statistics-2012 update : a report from the American Heart Association. Circulation 125 : e2-e220, 2012.
PubMed
8) Adler ED, et al : Palliative care in the treatment of advanced heart failure. Circulation 120 : 2597-2606, 2009.
PubMed
9) Giamouzis G, et al : Hospitalization epidemic in patients with heart failure : risk factors, risk prediction, knowledge gaps, and future directions. J Card Fail 17 : 54-75, 2011.
PubMed
10) Elis A, et al : Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure : a randomized, double-blind, placebo-controlled study. Clin Pharmacol Ther 63 : 682-685, 1998.
PubMed
11) Oliva F, et al : Intermittent 6-month low-dose dobutamine infusion in severe heart failure : DICE multicenter trial. Am Heart J 138 : 247-253, 1999.
PubMed
12) Gorodeski EZ, et al : Prognosis on chronic dobutamine or milrinone infusions for stage D heart failure. Circ Heart Fail 2 : 320-324, 2009.
PubMed
13) Hauptman PJ, et al : Chronic inotropic therapy in end-stage heart failure. Am Heart J 152 : 1096. e1-8, 2006.
 
14) 日本循環器学会/日本心不全学会合同ガイドライン. 急性・慢性心不全診療ガイドライン (2017年改訂版), 2018. [http://www.j-circ.or.jp/guideline/pdf/JCS2017_tsutsuLh.pdf] (2019年6月閲覧)
 
P.35 掲載の参考文献
1) 日本循環器学会, ほか : 日本循環器学会/日本心不全学会合同ガイドライン. 急性・慢性心不全診療ガイドライン (2017年改訂版), 2018.
 
2) Sakata Y, et al : Epidemiology of heart failure in Asia. Circ J 77 : 2209-2217, 2013.
PubMed
3) Ushigome R, Shimokawa H : Temporal trends in clinical characteristics, management and prognosis of patients with symptomatic heart failure in Japan-report from the CHART Studies. Circ J 79 : 2396-2407, 2015.
PubMed
4) Tsutsui H, et al : Clinical characteristics and outcome of hospitalized patients with heart failure in Japan. Circ J 70 : 1617-1623, 2006.
PubMed
5) Fearon WF, et al : Predictive value of the index of microcirculatory resistance in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 51 : 560-565, 2008.
PubMed
6) 日本循環器学会, ほか : 日本循環器学会/日本不整脈心電学会合同ガイドライン. 不整脈非薬物治療ガイドライン (2018年改訂版), 2019.
 
7) Baker DW, et al : Management of heart failure. III. The role of revascularization in the treatment of patients with moderate or severe left ventricular systolic dysfunction. JAMA 272 : 1528-1534, 1994.
PubMed
8) Nagueh SF, et al : Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography : An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 29 : 277-314, 2016.
PubMed
9) Lancellotti P, et al : The Clinical Use of Stress Echocardiography in Non-Ischaemic Heart Disease : Recommendations from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr 30 : 101-138, 2017.
PubMed
10) Velazquez EJ, et al : Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. N Engl J Med 374 : 1511-1520, 2016.
PubMed
11) Marui A, et al : Comparison of 5-Year Outcomes After Coronary Artery Bypass Grafting in Heart Failure Patients With Versus Without Preserved Left Ventricular Ejection Fraction (from the CREDO-Kyoto CABG Registry Cohort-2). Am J Cardiol 116 : 580-586, 2015.
PubMed
12) Tanaka H, et al : Improved regional myocardial diastolic function assessed by strain rate imaging in patients with coronary artery disease undergoing percutaneous coronary intervention. J Am Soc Echocardiogr 19 : 756-762, 2006.
 
13) Nishimura RA, et al : 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 70 : 252-289, 2017.
 
14) Baumgartner H, et al : 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 38 : 2739-2791, 2017.
PubMed
15) Stone GW, et al : Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med 379 : 2307-2318, 2018.
PubMed
P.40 掲載の参考文献
1) Levy D, et al : The progression from hypertension to congestive heart failure. JAMA 275 : 1557-1562, 1996.
PubMed
2) Tsutsui H, et al : Characteristics and outcomes of patients with heart failure in general practices and hospitals. Circ J 71 : 449-454, 2007.
PubMed
3) Tsuchihashi-Makaya M, et al : Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 73 : 1893-1900, 2009.
PubMed
4) Kannel WB, et al : Changing epidemiological features of cardiac failure. Br Heart J 72 (2 Suppl) : S3-S9, 1994.
 
5) 日本循環器学会, ほか : 日本循環器学会/日本心不全学会合同ガイドライン. 急性・慢性心不全診療ガイドライン (2017年改訂版), 2018.
 
6) Verdecchia P, et al : Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 97 : 48-54, 1998.
PubMed
7) Devereux RB, et al : Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol : the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 110 : 1456-1462, 2004.
PubMed
8) Julius S, et al : Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine : the VALUE randomised trial. Lancet 363 : 2022-2031, 2004.
 
9) McMurray JJ, et al : Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 : 993-1004, 2014.
PubMed
10) Taylor AL, et al : Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351 : 2049-2057, 2004.
PubMed
11) Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone : the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 283 : 1967-1975, 2000.
 
12) Yamamoto K, et al : Effects of carvedilol on heart failure with preserved ejection fraction : the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail 15 : 110-118, 2013.
PubMed
13) Solomon SD, et al : The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction : a phase 2 double-blind randomised controlled trial. Lancet 380 : 1387-1395, 2012.
PubMed
P.45 掲載の参考文献
1) 日本循環器学会, ほか : 日本循環器学会/日本心不全学会合同ガイドライン. 急性・慢性心不全診療ガイドライン (2017年改訂版), 2018. [http://www.j-circ.or.jp/guideline/pdf/JCS2017_tsutsui_h.pdf] (2019年7月閲覧)
 
2) Ueki Y, et al : Characteristics and Predictors of Mortality in Patients With Cardiovascular Shock in Japan-Results From the Japanese Circulation Society Cardiovascular Shock Registry. Circ J 80 : 852-859, 2016.
PubMed
3) Reynolds HR, Hochman JS : Cardiogenic shock : current concepts and improving outcomes. Circulation 117 : 686-697, 2008.
PubMed
4) Narasimhan M, et al : Advanced echocardiography for the critical care physician : part 1. Chest 145 : 129-134, 2014.
PubMed
5) De Backer D, et al : Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362 : 779-789, 2010.
 
6) Marik PE, Cavallazzi R : Does the central venous pressure predict Fluid responsiveness? An updated meta-analysis and a plea for some common sense. Crit Care Med 41 : 1774-1781, 2013.
 
7) Narasimhan M, et al : Advanced echocardiography for the critical care physician : part 2. Chest 145 : 135-142, 2014.
PubMed
P.50 掲載の参考文献
1) 日本循環器学会, ほか : 日本循環器学会/日本心不全学会合同ガイドライン. 急性・慢性心不全診療ガイドライン (2017年改訂版), 2018.
 
2) Tsutsui H, et al : Clinical characteristics and outcome of hospitalized patients with heart failure in Japan. Circ J 70 : 1617-1623, 2006.
PubMed
3) Ushigome R, et al : Temporal trends in clinical characteristics, management and prognosis of patients with symptomatic heart failure in Japan-report from the CHART Studies. Circ J 79 : 2396-2407, 2015.
PubMed
4) Kawashiro N, et al : Clinical characteristics and outcome of hospitalized patients with congestive heart failure : results of the HIJC-HF registry. Circ J 72 : 2015-2020, 2008.
PubMed
5) Spinar J, et al : Baseline characteristics and hospital mortality in the Acute Heart Failure Database (AHEAD) Main registry. Crit Care 15 : R291, 2011.
PubMed
6) Reddy YNV, et al : High-Output Heart Failure : A 15-Year Experience. J Am Coll Cardiol 68 : 473-482, 2016.
PubMed
7) Ni Z, et al : Up-regulation of renal and vascular nitric oxide synthase in iron-deficiency anemia. Kidney Int 52 : 195-201, 1997.
PubMed
8) 井口守丈, 赤尾昌治 : 甲状腺ホルモンと心不全. 甲状腺ホルモンと関連疾患, (赤水尚史, ほか編), p22-31, メディカルレビュー社, 2017.
 
9) Akamizu T, et al : Diagnostic criteria, clinical features, and incidence of thyroid storm based on nationwide surveys. Thyroid 22 : 661-679, 2012.
PubMed
10) 山本一博 : 心不全. 循環器専門医研修テキスト (吉川純一監), p140-151, 文光堂, 2011.
 
11) 和田靖明 : 高心拍出量性心不全. 心エコーハンドブック 心不全 (竹中克, 戸出浩之編), p178-180, 金芳堂, 2016.
 
12) Gordon AC, et al : Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis. N Engl J Med 375 : 1638-1648, 2016.
PubMed
13) Morelli A, et al : Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock : a randomized clinical trial. JAMA 310 : 1683-1691, 2013.
PubMed
14) Wang Z, et al : Combination therapy with milrinone and esmolol for heart protection in patients with severe sepsis : a prospective, randomized trial. Clin Drug Investig 35 : 707-716, 2015.
PubMed
15) Betrosian AP, et al : Occidental beriberi and sudden death. Am J Med Sci 327 : 250-252, 2004.
PubMed
P.58 掲載の参考文献
1) Mehra MR, et al : Right heart failure : toward a common language. J Heart Lung Transplant 33 : 123-126, 2014.
 
2) MacNee W : Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part One. Am J Respir Crit Care Med 150 : 833-852, 1994.
PubMed
3) Sztrymf B, et al : Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. Eur Respir J 35 : 1286-1293, 2010.
PubMed
4) 日本循環器学会, ほか 肺高血圧症治療ガイドライン (2017年改訂版), 2018.
 
5) 日本循環器学会, ほか 循環器病の診断と治療に関するガイドライン (2011年度合同研究班報告). 弁膜疾患の非薬物治療に関するガイドライン (2012年改訂版), 2012.
 
6) Sztrymf B, et al : Left ventricular ejection time in acute heart failure complicating precapillary pulmonary hypertension. Chest 144 : 1512-1520, 2013.
PubMed
7) Masuyama T, et al : Superiority of long-acting to short-acting loop diuretics in the treatment of congestive heart failure. Circ J 76 : 833-842, 2012.
PubMed
8) Maron BA, et al : Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials). Am J Cardiol 112 : 720-725, 2013.
 
9) Tanabe N, et al : Multi-institutional retrospective cohort study of patients with severe pulmonary hypertension associated with respiratory diseases. Respirology 20 : 805-812, 2015.
PubMed
P.62 掲載の参考文献
1) 日本循環器学会/日本心不全学会合同ガイドライン. 急性・慢性心不全診療ガイドライン (2017年改訂版), 2018. [http://www.j-circ.or.jp/guideline/pdf/JCS2017_tsutsui_h.pdf] (2019年7月閲覧)
 
2) Mebazaa A, et al : Acute heart failure and cardiogenic shock : a multidisciplinary practical guidance. Intensive Care Med 42 : 147-163, 2016.
PubMed
3) Staub NC : Pulmonary edema. Physiol Rev 54 : 678-811, 1974.
PubMed
4) Gray A, et al : Noninvasive ventilation in acute cardiogenic pulmonary edema. N Engl J Med 359 : 142-151, 2008.
PubMed
5) Sato N, et al : Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND Registry). Circ J 77 : 944-951, 2013.
PubMed
6) Chioncel O, et al : Clinical phenotypes and outcome of patients hospitalized for acute heart failure : the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 19 : 1242-1254, 2017.
 
7) Rihal CS, et al : The utility of clinical, electrocardiographic, and roentgenographic variables in the prediction of left ventricular function. Am J Cardiol 75 : 220-223, 1995.
PubMed
8) Ware LB, et al : Clinical practice. Acute pulmonary edema. N Engl J Med 353 : 2788-2796, 2005.
PubMed
9) Volpicelli G, et al : International evidence-based recommendations for point-of-care lung ultrasound. Intensive Care Med 38 : 577-591, 2012.
PubMed
10) ARDS Definition Task Force, et al : Acute respiratory distress syndrome : the Berlin Definition. JAMA 307 : 2526-2533, 2012.
PubMed
11) Donker DW, et al : Left ventricular unloading during veno-arterial ECMO : a review of percutaneous and surgical unloading interventions. Perfusion 34 : 98-105, 2019.
PubMed
P.66 掲載の参考文献
1) 日本心不全学会ガイドライン委員会 (編) : 高齢心不全患者の治療に関するステートメント. 日本心不全学会, 2016.
 
2) Kannel WB, Belanger AJ : Epidemiology of heart failure. Am Heart J 121 : 951-957, 1991.
PubMed
3) Bleumink GS, et al : Quantifying the heart failure epidemic : prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 25 : 1614-1619, 2004.
PubMed
4) Shiraishi Y, et al : 9-Year Trend in the Management of Acute Heart Failure in Japan : A Report From the National Consortium of Acute Heart Failure Registries. J Am Heart Assoc 7 : e008687, 2018.
PubMed
5) Gonzalez-Lopez E, et al : Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 36 : 2585-2594, 2015.
PubMed
6) Tresch DD, McGough MF : Heart failure with normal systolic function : a common disorder in older people. J Am Geriatr Soc 43 : 1035-1042, 1995.
 
7) McKee PA, et al : The natural history of congestive heart failure : the Framingham study. N Engl J Med 285 : 1441-1446, 1971.
PubMed
8) 日本循環器学会, ほか : 日本循環器学会/日本心不全学会合同ガイドライン. 急性・慢性心不全診療ガイドライン (2017年改訂版), 2018.
 
9) Ponikowski P, et al : 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure : The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37 : 2129-2200, 2016.
 
10) Ostrowska M, et al : Basic laboratory parameters as predictors of in-hospital death in patients with acute decompensated heart failure : data from a large single-centre cohort. Kardiol Pol 75 : 157-163, 2017.
PubMed
11) Pfisterer M, et al : BNP-guided vs symptom-guided heart failure therapy : the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 301 : 383-392, 2009.
PubMed
12) Takashio S, et al : Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis. ESC Heart Fail 5 : 27-35, 2018.
PubMed
13) Talreja DR, et al : Estimation of left ventricular filling pressure with exercise by Doppler echocardiography in patients with normal systolic function : asimultaneous echocardiographic-cardiac catheterization study. J Am Soc Echocardiogr 20 : 477-479, 2007.
 
14) Kraigher-Krainer E, et al : Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. J Am Coll Cardiol 63 : 447-456, 2014.
PubMed
15) Mack MJ, et al : Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med 380 : 1695-1705, 2019.
PubMed
P.71 掲載の参考文献
1) O'Connor CM, et al : Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 365 : 32-43, 2011.
PubMed
2) Teerlink JR, et al : Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF) : a randomised, placebo-controlled trial. Lancet 381 : 29-39, 2013.
PubMed
3) Teerlink JR, et al : Serelaxin in addition to standard therapy in acute heart failure : rationale and design of the RELAX-AHF-2 study. Eur J Heart Fail 19 : 800-809, 2017.
 
4) Packer M, et al : Comparison of omapatrilat and enalapril in patients with chronic heart failure : the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 106 : 920-926, 2002.
PubMed
5) McMurray JJ, et al : Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 : 993-1004, 2014.
PubMed
6) Velazquez EJ, et al : Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med 380 : 539-548, 2019.
PubMed
7) Solomon SD, et al : Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction : Rationale and Design of the PARAGON-HF Trial. JACC Heart Fail 5 : 471-482, 2017.
PubMed
8) Swedberg K, et al : Ivabradine and outcomes in chronic heart failure (SHIFT) : a randomised placebo-controlled study. Lancet 376 : 875-885, 2010.
PubMed
9) Bohm M, et al : Heart rate as a risk factor in chronic heart failure (SHIFT) : the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376 : 886-894, 2010.
 
10) Zinman B, et al : Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 373 : 2117-2128, 2015.
PubMed
11) Neal B, et al : Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 377 : 644-657, 2017.
PubMed
12) Wiviott SD, et al : Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 380 : 347-357, 2019.
PubMed
13) Furtado RHM, et al : Dapagliflozin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation 139 : 2516-2527, 2019.
PubMed
14) Nakagaito M, et al : Successful Withdrawal from Dobutamine by Canagliflozin in a Diabetic Patient with Stage D Heart Failure. Int Heart J 58 : 978-981, 2017.
 
15) Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure (Dapa-HF), ClinicalTrials. gov. [https://clinicaltrials.gov/ct2/show/NCT03036124] (2019年6月閲覧)
 
16) Butler J, et al : The potential role and rationale for treatment of heart failure with sodiumglucose co-transporter 2 inhibitors. Eur J Heart Fail 19 : 1390-1400, 2017.
 
17) Teerlink JR, et al : Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF) : a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet 388 : 2895-2903, 2016.
PubMed
18) Voors AA, et al : Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine AI Receptor Agonist, in Patients With Chronic Heart Failure. J Clin Pharmacol 57 : 440-451, 2017.
 
19) Armstrong PW, et al : A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator : The VICTORIA Trial. JACC Heart failure 6 : 96-104, 2018.
PubMed
20) Van Tassell BW, et al : Interleukin-1 blockade in heart failure with preserved ejection fraction : rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2). Clin Cardiol 40 : 626-632, 2017.
PubMed
P.76 掲載の参考文献
1) Werdan K, et al : Mechanical circulatory support in cardiogenic shock. Eur Heart J 35 : 156-167, 2014.
PubMed
2) Saku K, et al : Left Ventricular Mechanical Unloading by Total Support of Impella in Myocardial Infarction Reduces Infarct Size, Preserves Left Ventricular Function, and Prevents Subsequent Heart Failure in Dogs. Circ Heart Fail 11 : e004397, 2018.
PubMed
3) Kang G, et al : Pulmonary artery pulsatility index predicts right ventricular failure after left ventricular assist device implantation. J Heart Lung Transplant 35 : 67-73, 2016.
PubMed
4) Anderson M : Acute cardiac unloading and recovery. Cardiac Unloading and Myocardial Recovery : Clinical Utility from a Surgeon's Perspective. Interventional Cardiology Review 12 (1 Suppl 1) : 1-24, 2017.
 
5) Basir MB, et al : Feasibility of early mechanical circulatory support in acute myocardial infarction complicated by cardiogenic shock : The Detroit cardiogenic shock initiative. Catheter Cardiovasc Interv 91 : 454-461, 2018.
PubMed
6) Ouweneel DM, et al : Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump in Cardiogenic Shock After Acute Myocardial Infarction. J Am Coll Cardiol 69 : 278-287, 2017.
PubMed
7) Reyentovich A, et al : Management of refractory cardiogenic shock. Nat Rev Cardiol 13 : 481-492, 2016.
PubMed
P.81 掲載の参考文献
1) Aaronson KD, et al : Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation. Circulation 125 : 3191-3200, 2012.
PubMed
2) Milano CA, et al : HVAD : The ENDURANCE Supplemental Trial. JACC Heart Fail 6 : 792-802, 2018.
PubMed
3) Mehra MR, et al : A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure. N Engl J Med 376 : 440-450, 2017.
PubMed
4) Mehra MR, et al : A Fully Magnetically Levitated Left Ventricular Assist Device-Final Report. N Engl J Med 380 : 1618-1627, 2019.
PubMed
5) 日本胸部外科学会J-MACS委員会ホームページ. [http://www.jpats.org/modules/bulletin02/index.php?page=article&storyid=161] (2019年6月閲覧)
 
6) 補助人工心臓治療関連学会協議会ホームページ. [http://j-vad.jp/certification/] (2019年6月閲覧)
 
7) Imamura T, et al : Preoperative beta-blocker treatment is a key for deciding left ventricular assist device implantation strategy as a bridge to recovery. J Artif Organs 17 : 23-32, 2014.
 
8) Imamura T, et al : Acute pulmonary vasoreactivity test with sildenafil or nitric monoxide before left ventricular assist device implantation. J Artif Organs 16 : 389-392, 2013.
PubMed
9) Yoshitake S, et al : Single-center experience of the bridge-to-bridge strategy using the Nipro paracorporeal ventricular assist device. J Artif Organs 21 : 405-411, 2018.
 
10) Kormos RL, et al : The Society of Thoracic Surgeons Intermacs database annual report : Evolving indications, outcomes, and scientific partnerships. J Heart Lung Transplant 38 : 114-126, 2019.
 
P.86 掲載の参考文献
1) Khush KK, et al : The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation : Thirty-fifth Adult Heart Transplantation Report-2018 ; Focus Theme : Multiorgan Transplantation. J Heart Lung Transplant 37 : 1155-1168, 2018.
PubMed
2) Patel JK, Kobashigawa JA : Should we be doing routine biopsy after heart transplantation in a new era of anti-rejection? Curr Opin Cardiol 21 : 127-131, 2006.
 
3) Grattan MT, et al : Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 261 : 3561-3566, 1989.
PubMed
P.91 掲載の参考文献
1) 日本循環器学会, ほか : 循環器病の診断と治療に関するガイドライン (2011年度合同研究班報告) 心血管疾患におけるリハビリテーションに関するガイドライン (2012年改訂版), 2015 (更新版). [http://www.j-circ.or.jp/guideline/pdf/JCS2012_nohara_h.pdf] (2019年6月閲覧)
 
2) Belardinelli R, et al : Moderate exercise training improves functional capacity, quality of life, and endothelium-dependent vasodilation in chronic heart failure patients with implantable cardioverter defibrillators and cardiac resynchronization therapy. Eur J Cardiovasc Prev Rehabil 13 : 818-825, 2006.
PubMed
3) Belardinelli R, et al : Randomized, controlled trial of long-term moderate exercise training in chronic heart failure : effects on functional capacity, quality of life, and clinical outcome. Circulation 99 : 1173-1182, 1999.
PubMed
4) Headley S, et al : Exercise training improves HR responses and VO2peak in predialysis kidney patients. Med Sci Sports Exerc 44 : 2392-2399, 2012.
PubMed
5) Imamura T, et al : High pulmonary vascular resistance in addition to low right ventricular stroke work index effectively predicts biventricular assist device requirement. J Artif Organs 19 : 44-53, 2016.
 
6) Birks EJ, et al : Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med 355 : 1873-1884, 2006.
PubMed
7) Jondeau G, et al : Active skeletal muscle mass and cardiopulmonary reserve. Failure to attain peak aerobic capacity during maximal bicycle exercise in patients with severe congestive heart failure. Circulation 86 : 1351-1356, 1992.
PubMed
8) Adachi H : Cardiopulmonary Exercise Test. Int Heart J 58 : 654-665, 2017.
PubMed
9) Dunlay SM, et al : Changes in cardiopulmonary exercise testing parameters following continuous flow left ventricular assist device implantation and heart transplantation. J Card Fail 20 : 548-554, 2014.
PubMed
10) Wisloff U, et al : Superior cardiovascular effect of aerobic interval training versus moderate continuous training in heart failure patients : a randomized study. Circulation 115 : 3086-3094, 2007.
PubMed
11) Persinger R, et al : Consistency of the talk test for exercise prescription. Med Sci Sports Exerc 36 : 1632-1636, 2004.
PubMed
12) Piepoli MF, et al : Exercise training in heart failure : from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. Eur J Heart Fail 13 : 347-357, 2011.
 
13) Anker SD, von Haehling S : The obesity paradox in heart failure : accepting reality and making rational decisions. Clin Pharmacol Ther 90 : 188-190, 2011.
PubMed
14) 「日本人の食事摂取基準 (2015年度) 策定検討会」報告書 (厚生労働省健康局がん対策・健康増進課栄養指導室). 2014. [http://www.mhlw.go.jp/file/05-Shingikai-10901000-Kenkoukyoku-Soumuka/0000042647.pdf] (2019年6月閲覧)
 
15) Sherwood A, et al : Relationship of depression to death or hospitalization in patients with heart failure. Arch Intern Med 167 : 367-373, 2007.
 

II 心筋疾患

P.100 掲載の参考文献
1) Braunwald E : Cardiomyopathies : An Overview. Circ Res 121 : 711-721, 2017.
PubMed
2) Krehl L : Beitrag zur kentniss der idiopathischen herzmuskelerkrankungen. Dtsch Arch Klin Med 48 : 414-431, 1891.
 
3) Brigden W : Uncommon myocardial diseases ; the non-coronary cardiomyopathies. Lancet 273 : 1179-1184, 1957.
PubMed
4) Goodwin JF, et al : Clinical aspects of cardiomyopathy. Br Med J 1 : 69-79, 1961.
PubMed
5) Goodwin JF : Congestive and hypertrophic cardiomyopathies. A decade of study. Lancet 1 : 732-739, 1970.
PubMed
6) Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies. Br Heart J 44 : 672-673, 1980.
PubMed
7) Brent LB, et al : Familial muscular subaortic stenosis : an unrecognized form of "idiopathic heart diseases," with clinical and autopsy observations. Circulation 21 : 167-180, 1960.
PubMed
8) Geisterfer-Lowrance AA, et al : A molecular basis for familial hypertrophic cardiomyopathy : a beta cardiac myosin heavy chain gene missense mutation. Cell 62 : 999-1006, 1990.
PubMed
9) Maron BJ, et al : Contemporary definitions and classification of the cardiomyopathies : an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee : Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups ; and Council on Epidemiology and Prevention. Circulation 113 : 1807-1816, 2006.
PubMed
10) Elliott P, et al : Classification of the cardiomyopathies : a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 29 : 270-276, 2008.
 
11) Arbustini E, et al : The MOGE (S) classification of cardiomyopathy for clinicians. J Am Coll Cardiol 64 : 304-318, 2014.
PubMed
12) 日本循環器学会, ほか : 日本循環器学会/日本心不全学会合同ガイドライン. 心筋症診療ガイドライン (2018年改訂版), 2019. [http://www.j-circ.or.jp/guideline/pdf/JCS2018_tsutsui_kitaoka.pdf] (2019年6月閲覧)
 
P.104 掲載の参考文献
1) Geisterfer-Lowrance AA, et al : A molecular basis for familial hypertrophic cardiomyopathy : a beta cardiac myosin heavy chain gene missense mutation. Cell 62 : 999-1006, 1990.
PubMed
2) Thierfelder L, et al : Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy : a disease of the sarcomere. Cell 77 : 701-712, 1994.
PubMed
3) Kamisago M, et al : Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med 343 : 1688-1696, 2000.
PubMed
4) 日本循環器学会, ほか : 日本循環器学会/日本心不全学会合同ガイドライン : 心筋症診療ガイドライン (2018年改訂版), 2019.
 
5) Writing Committee Members ; Yancy CW, et al : 2013 ACCF/AHA guideline for the management of heart failure : a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines, Circulation 128 : e240-327, 2013.
 
6) Authors/Task Force members, et al : 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy : the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35 : 2733-2779, 2014.
 
7) Marian AJ, Braunwald E : Hypertrophic Cardiomyopathy : Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circ Res 121 : 749-770, 2017.
PubMed
8) 森田啓行 : 遺伝子から心筋症をみる. 日本内科学会雑誌 103 : 285-292, 2014.
 
9) Herman DS, et al : Truncations of titin causing dilated cardiomyopathy. N Engl J Med 366 : 619-628, 2012.
PubMed
10) Arbustini E, et al : Autosomal dominant dilated cardiomyopathy with atrioventricular block : a lamin A/C defect-related disease. J Am Coll Cardiol 39 : 981-990, 2002.
 
11) Olivotto I, et al : Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. J Am Coll Cardiol 58 : 839-848, 2011.
PubMed
12) Fujita T, et al : Sarcomere gene mutations are associated with increased cardiovascular events in left ventricular hypertrophy : results from multicenter registration in Japan. JACC Heart Fail 1 : 459-466, 2013.
PubMed
13) van Rijsingen IA, et al : Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. J Am Coll Cardiol 59 : 493-500, 2012.
PubMed
14) Tobita T, et al : Genetic basis of cardiomyopathy and the genotypes involved in prognosis and left ventricular reverse remodeling. Sci Rep 8 : 1998, 2018.
PubMed
15) Kelly M, Semsarian C : Multiple mutations in genetic cardiovascular disease : a marker of disease severity? Circ Cardiovasc Genet 2 : 182-190, 2009.
PubMed
P.108 掲載の参考文献
1) 日本循環器学会, ほか : 日本循環器学会/日本心不全学会合同ガイドライン. 心筋症診療ガイドライン (2018年改訂版) 第3章 肥大型心筋症, 2019.
 
2) Maron BJ, et al : Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities. J Am Coll Cardiol 33 : 1590-1595, 1999.
PubMed
3) Bick AG, et al : Burden of rare sarcomere gene variants in the Framingham and Jackson Heart Study cohorts. Am J Hum Genet 91 : 513-519, 2012.
PubMed
4) Maron BJ, et al : Prevalence of hypertrophic cardiomyopathy in an outpatient population referred for echocardiographic study. Am J Cardiol 73 : 577-580, 1994.
 
5) Semsarian C, et al : New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol 65 : 1249-1254, 2015.
PubMed
6) Walsh R, et al : Defining the genetic architecture of hypertrophic cardiomyopathy : re-evaluating the role of non-sarcomeric genes. Eur Heart J. 38 : 3461-3468, 2017.
PubMed
7) Walsh R, et al : Reassessment of Mendelian gene pathogenicity using 7, 855 cardiomyopathy cases and 60,706 reference samples. Genet Med 19 : 192-203, 2017.
 
8) Yin L, et al : 3.0 T magnetic resonance myocardial perfusion imaging for semi-quantitative evaluation of coronary microvascular dysfunction in hypertrophic cardiomyopathy. Int J Cardiovasc Imaging 33 : 1949-1959, 2017.
 
9) Monserrat L, et al : Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy : an independent marker of sudden death risk in young patients. J Am Coll Cardiol 42 : 873-879, 2003.
PubMed
10) Adabag AS, et al : Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J Am Coll Cardiol 45 : 697-704, 2005.
PubMed
11) Olivotto I, et al : Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 104 : 2517-2524, 2001.
PubMed
12) Authors/Task Force members, et al : 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy : the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35 : 2733-2779, 2014.
 
13) American College of Cardiology Foundation/American Heart Association Task Force on Practice, et al : 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy : a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg 142 : e153-203, 2011.
 
14) Kubo T, et al : Patients' Characteristics and Clinical Course of Hypertrophic Cardiomyopathy in a Regional Japanese Cohort-Results From Kochi RYOMA Study. Circ J 82 : 824-830, 2018.
 
P.113 掲載の参考文献
1) Maron BJ, Spirito P : Implications of left ventricular remodeling in hypertrophic cardiomyopathy. Am J Cardiol 81 : 1339-1344, 1998.
PubMed
2) ten Cate FJ, Roelandt J : Progression to left ventricular dilatation in patients with hypertrophic obstructive cardiomyopathy. Am Heart J 97 : 762-765, 1979.
PubMed
3) Thaman R, et al : Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy. Heart 91 : 920-925, 2005.
PubMed
4) Biagini E, et al : Dilated-hypokinetic evolution of hypertrophic cardiomyopathy : prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients. J Am Coll Cardiol 46 : 1543-1550, 2005.
PubMed
5) Hecht GM, et al : Coexistence of sudden cardiac death and end-stage heart failure in familial hypertrophic cardiomyopathy. J Am Coll Cardiol 22 : 489-497, 1993.
PubMed
6) Elliott P, et al : Classification of the cardiomyopathies : a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 29 : 270-276, 2008.
 
7) Harris KM, et al : Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 114 : 216-225, 2006.
PubMed
8) Aizawa Y, et al : Incidence, clinical characteristics, and long-term outcome of the dilated phase of hypertrophic cardiomyopathy. Keio J Med, 2018. [Epub ahead of print]
 
9) Kawarai H, et al : Risk of sudden death in end-stage hypertrophic cardiomyopathy. J Card Fail 17 : 459-464, 2011.
PubMed
10) Garcia-Pavia P, et al : Genetic basis of end-stage hypertrophic cardiomyopathy. Eur J Heart Fail 13 : 1193-1201, 2011.
PubMed
11) Hitomi N, et al : A frameshift deletion mutation in the cardiac myosin-binding protein C gene associated with dilated phase of hypertrophic cardiomyopathy and dilated cardiomyopathy. J Cardiol 56 : 189-196, 2010.
PubMed
12) Doi K, et al : Clinical analysis of hypertrophic cardiomyopathy which evolved into dilated phase during long-term follow-up. Jpn Heart J 40 : 579-587, 1999.
PubMed
13) Xiao Y, et al : Clinical Characteristics and Prognosis of End-stage Hypertrophic Cardiomyopathy. Chin Med J 128 : 1483-1489, 2015.
PubMed
14) Goto D, et al : Clinical characteristics and outcomes of dilated phase of hypertrophic cardiomyopathy : report from the registry data in Japan. J Cardiol 61 : 65-70, 2013.
PubMed
15) Kubo T, et al : Prognostic Significance of Non-Dilated Left Ventricular Size and Mitral Regurgitation in Patients With Dilated Phase of Hypertrophic Cardiomyopathy. Int Heart J 58 : 63-68, 2017.
PubMed
P.118 掲載の参考文献
1) 日本循環器学会, ほか : 日本循環器学会/日本心不全学会合同ガイドライン. 心筋症診療ガイドライン (2018年改訂版), 2019.
 
2) Maron MS, et al : Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 114 : 2232-2239, 2006,
PubMed
3) Sherrid MV : Pathophysiology and treatment of hypertrophic cardiomyopathy. Prog Cardiovasc Dis 49 : 123-151, 2006.
PubMed
4) Maron BJ, et al : Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 281 : 650-655, 1999.
 
5) Aoyama R, et al : Evaluation of myocardial glucose metabolism in hypertrophic cardiomyopathy using 18F-fluorodeoxyglucose positron emission tomography. PLoS ONE 12 : e0188479, 2017.
PubMed
6) O'Mahony C, et al : A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J 35 : 2010-2020, 2014.
 
7) Nishimura RA, et al : Hypertrophic Obstructive Cardiomyopathy : Surgical Myectomy and Septal Ablation. Circ Res 121 : 771-783, 2017.
PubMed
8) Hamada M, et al : Impact of chronic use of cibenzoline on left ventricular pressure gradient and left ventricular remodeling in patients with hypertrophic obstructive cardiomyopathy. J Cardiol 67 : 279-286, 2016.
PubMed
9) Morrow AG, Brockenbrough EC : Surgical treatment of idiopathic hypertrophic subaortic stenosis : technic and hemodynamic results of subaortic ventriculomyotomy. Ann Surg 154 : 181-189, 1961.
PubMed
10) Hang D, et al : Combined transaortic and transapical approach to septal myectomy in patients with complex hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg 155 : 2096-2102, 2018.
PubMed
11) Sigwart U : Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 346 : 211-214, 1995.
PubMed
12) Maron BJ, Nishimura RA : Surgical septal myectomy versus alcohol septal ablation : assessing the status of the controversy in 2014. Circulation 130 : 1617-1624, 2014.
PubMed
13) Mohr R, et al : Results of operation for hypertrophic obstructive cardiomyopathy in children and adults less than 40 years of age. Circulation 80 : I191-196, 1989.
PubMed
14) Seggewiss H, et al : Long-term follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Clin Res Cardiol 96 : 856-863, 2007.
PubMed
15) Kim LK, et al : Hospital Volume Outcomes After Septal Myectomy and Alcohol Septal Ablation for Treatment of Obstructive Hypertrophic Cardiomyopathy : US Nationwide Inpatient Database, 2003-2011. JAMA Cardiol 1 : 324-332, 2016.
PubMed
P.123 掲載の参考文献
1) Sakamoto T, et al : Giant T wave inversion as a manifestation of asymmetrical apical hypertrophy (AAH) of the left ventricle. Echocardiographic and ultrasono-cardiotomographic study. Jpn Heart J 17 : 611-629, 1976.
PubMed
2) Jan MF, et al : Apical hypertrophic cardiomyopathy : Present status. Int J Cardiol 222 : 745-759, 2016.
PubMed
3) Kubo T, et al : Clinical profiles of hypertrophic cardiomyopathy with apical phenotype-comparison of pure-apical form and distal-dominant form. Circ J 73 : 2330-2336, 2009.
PubMed
4) Gersh BJ, et al : 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy : a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 58 : e212-260, 2011.
 
5) Authors/Task Force members, et al : 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy : the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35 : 2733-2779, 2014.
 
6) Moon J, et al : Clinical and echocardiographic predictors of outcomes in patients with apical hypertrophic cardiomyopathy. Am J Cardiol 108 : 1614-1619, 2011.
PubMed
7) Kitaoka H, et al : Comparison of prevalence of apical hypertrophic cardiomyopathy in Japan and the United States. Am J Cardiol 92 : 1183-1186, 2003.
PubMed
8) Eriksson MJ, et al : Long-term outcome in patients with apical hypertrophic cardiomyopathy. J Am Coli Cardiol 39 : 638-645, 2002.
 
9) Arad M, et al : Gene mutations in apical hypertrophic cardiomyopathy. Circulation 112 : 2805-2811, 2005.
PubMed
10) Lee SE, et al : Impact of atrial fibrillation on the clinical course of apical hypertrophic cardiomyopathy. Heart 103 : 1496-1501, 2017.
PubMed
11) Minami Y, et al : Clinical implications of midventricular obstruction in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 57 : 2346-2355, 2011.
PubMed
12) Minami Y, et al : Phenotypic overlap in hypertrophic cardiomyopathy : apical hypertrophy, midventricular obstruction, and apical aneurysm. J Cardiol 64 : 463-469, 2014.
PubMed
13) Seggewiss H, Faber L : Percutaneous septal ablation for hypertrophic cardiomyopathy and midventricular obstruction. Eur J Echocardiogr 1 : 277-280, 2000.
PubMed
14) Schulte HD, et al : Surgical aspects of typical subaortic and atypical midventricular hypertrophic obstructive cardiomyopathy (HOCM). Thorac Cardiovasc Surg 29 : 375-380, 1981.
PubMed
15) Klarich KW, et al : Risk of death in long-term follow-up of patients with apical hypertrophic cardiomyopathy. Am J Cardiol 111 : 1784-1791, 2013.
PubMed
P.130 掲載の参考文献
1) 厚生労働省難治性疾患克服研究事業 特発性心筋症調査研究班 : 心筋症 : 診断の手引きとその解説 (北畠顕, 友池仁暢編), かりん舎, 2005.
 
2) 日本循環器学会, ほか : 循環器病の診断と治療に関するガイドライン (2009-2010年度合同研究班報告). 拡張型心筋症ならびに関連する二次性心筋症の診療に関するガイドライン, 2011.
 
3) 日本循環器学会, ほか : 日本循環器学会/日本心不全学会合同ガイドライン. 心筋症診療ガイドライン (2018年改訂版), 2019.
 
4) Marcus FI, et al : Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia : proposed modification of the task force criteria. Circulation 121 : 1533-1541, 2010.
PubMed
5) Morita H : Secondary Cardiomyopathy in Polycystic Kidney Disease Syndrome. Int Heart J 60 : 10-11, 2019.
PubMed
6) 森田啓行 : 遺伝子から心筋症をみる. 日本内科学会雑誌 103 : 285-292, 2014.
 
7) Herman DS, et al : Truncations of titin causing dilated cardiomyopathy. N Engl J Med 366 : 619-628, 2012.
PubMed
8) Norton N, et al : Exome sequencing and genome-wide linkage analysis in 17 families illustrate the complex contribution of TTN truncating variants to dilated cardiomyopathy. Circ Cardiovasc Genet 6 : 144-153, 2013.
PubMed
9) Writing Committee Members ; Yancy CW, et al : 2013 ACCF/AHA guideline for the management of heart failure : a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128 : e240-327, 2013.
 
10) Bozkurt B, et al : Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies : A Scientific Statement From the American Heart Association. Circulation 134 : e579-e646, 2016.
PubMed
11) Tobita T, et al : Genetic basis of cardiomyopathy and the genotypes involved in prognosis and left ventricular reverse remodeling. Sci Rep 8 : 1998, 2018.
PubMed
P.137 掲載の参考文献
1) Kimura A : Molecular genetics and pathogenesis of cardiomyopathy. J Hum Genet 61 : 41-50, 2016.
PubMed
2) Arimura T, et al : Overexpression of heart-specific small subunit of myosin light chain phosphatase results in heart failure and conduction disturbance. Am J Physiol Heart Circ Physiol 314 : H1192-H1202, 2018.
PubMed
3) Purevjav E, et al : Molecular basis for clinical heterogeneity in inherited cardiomyopathies due to myopalladin mutations. Hum Mol Genet 21 : 2039-2053, 2012.
PubMed
4) Herman DS, et al : Truncations of titin causing dilated cardiomyopathy. N Engl J Med 366 : 619-628, 2012.
PubMed
5) Ware JS, et al : Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. N Engl J Med 374 : 233-241, 2016.
PubMed
6) Golbus JR, et al : Population-based variation in cardiomyopathy genes. Circ Cardiovasc Genet 5 : 391-399, 2012.
PubMed
7) Schafer S, et al : Titin-truncating variants affect heart function in disease cohorts and the general population. Nat Genet 49 : 46-53, 2017.
PubMed
8) Ware JS, et al : Genetic Etiology for Alcohol-Induced Cardiac Toxicity. J Am Coll Cardiol 71 : 2293-2302, 2018.
PubMed
9) Murayama R, et al : Phosphorylation of the RSRSP stretch is critical for splicing regulation by RNA-Binding Motif Protein 20 (RBM20) through nuclear localization, Sci Rep 8 : 8970, 2018.
PubMed
10) Walsh R, et al : Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. Genet Med 19 : 192-203, 2017.
 
P.147 掲載の参考文献
1) Iwai K, et al : Racial difference in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis 11 : 26-31, 1994.
PubMed
2) Homma JY, et al : Bacteriological investigation on biopsy specimens from patients with sarcoidosis. Jpn J Exp Med 48 : 251-255, 1978.
PubMed
3) Negi M, et al : Localization of propionibacterium acnes in granulomas supports a possible etiologic link between sarcoidosis and the bacterium. Mod Pathol 25 : 1284-1297, 2012.
PubMed
4) Ishibashi K, et al : Japanese Antibacterial Drug Management for Cardiac Sarcoidosis (JACNES) : A multicenter, open-label, randomized, controlled study. J Arrhythm 34 : 520-526, 2018.
PubMed
5) Song Z, et al : Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J Exp Med 201 : 755-767, 2005.
PubMed
6) Terasaki F, et al : Enhanced expression of type 1 helper T-cell cytokines in the myocardium of active cardiac sarcoidosis. Circ J 72 : 1303-1307, 2008.
PubMed
7) Miyara M, et al : The immune paradox of sarcoidosis and regulatory T cells. J Exp Med 203 : 359-370, 2006.
PubMed
8) 日本循環器学会 (班長寺崎文生) : 2016年版 心臓サルコイドーシスの診療ガイドライン, 2017. [http://www.j-circ.or.jp/guideline/pdf/JCS2016_terasakLh.pdf]
 
9) 日本サルコイドーシス/肉芽腫性疾患学会 : サルコイドーシス診療の手引き 2018, 2018. [http://jssog.com/www/top/kenkai20118.html]
 
10) 日本サルコイドーシス/肉芽腫性疾患学会, ほか (編) : サルコイドーシス治療に関する見解-2003. 日本サルコイドーシス/肉芽腫性疾患学会雑誌 23 : 105-114, 2003.
 
11) 加藤靖周, 森本紳一郎 : サルコイドーシス心病変の診断と治療. 日本サルコイドーシス/肉芽腫性疾患学会雑誌 28 : 15-24, 2008.
 
12) Nagai S, et al : Treatment with methotrexate and low-dose corticosteroids in sarcoidosis patients with cardiac lesions. Intern Med 53 : 427-433, 2014.
PubMed
13) Segawa M, et al : Time Course and Factors Correlating With Ventricular Tachyarrhythmias After Introduction of Steroid Therapy in Cardiac Sarcoidosis. Circ Arrhythm Electrophysiol 9 : 2016.
PubMed
14) Yodogawa K, et al : Effect of corticosteroid therapy on ventricular arrhythmias in patients with cardiac sarcoidosis. Ann Noninvasive Electrocardiol 16 : 140-147, 2011.
 
15) Terasaki F, et al : Deterioration of cardiac function during the progression of cardiac sarcoidosis : diagnosis and treatment. Intern Med 53 : 1595-1605, 2014.
PubMed
16) Birnie DH, et al : Cardiac Sarcoidosis. J Am Coll Cardiol 68 : 411-421, 2016.
PubMed
17) Crawford T, et al : Magnetic resonance imaging for identifying patients with cardiac sarcoidosis and preserved or mildly reduced left ventricular function at risk of ventricular arrhythmias. Circ Arrhythm Electrophysiol 7 : 1109-1115, 2014.
PubMed
P.152 掲載の参考文献
1) Falk RH : Diagnosis and management of the cardiac amyloidoses. Circulation 112 : 2047-2060, 2005.
PubMed
2) Falk RH : Cardiac amyloidosis : a treatable disease, often overlooked. Circulation 124 : 1079-1085, 2011.
PubMed
3) Falk RH, et al : The systemic amyloidoses. N Engl J Med 337 : 898-909, 1997.
PubMed
4) Gillmore JD, et al : Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation 133 : 2404-2412, 2016.
PubMed
5) Klein AL, et al : Doppler characterization of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 13 : 1017-1026, 1989.
PubMed
6) Klein AL, et al : Serial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 16 : 1135-1141, 1990.
PubMed
7) Klein AL, et al : Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis. A Doppler echocardiography study. Circulation 83 : 808-816, 1991.
PubMed
8) Koyama J, et al : Usefulness of pulsed tissue Doppler imaging for evaluating systolic and diastolic left ventricular function in patients with AL (primary) amyloidosis. Am J Cardiol 89 : 1067-1071, 2002.
PubMed
9) Buss SJ, et al : Longitudinal left ventricular function for prediction of survival in systemic lightchain amyloidosis : incremental value compared with clinical and biochemical markers. J Am Coll Cardiol 60 : 1067-1076, 2012.
PubMed
10) Liu D, et al : Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy. Circ Cardiovasc Imaging 6 : 1066-1072, 2013.
PubMed
11) Phelan D, et al : Application of a parametric display of two-dimensional speckle-tracking longitudinal strain to improve the etiologic diagnosis of mild to moderate left ventricular hypertrophy. J Am Soc Echocardiogr 27 : 888-895, 2014.
PubMed
12) Muchtar E, et al : Immunoglobulin Light-Chain Amyloidosis : From Basics to New Developments in Diagnosis, Prognosis and Therapy. Acta Haematol 135 : 172-190, 2016.
PubMed
13) Kumar S, et al : Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 30 : 989-995, 2012.
PubMed
14) Maurer MS, et al : Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379 : 1007-1016, 2018.
PubMed
P.157 掲載の参考文献
1) Desnick RJ, et al : α-Galactosidase A deficiency : Fabry disease. In : The Metabolic and Molecular Bases of Inherited Disease, 8th ed (ed by Scriver CR, et al), p3733-3774, McGraw-Hill, New York, 2001.
 
2) Nakao S, et al : An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 333 : 288-293, 1995.
PubMed
3) Wu JC, et al : Cardiovascular manifestations of Fabry disease : relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity. Eur Heart J 31 : 1088-1097, 2010.
PubMed
4) Takenaka T, et al : Terminal stage cardiac findings in patients with cardiac Fabry disease : an electrocardiographic, echocardiographic, and autopsy study. J Cardiol 51 : 50-59, 2008.
PubMed
5) Kampmann C, et al : Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll Cardiol 40 : 1668-1674, 2002.
PubMed
6) Monserrat L, et al : Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 50 : 2399-2403, 2007.
 
7) Kubo T, et al : Prevalence and clinical features of Fabry disease in Japanese male patients with diagnosis of hypertrophic cardiomyopathy. J Cardiol 69 : 302-307, 2017.
PubMed
8) Winchester B, Young E : Biochemical and genetic diagnosis of Fabry disease. In : Fabry Disease : Perspectives from 5 Years of FOS (ed by Mehta A, et al), Chapter 18, Oxford Pharma Genesis, Oxford, 2006.
 
9) Togawa T, et al : Plasma globotriaosylsphingosine as a biomarker of Fabry disease. Mol Genet Metab 100 : 257-261, 2010.
PubMed
10) Maruyama H, et al : Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis. Genet Med 21 : 44-52, 2019.
PubMed
11) Weidemann F, et al : Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease : a prospective strain rate imaging study. Circulation 108 : 1299-1301, 2003.
PubMed
12) Banikazemi M, et al : Agalsidase-beta therapy for advanced Fabry disease : a randomized trial. Ann Intern Med 146 : 77-86, 2007.
PubMed
13) Beck M, et al : Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease : A Fabry Outcome Survey analysis. Mol Genet Metab Rep 3 : 21-27, 2015.
PubMed
14) Hopkin RJ, et al : Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy : Data from the Fabry Registry. Mol Genet Metab 119 : 151-159, 2016.
PubMed
15) Germain DP, et al : Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat. N Engl J Med 375 : 545-555, 2016.
PubMed
P.162 掲載の参考文献
1) Adams PC, et al : Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 352 : 1769-1778, 2005.
 
2) Ikuta K, et al : Iron overload patients with unknown etiology from national survey in Japan. Int J Hematol 105 : 353-360, 2017.
PubMed
3) Takatoku M, et al : Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol 78 : 487-494, 2007.
PubMed
4) 研究代表者小澤敬也 : 輸血後鉄過剰症の診療ガイド. 厚生労働科学研究費補助金難治性疾患克服研究事業「特発性造血障害に関する調査研究」 (平成20年度), 2008.
 
5) Hayashi H, et al : Genetic background of primary iron overload syndromes in Japan. Intern Med 45 : 1107-1111, 2006.
PubMed
6) Hattori A, et al : Clinicopathological study of Japanese patients with genetic iron overload syndromes. Pathol Int 62 : 612-618, 2012.
PubMed
7) Nagayoshi Y, et al : A Q312X mutation in the hemojuveiin gene is associated with cardiomyopathy due to juvenile haemochromatosis. Eur J Heart Fail 10 : 1001-1006, 2008.
PubMed
8) Crowe S, Bartfay WJ : Amlodipine decreases iron uptake and oxygen free radical production in the heart of chronically iron overloaded mice. Biol Res Nurs 3 : 189-197, 2002.
PubMed
9) Das SK, et al : Iron-overload injury and cardiomyopathy in acquired and genetic models is attenuated by resveratrol therapy. Sci Rep 5 : 18132, 2015.
PubMed
10) Olivieri NF, Brittenham GM : Iron-chelating therapy and the treatment of thalassemia. Blood 89 : 739-761, 1997.
PubMed
11) Kirk P, et al : Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 120 : 1961-1968, 2009.
PubMed
12) Sakuta J, et al : Estimation of cardiac left ventricular ejection fraction in transfusional cardiac iron overload by R2*magnetic resonance. Int J Hematol 92 : 708-712, 2010.
PubMed
13) Kaneko Y, et al : Measurement of serum hepcidin-25 levels as a potential test for diagnosing hemochromatosis and related disorders. J Gastroenterol 45 : 1163-1171, 2010.
PubMed
14) Ho PJ, et al : Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study). Eur J Haematol 98 : 97-105, 2017.
PubMed
15) Rombout-Sestrienkova E, et al : End-stage cardiomyopathy because of hereditary hemochromatosis successfully treated with erythrocytapheresis in combination with left ventricular assist device support. Circ Heart Fail 7 : 541-543, 2014.
PubMed
P.167 掲載の参考文献
1) Raymond-Paquin A, et al : Mechanisms and Clinical Significance of Arrhythmia-Induced Cardiomyopathy. Can J Cardiol 34 : 1449-1460, 2018.
PubMed
2) Gopinathannair R, et al : Arrhythmia-Induced Cardiomyopathies : Mechanisms, Recognition, and Management. J Am Coll Cardiol 66 : 1714-1728, 2015.
PubMed
3) Fenelon G, et al : Tachycardiomyopathy : mechanisms and clinical implications. Pacing Clin Electrophysiol 19 : 95-106, 1996.
 
4) Santhanakrishnan R, et al : Atrial Fibrillation Begets Heart Failure and Vice Versa : Temporal Associations and Differences in Preserved Versus Reduced Ejection Fraction. Circulation 133 : 484-492, 2016.
PubMed
5) Shinbane JS, et al : Tachycardia-induced cardiomyopathy : a review of animal models and clinical studies. J Am Coll Cardiol 29 : 709-715, 1997.
PubMed
6) Fujino T, et al : Characteristics of congestive heart failure accompanied by atrial fibrillation with special reference to tachycardia-induced cardiomyopathy. Circ J 71 : 936-940, 2007.
PubMed
7) Jeong YH, et al : Diagnostic approach and treatment strategy in tachycardia-induced cardiomyopathy. Clin Cardiol 31 : 172-178, 2008.
PubMed
8) Tomita M, et al : Changes in left ventricular volume, mass, and function during the development and regression of supraventricular tachycardia-induced cardiomyopathy. Disparity between recovery of systolic versus diastolic function. Circulation 83 : 635-644, 1991.
PubMed
9) Nia AM, et al : Diagnostic accuracy of NT-proBNP ratio (BNP-R) for early diagnosis of tachycardia-mediated cardiomyopathy : a pilot study. Clin Res Cardiol 100 : 887-896, 2011.
PubMed
10) Okada A, et al : Diagnostic Value of Right Ventricular Dysfunction in Tachycardia-Induced Cardiomyopathy Using Cardiac Magnetic Resonance Imaging. Circ J 80 : 2141-2148, 2016.
PubMed
11) Kusunose K, et al : Clinical Utility of Longitudinal Strain to Predict Functional Recovery in Patients With Tachyarrhythmia and Reduced LVEF. JACC Cardiovasc Imaging 10 : 118-126, 2017.
PubMed
12) Mueller KAL, et al : Histopathological and Immunological Characteristics of Tachycardia-Induced Cardiomyopathy. J Am Coll Cardiol 69 : 2160-2172, 2017.
PubMed
13) Roy D, et al : Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358 : 2667-2677, 2008.
PubMed
14) Marrouche NF, et al : Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med 378 : 417-427, 2018.
PubMed
15) Packer DL, et al : Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation : The CABANA Randomized Clinical Trial. JAMA, 2019. [Epub ahead of print]
 
P.171 掲載の参考文献
1) Zamorano JL, et al : 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines : The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37 : 2768-2801, 2016.
 
2) Plana JC, et al : Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy : a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 27 : 911-939, 2014,
PubMed
3) Garcia-Pavia P, et al : Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy. Circulation 140 : 31-41, 2019.
PubMed
4) Cramer L, et al : Cardiovascular function and predictors of exercise capacity in patients with colorectal cancer. J Am Coll Cardiol 64 : 1310-1319, 2014.
PubMed
5) Ewer MS, Lippman SM : Type II chemotherapy-related cardiac dysfunction : time to recognize a new entity. J Clin Oncol 23 : 2900-2902, 2005.
PubMed
6) Cardinale D, et al : Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 131 : 1981-1988, 2015.
PubMed
7) Guarneri V, et al : Long-term cardiac tolerability of trastuzumab in metastatic breast cancer : the M. D. Anderson Cancer Center experience. J Clin Oncol 24 : 4107-4115, 2006.
 
8) Johnson DB, et al : Fulminant Myocarditis with Combination lmmune Checkpoint Blockade. N Engl J Med 375 : 1749-1755, 2016.
 
9) Sawaya H, et al : Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab, Circ Cardiovasc Imaging 5 : 596-603, 2012.
PubMed
P.177 掲載の参考文献
1) 日本循環器学会, ほか : 循環器病の診断と治療に関するガイドライン (2009-2010年度合同研究班報告. 拡張型心筋症ならびに関連する二次性心筋症の診療に関するガイドライン, 2011.
 
2) Hensley ML, et al : American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 17 : 3333-3355, 1999.
 
3) Yamamoto M, et al : Dopamine agonists and cardiac valvulopathy in Parkinson disease : a case-control study. Neurology 67 : 1225-1229, 2006.
PubMed
4) Zanettini R, et al : Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356 : 39-46, 2007.
PubMed
5) パーキンソン病治療ガイドライン作成委員会 (編) : パーキンソン病診療ガイドライン 2018 (日本神経学会監), 2018. [https://www.neurology-jp.org/guidelinem/parkinson_2018.html] (2019年7月閲覧)
 
6) Zanettini R, et al : Regression of cardiac valvulopathy related to ergot-derived dopamine agonists. Cardiovasc Ther 29 : 404-410, 2011.
PubMed
7) Degenhardt L, et al : Toward a global view of alcohol, tobacco, cannabis, and cocaine use : findings from the WHO World Mental Health Surveys. PLoS Med 5 : e141, 2008.
 
8) Qureshi AI, et al : Cocaine use and the likelihood of nonfatal myocardial infarction and stroke : data from the Third National Health and Nutrition Examination Survey. Circulation 103 : 502-506, 2001.
PubMed
9) Gurudevan SV, et al : Cocaine-induced vasoconstriction in the human coronary microcirculation : new evidence from myocardial contrast echocardiography. Circulation 128 : 598-604, 2013.
PubMed
10) Kugelmass AD, et al : Intravenous cocaine induces platelet activation in the conscious dog. Circulation 91 : 1336-1340, 1995.
PubMed
11) Anderson JL, et al : 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction : a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 61 : e179-347, 2013.
 
12) Domanski MJ, et al : Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus. J Pediatr 127 : 137-146, 1995.
PubMed
13) Nelson MD, et al : Cardiac steatosis and left ventricular dysfunction in HIV-infected patients treated with highly active antiretroviral therapy. JACC Cardiovasc Imaging 7 : 1175-1177, 2014.
PubMed
14) 及川雅啓, ほか : 化学療法誘発性心筋症. 医学のあゆみ 252 : 1112-1116, 2015.
Medical*Online
P.181 掲載の参考文献
1) Bianchi VE : Impact of Nutrition on Cardiovascular Function. Curr Probl Cardiol, 2018. [Epub ahead of print]
 
2) Casiero D, et al : Cardiovascular complications of eating disorders. Cardiol Rev 14 : 227-231, 2006.
PubMed
3) 中屋豊ほか : リフィーディング症候群. 四国医学雑誌 68 : 23-28, 2012.
 
4) National Collaborating Centre for Acute Care : National Institute for Health and Clinical Excellence : Guidance. In : Nutrition Support for Adults : Oral Nutrition Support, Enteral Tube Feeding and Parenteral Nutrition, National Collaborating Centre for Acute Care (UK), London, 2006.
 
5) Sriram K, et al : Thiamine in nutrition therapy. Nutr Clin Pract 27 : 41-50, 2012.
PubMed
6) Lonsdale D, Shamberger RJ : Red cell transketolase as an indicator of nutritional deficiency. Am J Clin Nutr 33 : 205-211, 1980.
PubMed
7) Essa E, et al : Cardiovascular magnetic resonance in wet beriberi. J Cardiovasc Magn Reson 13 : 41, 2011.
PubMed
8) Kawano H, et al : Histopathological changes of biopsied myocardium in Shoshin beriberi. Int Heart J 46 : 751-759, 2005.
PubMed
9) Massoure PL, et al : Bilateral leg oedema after bariatric surgery : A selenium-deficient cardiomyopathy. Obes Res Clin Pract 11 : 622-626, 2017.
PubMed
10) 日本臨床栄養学会 (編) : セレン欠乏症の診療指針 2016, 2016. [http://www.jscn.gr.jp/pdf/selen2016.pdf] (2019年7月閲覧)
 
11) 厚生労働省 : 「日本人の食事摂取基準 (2015年版) 」策定検討会報告書, 2014. [https://www.mhlw.go.jp/file/05-Shingikai-10901000-Kenkoukyoku-Soumuka/0000114399.pdf] (2019年7月閲覧)
 
P.185 掲載の参考文献
1) 日本循環器学会 : 日本循環器学会/日本心不全学会合同ガイドライン : 心筋症診療ガイドライン (2018年改訂版), 2019.
 
2) 日本循環器学会 : 日本循環器学会/日本心不全学会合同ガイドライン : 急性・慢性心不全診療ガイドライン (2017年改訂版), 2018.
 
3) Dor V, et al : Favorable effects of left ventricular reconstruction in patients excluded from the Surgical Treatments for Ischemic Heart Failure (STICH) trial. J Thorac Cardiovasc Surg 141 : 905-916, 916. el-4, 2011.
 
4) Isomura T, et al : Indication of posterior restoration and surgical results in patients with dilated cardiomyopathy. Eur J Cardiothorac Surg 38 : 171-175, 2010.
PubMed
5) Dargie HJ : Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction : the CAPRICORN randomised trial. Lancet 357 : 1385-1390, 2001.
PubMed
6) Moss AJ, et al : Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 : 877-883, 2002.
PubMed
7) Bristow MR, et al : Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350 : 2140-2150, 2004.
 
8) Cho Y, et al : Non-heart transplant surgical approaches with left ventricular restoration and mitral valve operation for advanced ischaemic cardiomyopathy. Eur J Cardiothorac Surg 46 : 849-856, 2014.
PubMed
9) Cho Y, et al : Long-term results and mid-term features of left ventricular reconstruction procedures on left ventricular volume, geometry, function and mitral regurgitation. Eur J Cardiothorac Surg 42 : 462-469, 2012.
PubMed
10) Matsui Y, et al : Integrated overlapping ventriculoplasty combined with papillary muscle plication for severely dilated heart failure. J Thorac Cardiovasc Surg 127 : 1221-1223, 2004.
PubMed
11) Jones RH, et al : Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med 360 : 1705-1717, 2009.
 
12) Wakasa S, et al : Risk scores for predicting mortality after surgical ventricular reconstruction for ischemic cardiomyopathy : results of a Japanese multicenter study. J Thorac Cardiovasc Surg 147 : 1868-1874, 1874. e1-2, 2014.
 
13) Magne J, et al : Ischemic mitral regurgitation : a complex multifaceted disease. Cardiology 112 : 244-259, 2009.
PubMed
14) Atluri P, et al : Ventricular assist device implant in the elderly is associated with increased, but respectable risk : a multi-institutional study. Ann Thorac Surg 96 : 141-147, 2013,
 
15) Sawa Y, et al : Safety and Efficacy of Autologous Skeletal Myoblast Sheets (TCD-51073) for the Treatment of Severe Chronic Heart Failure Due to Ischemic Heart Disease. Circ J 79 : 991-999, 2015.
PubMed
P.192 掲載の参考文献
1) Richardson P, et al : Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 93 : 841-842, 1996.
PubMed
2) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編) : 高血圧治療ガイドライン 2014 (JSH2014), 2014.
 
3) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編) : 高血圧治療ガイドライン 2019 (JSH2019). 2019.
 
4) Milani RV, et al : Left ventricular geometry and survival in patients with normal left ventricular ejection fraction. Am J Cardiol 97 : 959-963, 2006.
PubMed
5) Querejeta R, et al : Increased collagen type I synthesis in patients with heart failure of hypertensive origin : relation to myocardial fibrosis. Circulation 110 : 1263-1268, 2004.
PubMed
6) Weber KT : Fibrosis and hypertensive heart disease. Curr Opin Cardiol 15 : 264-272, 2000.
PubMed
7) Fujita S, et al : Atrial natriuretic peptide exerts protective action against angiotensin II-induced cardiac remodeling by attenuating inflammation via endothelin-1/endothelin receptor A cascade. Heart Vessels 28 : 646-657, 2013.
PubMed
8) Rautaharju PM, et al : Electrocardiographic left ventricular hypertrophy and the risk of adverse cardiovascular events : a critical appraisal. J Electrocardiol 47 : 649-654, 2014.
 
9) Okin PM, et al : Relationship of the electrocardiographic strain pattern to left ventricular structure and function in hypertensive patients : the LIFE study. Losartan Intervention For End point. J Am Coll Cardiol 38 : 514-520, 2001.
 
10) Okin PM, et al : Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment : the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE). Circulation 119 : 1883-1891, 2009.
PubMed
11) Bang CN, et al : Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction-A LIFE review. J Electrocardiol 47 : 630-635, 2014.
PubMed
12) Kuruvilla S, et al : Increased extracellular volume and altered mechanics are associated with LVH in hypertensive heart disease, not hypertension alone. JACC Cardiovasc Imaging 8 : 172-180, 2015.
 
P.196 掲載の参考文献
1) Isogai T, Kamiya CA : Worldwide Incidence of Peripartum Cardiomyopathy and Overall Maternal Mortality. Int Heart J 60 : 503-511, 2019.
PubMed
2) Pearson GD, et al : Peripartum cardiomyopathy : National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA 283 : 1183-1188, 2000.
PubMed
3) Demakis JG, Rahimtoola SH : Peripartum cardiomyopathy. Circulation 44 : 964-968, 1971.
PubMed
4) Ruys TP, et al : Heart failure in pregnant women with cardiac disease : data from the ROPAC. Heart 100 : 231-238, 2014.
PubMed
5) Elkayam U, et al : Pregnancy-associated cardiomyopathy : clinical characteristics and a comparison between early and late presentation. Circulation 111 : 2050-2055, 2005.
 
6) 厚生労働科学研究 (難治性疾患政策研究事業) 「周産期心筋症ガイドライン作成」班・「特発性心筋症に関する調査研究」班 (編) : 周産期心筋症診療の手引き. 中外医学社, 2019.
 
7) Kamiya CA, et al : Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders. -Results from the Japanese Nationwide survey of peripartum cardiomyopathy-. Circ J 75 : 1975-1981, 2011.
PubMed
8) Bello N, et al : The relationship between Pre-eclampsia and Peripartum Cardiomyopathy : a Systematic Review and Meta-Analysis. J Am Coll Cardiol 62 : 1715-1723, 2013.
PubMed
9) Hilfiker-Kleiner D, et al : A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 128 : 589-600, 2007.
PubMed
10) Patten IS, et al : Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 485 : 333-338, 2012.
PubMed
11) Ware JS, et al : Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies, N Engl J Med 374 : 233-241, 2016.
PubMed
12) Rogers FJ, Cooper S : Peripartum heart failure caused by left ventricular diastolic dysfunction. J Am Osteopath Assoc 110 : 87-90, 2010.
PubMed
13) Kakogawa J, et al : Peripartum heart failure caused by left ventricular diastolic dysfunction : a case report. Acta Obstet Gynecol Scand 93 : 835-838, 2014.
PubMed
14) Sliwa K, et al : Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy : a proof-of-concept pilot study. Circulation 121 : 1465-1473, 2010.
PubMed
15) Hilfiker-Kleiner D, et al : Bromocriptine for the treatment of peripartum cardiomyopathy : a multicentre randomized study. Eur Heart J 38 : 2671-2679, 2017.
PubMed
P.202 掲載の参考文献
1) Mirijello A, et al : Alcoholic cardiomyopathy : What is known and what is not known. Eur J Intern Med 43 : 1-5, 2017.
 
2) Goncalves A, et al : Relationship between alcohol consumption and cardiac structure and function in the elderly : the atherosclerosis risk in communities study. Circ Cardiovasc Imaging 8, pii : e002846 2015
 
3) Fernandez-Sola J : Cardiovascular risks and benefits of moderate and heavy alcohol consumption. Nat Rev Cardiol 12 : 576-587, 2015.
PubMed
4) Richard A, Lange LDH : Cardiomyopathies induced by drugs or toxins. In : Braunwald's Heart Disease : A Textbook of Cardiovascular Medicine, 77th ed, p1631-1634, Elsevier/Saunders, Philadelphia, 2019.
 
5) Manthey J, et al : National, regional and global mortality due to alcoholic cardiomyopathy in 2015. Heart 104 : 1663-1669, 2018.
PubMed
6) Cheng CP, et al : Angiotensin II type 1 receptor blockade prevents alcoholic cardiomyopathy. Circulation 114 : 226-236, 2006.
PubMed
7) Millwood IY, et al : Conventional and genetic evidence on alcohol and vascular disease aetiology : a prospective study of 500 000 men and women in China. Lancet 393 : 1831-1842, 2019.
PubMed
8) Manolis TA, et al : Cardiovascular effects of alcohol : A double-edged sword/how to remain at the nadir point of the J-Curve? Alcohol 76 : 117-129, 2019.
 
9) Fernandez-Sola J, et al : The relation of alcoholic myopathy to cardiomyopathy. Ann Intern Med 120 : 529-536, 1994.
PubMed
10) Fauchier L, et al : Comparison of long-term outcome of alcoholic and idiopathic dilated cardiomyopathy. Eur Heart J 21 : 306-314, 2000.
PubMed
11) Guzzo-Merello G, et al : Natural history and prognostic factors in alcoholic cardiomyopathy. JACC Heart Fail 3 : 78-86, 2015.
PubMed
12) Guzzo-Merello G, et al : Malignant ventricular arrhythmias in alcoholic cardiomyopathy. Int J Cardiol 199 : 99-105, 2015.
PubMed
P.206 掲載の参考文献
1) Caforio ALP, et al : Myocarditis : A Clinical Overview. Curr Cardiol Rep 19 : 63, 2017.
 
2) Lieberman EB, et al : Clinicopathologic description of myocarditis. J Am Coll Cardiol 18 : 1617-1626, 1991.
PubMed
3) McCarthy RE, et al : Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 342 : 690-695, 2000.
PubMed
4) Ammirati E, et al : Survival and Left Ventricular Function Changes in Fulminant Versus Nonfulminant Acute Myocarditis. Circulation 136 : 529-545, 2017.
PubMed
5) Merlo M, et al : Persistent left ventricular dysfunction after acute lymphocytic myocarditis : Frequency and predictors. PLoS ONE 14 : e0214616, 2019.
PubMed
6) Sawamura A, et al : Early Prediction Model for Successful Bridge to Recovery in Patients With Fulminant Myocarditis Supported With Percutaneous Venoarterial Extracorporeal Membrane Oxygenation-Insights From the CHANGE PUMP Study. Circ J 82 : 699-707, 2018.
PubMed
7) Sawamura A, et al : Prognostic Value of Electrocardiography in Patients With Fulminant Myocarditis Supported by Percutaneous Venoarterial Extracorporeal Membrane Oxygenation-Analysis From the CHANGE PUMP Study. Circ J 82 : 2089-2095, 2018.
PubMed
8) Tsukada B, et al : High prevalence of chronic myocarditis in dilated cardiomyopathy referred for left ventriculoplasty : expression of tenascin C as a possible marker for inflammation. Hum Pathol 40 : 1015-1022, 2009.
PubMed
9) Nakayama T, et al : Clinical impact of the presence of macrophages in endomyocardial biopsies of patients with dilated cardiomyopathy. Eur J Heart Fail 19 : 490-498, 2017.
 
10) Anzai T : Inflammatory Mechanisms of Cardiovascular Remodeling. Circ J 82 : 629-635, 2018.
PubMed
11) Yu ZX, et al : On the interstitial fibrotic changes in acute and convalescent myocarditis obtained by serial endomyocardial biopsy. Jpn Circ J 49 : 1270-1276, 1985.
PubMed
12) Hasumi M, et al : Analysis of histopathologic findings in cases with dilated cardiomyopathy with special reference to formulating diagnostic criteria on the possibility of postmyocarditic change. Jpn Circ J 50 : 1280-1287, 1986.
PubMed
13) Guideline for diagnosing chronic myocarditis. Japanese Circulation Society (JCS) Task Force Committee on Chronic Myocarditis. Jpn Circ J 60 : 263-264, 1996.
PubMed
14) 加藤誠也, 岡部眞典 : 「慢性心筋炎」を見直す. Cardiac Practice 30 : 7-11, 2019.
Medical*Online
15) Caforio AL, et al : Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis : a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34 : 2636-2648, 2648a-2648d, 2013.
 
P.210 掲載の参考文献
1) 日本神経学会, ほか (監) : デュシェンヌ型筋ジストロフィー診療ガイドライン 2014, p104-129, 南江堂, 2014.
 
2) 木村公一 : 二次性心筋症へのトータルアプローチ. 筋ジストロフィー. 心エコー 19 : 174-180, 2018.
 
3) Kimura K, et al : Prognostic impact of left ventricular noncompaction in patients with Duchenne/Becker muscular dystrophy-prospective multicenter cohort study. Int J Cardiol 168 : 1900-1904, 2013.
PubMed
4) Kamdar F, Garry DJ : Dystrophin-Deficient Cardiomyopathy. J Am Coll Cardiol 67 : 2533-2546, 2016.
PubMed
5) Birnkrant DJ, et al : Diagnosis and management of Duchenne muscular dystrophy, part 2 : respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol 17 : 347-361, 2018.
PubMed
P.214 掲載の参考文献
1) 日本循環器学会, ほか : 循環器病の診断と治療に関するガイドライン 2011, 拡張型心筋症ならびに関連する二次性心筋症の診療に関するガイドライン, 2012.
 
2) Doherty NE, Siegel RJ : Cardiovascular manifestations of systemic lupus erythematosus. Am Heart J 110 : 1257-1265, 1985.
PubMed
3) Appenzeller S, et al : Acute lupus myocarditis : Clinical features and outcome. Lupus 20 : 981-988, 2011.
PubMed
4) 福岡秀介, ほか : SLE関連心膜心筋炎の2症例. 心臓 46 : 79-87, 2014.
Medical*Online
5) 波多野将 : 重要な臓器障害 心臓 (特集 リウマチ・膠原病における重要臓器障害と難治性病態-病態と治療の進歩). 日本内科学会雑誌 102 : 2543-2548, 2013.
 
6) Khamashta MA, et al : Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet 335 : 1541-1544, 1990.
PubMed
7) Zuily S, et al : Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus : meta-analysis of echocardiographic studies. Circulation 124 : 215-224, 2011.
PubMed
8) Bissell LA, et al : Consensus best practice pathway of the UK Systemic Sclerosis Study group : management of cardiac disease in systemic sclerosis. Rheumatology (Oxford) 56 : 912-921, 2017.
 
9) Hinchcliff M, et al : Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) : baseline characteristics and description of study population. J Rheumatol 38 : 2172-2179, 2011.
PubMed
10) Lundberg IE : The heart in dermatomyositis and polymyositis. Rheumatology (Oxford) 45 (Suppl 4) iv18-21, 2006.
 
11) Knockaert DC : Cardiac involvement in systemic inflammatory diseases. Eur Heart J 28 : 1797-1804, 2007.
PubMed
12) Dennert RM, et al : Cardiac involvement in Churg-Strauss syndrome. Arthritis Rheum 62 : 627-634, 2010.
PubMed
13) Greco A, et al : Churg-Strauss syndrome. Autoimmun Rev 14 : 341-348, 2015.
PubMed
14) Prasad M, et al : Cardiorheumatology : cardiac involvement in systemic rheumatic disease. Nat Rev Cardiol 12 : 168-176, 2015.
PubMed
P.218 掲載の参考文献
1) 甲状腺疾患と心臓. 甲状腺専門医ガイドブック [改訂第2版] (日本甲状腺学会編), p271-276, 診断と治療社, 2018.
 
2) 吉村弘, ほか : バセドウ病治療ガイドライン 2019 (日本甲状腺学会編), 南江堂, 2019.
 
3) Rueda D, et al : Takotsubo Myocardiopathy and Hyperthyroidism : A Case Report and Literature Review. Am J Case Rep 18 : 865-870, 2017.
PubMed
4) Richardson P, et al : Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 93 : 841-842, 1996.
PubMed
5) 厚生労働省難治性疾患克服研究事業特発性心筋症調査研究班 : 心筋症 : 診断の手引きとその解説 (北畠顕, 友池仁暢編), かりん舎, 2005.
 
6) 日本循環器学会, ほか : 日本循環器学会/日本心不全学会合同ガイドライン. 心筋症診療ガイドライン (2018年改訂版), 2019.
 
7) Ladenson PW, et al : Reversible alterations in myocardial gene expression in a young man with dilated cardiomyopathy and hypothyroidism. Proc Natl Acad Sci USA 89 : 5251-5255, 1992.
 
8) Gencer B, et al : Subclinical thyroid dysfunction and the risk of heart failure events : an individual participant data analysis from 6 prospective cohorts. Circulation 126 : 1040-1049, 2012.
PubMed
P.223 掲載の参考文献
1) Ribeiro-Oliveira A Jr, Barkan A : The changing face of acromegaly-advances in diagnosis and treatment. Nat Rev Endocrinol 8 : 605-611, 2012.
PubMed
2) 片上秀喜 : アクロメガリー 下垂体性巨人症の発症率と有病率について : 宮崎県 (人口100万人) での検討. 第2回アクロメガリーフォーラム記録集 2007, 2007.
 
3) 清水直容 : 厚生省特定疾患「間脳下垂体機能障害調査研究班」 平成元年度総括研究事業報告書, 1990.
 
4) Kahaly G, et al : Arrhythmia profile in acromegaly. Eur Heart J 13 : 51-56, 1992.
PubMed
5) Bihan H, et al : Long-term outcome of patients with acromegaly and congestive heart failure. J Clin Endocrinol Metab 89 : 5308-5313, 2004.
PubMed
6) Esposito D, et al : Decreasing mortality and changes in treatment patterns in patients with acromegaly from a nationwide study. Eur J Endocrinol 178 : 459-469, 2018.
PubMed
7) Sharma AN, et al : Acromegalic cardiomyopathy : Epidemiology, diagnosis, and management. Clin Cardiol 41 : 419-425, 2018.
PubMed
8) Nascimento GC, et al : Acromegalic cardiomyopathy in an extensively admixed population : is there a role for GH/IGF-I axis? Clin Endocrinol (Oxf) 78 : 94-101, 2013.
 
9) Colao A : Improvement of cardiac parameters in patients with acromegaly treated with medical therapies. Pituitary 15 : 50-58, 2012.
PubMed
10) Pereira AM, et al : Increased prevalence of regurgitant valvular heart disease in acromegaly. J Clin Endocrinol Metab 89 : 71-75, 2004.
PubMed
11) Castellano G, et al : The GH/IGF-1 Axis and Heart Failure. Curr Cardiol Rev 5 : 203-215, 2009.
PubMed
12) Suzuki T, Tokuda Y : Face the truth : a 76-year-old man with chronic heart failure of unknown origin. BMJ Case Rep, 2014. pii : bcr2014204789, 2014.
 
13) Vitale G, et al : Prevalence and determinants of ieft ventricular hypertrophy in acromegaly : impact of different methods of indexing left ventricular mass. Clin Endocrinol (Oxf) 60 : 343-349, 2004.
 
14) Lopez-Velasco R, et al : Cardiac involvement in acromegaly : specific myocardiopathy or consequence of systemic hypertension? J Clin Endocrinol Metab 82 : 1047-1053, 1997.
PubMed
15) Andrysiak-Mamos E, et al : Simpson-Golabi-Behmel syndrome in a 39-year-old male patient with suspected acromegaly-A case study. Am J Med Genet A 179 : 322-328, 2019.
 
16) Orme SM, et al : Mortality and cancer incidence in acromegaly : a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 83 : 2730-2734, 1998.
 
17) Colao A, et al : Growth hormone and the heart. Clin Endocrinol (Oxf) 54 : 137-154, 2001.
PubMed
18) Minniti G, et al : Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients. Clin Endocrinol (Oxf) 55 : 307-313, 2001.
PubMed
19) Chanson P, et al : Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Ann Intern Med 113 : 921-925, 1990.
PubMed
20) Mercado M, et al : Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J Clin Endocrinol Metab 99 : 4438-4446, 2014.
 
21) Tachibana H, et al : Improvement of ventricular arrhythmia by octreotide treatment in acromegalic cardiomyopathy. Jpn Heart J 44 : 1027-1031, 2003.
PubMed
22) Damjanovic SS, et al : High output heart failure in patients with newly diagnosed acromegaly. Am J Med 112 : 610-616, 2002.
PubMed
23) Ohtsuka G, et al : Heart valve operation in acromegaly. Ann Thorac Surg 64 : 390-393, 1997.
PubMed
24) Annamalai AK, et al : A comprehensive study of clinical, biochemical. radiological. vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. J Clin Endocrinol Metab 98 : 1040-1050, 2013.
 
P.228 掲載の参考文献
1) Kawai S, et al : Guidelines for diagnosis of takotsubo (ampulla) cardiomyopathy. Circ J 71 : 990-992, 2007.
PubMed
2) Scantlebury DC, Prasad A : Diagnosis of Takotsubo cardiomyopathy. Circ J 78 : 2129-2139, 2014.
PubMed
3) Sinclair AM, et al : Secondary hypertension in a blood pressure clinic. Arch Intern Med 147 : 1289-1293, 1987.
 
4) Omura M, et al : Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 27 : 193-202, 2004.
PubMed
5) Young WF Jr : Management approaches to adrenal incidentalomas. A view from Rochester, Minnesota. Endocrinol Metab Clin North Am 29 : 159-185, 2000.
PubMed
6) Giavarini A, et al : Acute catecholamine cardiomyopathy in patients with phaeochromocytoma or functional paraganglioma. Heart 99 : 1438-1444, 2013.
PubMed
7) Otusanya O, et al : A vicious cycle of acute catecholamine cardiomyopathy and circulatory collapse secondary to pheochromocytoma. Oxf Med Case Reports 2015 : 343-345, 2015.
PubMed
8) Van Vliet PD, et al : Focal myocarditis associated with pheochromocytoma. N Engl J Med 274 : 1102-1108, 1966.
PubMed
9) Sardesai SH, et al : Phaeochromocytoma and catecholamine induced cardiomyopathy presenting as heart failure. Br Heart J 63 : 234-237, 1990.
PubMed
10) Prejbisz A, et al : Cardiovascular manifestations of phaeochromocytoma. J Hypertens 29 : 2049-2060, 2011.
PubMed
11) Ullal J, et al : Case Report : Pheochromocytoma-related catecholamine cardiomyopathy with successful outcomes after orthotopic heart transplantation. F1000Research 4 : 469, 2015.
 
12) 松本健吾, ほか : Catecholamine cardiomyopathyに対し, β-1遮断薬, α-1遮断薬併用療法が著効した悪性褐色細胞腫の1手術例. 心臓 28 : 749-754, 1996.
Medical*Online
13) Mitsuma W, et al : Irreversible dilated cardiomyopathy after surgical resection of pheochromocytomas associated with von Hippel-Lindau disease. Int J Cardiol 131 : e95-96, 2009.
PubMed
14) Sakamoto K, et al : Pheochromocytoma multisystem crisis with transient stress cardiomyopathy due to ruptured pheochromocytoma. BMJ Case Rep 2015. pii : bcr2015212456, 2015.
 
15) Hekimian G, et al : Extracorporeal membrane oxygenation for pheochromocytoma-induced cardiogenic shock. Ann Intensive Care 6 : 117, 2016.
PubMed
P.234 掲載の参考文献
1) Lyon AR, et al : Current state of knowledge on Takotsubo syndrome : a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 18 : 8-27, 2016.
 
2) Ghadri JR, et al : Long-Term Prognosis of Patients With Takotsubo Syndrome. J Am Coll Cardiol 72 : 874-882, 2018.
PubMed
3) Akashi YJ, et al : Takotsubo cardiomyopathy : a new form of acute, reversible heart failure. Circulation 118 : 2754-2762, 2008.
PubMed
4) Deshmukh A, et al : Prevalence of Takotsubo cardiomyopathy in the United States. Am Heart J 164 : 66-71. e1, 2012.
 
5) Ghadri JR, et al : International Expert Consensus Document on Takotsubo Syndrome (Part I) : Clinical Characteristics, Diagnostic Criteria, and Pathophysiology. Eur Heart J 39 : 2032-2046, 2018.
PubMed
6) Elgendy AY, et al : Clinical presentations and outcomes of Takotsubo syndrome in the setting of subarachnoid hemorrhage : A systematic review and meta-analysis. Eur Heart J Acute Cardiovasc Care 7 : 236-245, 2018.
PubMed
7) Ghadri JR, et al : Happy heart syndrome : role of positive emotional stress in takotsubo syndrome. Eur Heart J 37 : 2823-2829, 2016.
PubMed
8) Templin C, et al : Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. N Engl J Med 373 : 929-938, 2015.
PubMed
9) Randhawa MS, et al : Diagnostic utility of cardiac biomarkers in discriminating Takotsubo cardiomyopathy from acute myocardial infarction. J Card Fail 20 : 377. e25-31, 2014.
 
10) Wittstein IS, et al : Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med 352 : 539-548, 2005.
PubMed
11) Kosuge M, et al : Simple and accurate electrocardiographic criteria to differentiate takotsubo cardiomyopathy from anterior acute myocardial infarction. J Am Coll Cardiol 55 : 2514-2516, 2010.
PubMed
12) Kosuge M, et al : Differences in negative T waves between takotsubo cardiomyopathy and reperfused anterior acute myocardial infarction. Circ J 76 : 462-468, 2012.
PubMed
13) Isogai T, et al : Clinical characteristics of patients with Takotsubo syndrome diagnosed without coronary artery evaluation : A retrospective nationwide study. J Cardiol 71 : 268-276, 2018.
PubMed
14) Pathik B, et al : Troponin-positive chest pain with unobstructed coronary arteries : incremental diagnostic value of cardiovascular magnetic resonance imaging. Eur Heart J Cardiovasc Imaging 17 : 1146-1152, 2016.
PubMed
15) Eitel I, et al : Clinical characteristics and cardiovascular magnetic resonance findings in stress (takotsubo) cardiomyopathy. JAMA 306 : 277-286, 2011.
PubMed
16) Hasbak P, et al : Preserved myocardial blood flow in the apical region involved in takotsubo cardiomyopathy by quantitative cardiac PET assessment. J Nucl Cardiol 19 : 169-171, 2012.
 
17) Akashi YJ, et al : 123I-MIBG myocardial scintigraphy in patients with "takotsubo" cardiomyopathy. J Nucl Med 45 : 1121-1127, 2004.
PubMed
18) Singh K, et al : Systematic review and meta-analysis of incidence and correlates of recurrence of takotsubo cardiomyopathy. Int J Cardiol 174 : 696-701, 2014.
PubMed
19) Palla AR, et al : Pretreatment with low-dose β-adrenergic antagonist therapy does not affect severity of Takotsubo cardiomyopathy. Clin Cardiol 35 : 478-481, 2012.
 
20) Isogai T, et al : Early β-blocker use and in-hospital mortality in patients with Takotsubo cardiomyopathy. Heart 102 : 1029-1035, 2016.
 
21) Isogai T, et al : Out-of-hospital versus in-hospital Takotsubo cardiomyopathy : analysis of 3719 patients in the Diagnosis Procedure Combination database in Japan. Int J Cardiol 176 : 413-417, 2014.
PubMed
22) Stiermaier T, et al : Prognostic Usefulness of the Ballooning Pattern in Patients With Takotsubo Cardiomyopathy. Am J Cardiol 118 : 1737-1741, 2016.
PubMed
P.240 掲載の参考文献
1) Marcus FI, et al : Right ventricular dysplasia : a report of 24 adult cases. Circulation 65 : 384-398, 1982.
PubMed
2) McKenna WJ, et al : Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. Br Heart J 71 : 215-218, 1994.
 
3) Marcus FI, et al : Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia : proposed modification of the task force criteria. Circulation 121 : 1533-1541, 2010.
PubMed
4) Groeneweg JA, et al : Clinical Presentation, Long-Term Follow-Up, and Outcomes of 1001 Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Patients and Family Members. Circ Cardiovasc Genet 8 : 437-446, 2015.
PubMed
5) Wada Y, et al : Unique genetic background and outcome of non-Caucasian Japanese probands with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Mol Genet Genomic Med 5 : 639-651, 2017.
PubMed
6) Corrado D, et al : Arrhythmogenic Right Ventricular Cardiomyopathy. N Engl J Med 376 : 61-72, 2017.
PubMed
7) James CA, et al : Exercise increases age-related penetrance and arrhythrnic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol 62 : 1290-1297, 2013.
PubMed
8) Sawant AC, et al : Safety of American Heart Association-recommended minimum exercise for desmosomal mutation carriers. Heart Rhythm 13 : 199-207, 2016.
PubMed
9) Thiene G, et al : Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med 318 : 129-133, 1988.
PubMed
10) Corrado D, et al : Arrhythmogenic Cardiomyopathy. Circ Res 121 : 784-802, 2017.
PubMed
11) Marcus GM, et al : Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy : a report from the North American ARVC Registry. J Am Coll Cardiol 54 : 609-615, 2009.
PubMed
12) Wichter T, et al : Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia. Circulation 86 : 29-37, 1992.
PubMed
13) Ermakov S, et al : Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm 14 : 564-569, 2017.
PubMed
14) Mahida S, et al : Ablation compared with drug therapy for recurrent ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy : Results from a multicenter study. Heart Rhythm 16 : 536-543, 2019.
PubMed
15) Mazzanti A, et al : Arrhythmogenic Right Ventricular Cardiomyopathy : Clinical Course and Predictors of Arrhythmic Risk. J Am Coll Cardiol 68 : 2540-2550, 2016.
 
P.245 掲載の参考文献
1) Anan R, et al : Cardiac involvement in mitochondrial diseases. A study on 17 patients with documented mitochondrial DNA defects. Circulation 91 : 955-961, 1995.
 
2) Meyers DE, et al : Mitochondrial cardiomyopathy : pathophysiology, diagnosis, and management. Tex Heart Inst J 40 : 385-394, 2013.
PubMed
3) Linnane AW, et al : Mitochondrial DNA mutations as an important contributor to ageing and degenerative diseases. Lancet 1 : 642-645, 1989.
PubMed
4) Loeffen J, et al : Mutations in the complex I NDUFS2 gene of patients with cardiomyopathy and encephalomyopathy. Ann Neurol 49 : 195-201, 2001.
PubMed
5) Benit P, et al : Mutant NDUFV2 subunit of mitochondrial complex I causes early onset hypertrophic cardiomyopathy and encephalopathy. Hum Mutat 21 : 582-586, 2003.
PubMed
6) Berger I, et al : Mitochondrial complex I deficiency caused by a deleterious NDUFA11 mutation. Ann Neurol 63 : 405-408, 2008.
PubMed
7) 荒井悌子, ほか : 診断の過程で心臓MRIが有用であったミトコンドリア心筋症の1例. 心臓 43 : 362-368, 2011.
Medical*Online
8) Bates MG, et al : Mitochondrial respiratory chain disease in children undergoing cardiac transplantation : a prospective study. Int J Cardiol 155 : 305-306, 2012.
PubMed
9) Florian A, et al : Characteristic cardiac phenotypes are detected by cardiovascular magnetic resonance in patients with different clinical phenotypes and genotypes of mitochondrial myopathy. J Cardiovasc Magn Reson 17 : 40, 2015.
PubMed
10) 村山圭, ほか : ミトコンドリア病 診療マニュアル 2017 (日本ミトコンドリア学会編), p67-80, 診断と治療社, 2016.
 
11) Nakao S, et al : An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 333 : 288-293, 1995.
PubMed
12) 日本循環器学会, ほか : 日本循環器学会/日本心不全学会合同ガイドライン. 心筋症診療ガイドライン (2018年改訂版), 2019.
 
13) Agnetti G, et al : Modulation of mitochondrial proteome and improved mitochondrial function by biventricular pacing of dyssynchronous failing hearts. Circ Cardiovasc Genet 3 : 78-87, 2010.
PubMed
P.251 掲載の参考文献
1) Richardson P, et al : Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 93 : 841-842, 1996.
PubMed
2) 日本循環器学会, ほか : 日本循環器学会/日本心不全学会合同ガイドライン. 心筋症診療ガイドライン (2018年改訂版), 2019.
 
3) Klein I, Ojamaa K : Thyroid hormone and the cardiovascular system. N Engl J Med 344 : 501-509, 2001.
PubMed
4) Feller M, et al : Association of Thyroid Hormone Therapy With Quality of Life and Thyroid-Related Symptoms in Patients With Subclinical Hypothyroidism : A Systematic Review and Meta-analysis. JAMA 320 : 1349-1359, 2018.
PubMed
5) Berg C, et al : Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly : comparison with matched data from the general population and the effect of disease control. J Clin Endocrinol Metab 95 : 3648-3656, 2010.
PubMed
6) Clayton RN : Cardiovascular function in acromegaly. Endocr Rev 24 : 272-277, 2003.
PubMed
7) Bando YK, Murohara T : Diabetes-related heart failure. Circ J 78 : 576-583, 2014.
PubMed
8) Jia G, et al : Diabetic Cardiomyopathy : An Update of Mechanisms Contributing to This Clinical Entity. Circ Res 122 : 624-638, 2018.
PubMed
9) Falk RH : Cardiac amyloidosis : a treatable disease, often overlooked. Circulation 124 : 1079-1085, 2011.
PubMed
10) Maurer MS, et al : Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med 379 : 1007-1016, 2018.
PubMed
11) Nakao S, et al : An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 333 : 288-293, 1995.
PubMed
12) Elliott P, et al : Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy : the European Anderson-Fabry Disease survey. Heart 97 : 1957-1960, 2011.
PubMed
13) Murphy CJ, Oudit GY : Iron-overload cardiomyopathy : pathophysiology, diagnosis, and treatment. J Card Fail 16 : 888-900, 2010.
PubMed
14) van der Ploeg AT, et al : A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med 362 : 1396-1406, 2010.
PubMed
15) Kakkis ED, et al : Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 344 : 182-188, 2001.
PubMed
P.256 掲載の参考文献
1) MacDonald MR, et al : Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure : an analysis of the Candesartan in Heart failure : Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 29 : 1377-1385, 2008.
PubMed
2) McMurray JJ, et al : Heart failure : a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol 2 : 843-851, 2014.
PubMed
3) Kristensen SL, et al : Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction : A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation 135 : 724-735, 2017.
PubMed
4) Zinman B, et al : Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 373 : 2117-2128, 2015.
PubMed
5) Seferovic PM, et al : Type 2 diabetes mellitus and heart failure : a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 20 : 853-872, 2018.
 
6) Maack C, et al : Heart failure and diabetes : metabolic alterations and therapeutic interventions : a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. Eur Heart J 39 : 4243-4254, 2018.
 
7) Liu CY, et al : Myocardial steatosis and its association with obesity and regional ventricular dysfunction : evaluated by magnetic resonance tagging and IH spectroscopy in healthy African Americans. Int J Cardiol 172 : 381-387, 2014.
 
8) Cimen I, et al : Prevention of atherosclerosis by bioactive palmitoleate through suppression of organelle stress and inflammasome activation. Sci Transl Med 8 : 358ra126, 2016.
PubMed
9) Abel ED, et al : Insulin resistance : metabolic mechanisms and consequences in the heart. Arterioscler Thromb Vasc Biol 32 : 2068-2076, 2012.
PubMed
10) He C, et al : Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis. Nature 481 : 511-515, 2012.
PubMed
11) Tong M, et al : Mitophagy Is Essential for Maintaining Cardiac Function During High Fat Diet-Induced Diabetic Cardiomyopathy. Circ Res 124 : 1360-1371, 2019.
PubMed
12) Jia G, et al : Diabetic Cardiomyopathy : An Update of Mechanisms Contributing to This Clinical Entity. Circ Res 122 : 624-638, 2018.
PubMed
13) Multhaup ML, et al : Mouse-human experimental epigenetic analysis unmasks dietary targets and genetic liability for diabetic phenotypes. Cell Metab 21 : 138-149, 2015,
PubMed
14) Feinberg AP : The Key Role of Epigenetics in Human Disease Prevention and Mitigation. N Engl J Med 378 : 1323-1334, 2018.
PubMed
P.261 掲載の参考文献
1) Wang X, Shapiro JI : Evolving concepts in the pathogenesis of uraemic cardiomyopathy. Nat Rev Nephrol 15 : 159-175, 2019.
PubMed
2) Imai E, et al : Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol 13 : 621-630, 2009.
PubMed
3) 日本透析医学会 : 図説 わが国の慢性透析療法の現況 (2016年12月31日現在), 2017.
 
4) UNITED STATES RENAL DATA SYSTEM (USRDS). End-stage Renal Disease (ESRD) in the United States, CHAPTER 5 : Mortality, 2018.
 
5) Mark PB, et al : Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney Int 69 : 1839-1845, 2006.
PubMed
6) Park M, et al : Associations between kidney function and subclinical cardiac abnormalities in CKD. J Am Soc Nephrol 23 : 1725-1734, 2012.
PubMed
7) Obokata M, et al : Incremental Prognostic Value of Ventricular-Arterial Coupling over Ejection Fraction in Patients with Maintenance Hemodialysis. J Am Soc Echocardiogr 30 : 444-453. e2, 2017.
 
8) Obokata M, et al : Echocardiography-based pressure-volume loop assessment in the evaluation for the effects of indoxyl sulfate on cardiovascular function. J Echocardiogr, 17 : 35-43, 2019.
PubMed
9) Kahn MR, et al : Management of cardiovascular disease in patients with kidney disease. Nat Rev Cardiol 10 : 261-273, 2013.
PubMed
10) Obokata M, et al : Comparison of different interdialytic intervals among hemodialysis patients on their echocardiogram-based cardiovascular parameters. Am Heart J 169 : 523-530. e2, 2015.
 
11) Lang RM, et al : Recommendations for cardiac chamber quantification by echocardiography in adults : an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 16 : 233-270, 2015.
PubMed
12) Nagueh SF, et al : Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography : An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 29 : 277-314, 2016.
PubMed
13) Obokata M, et al : Role of Diastolic Stress Testing in the Evaluation for Heart Failure With Preserved Ejection Fraction : A Simultaneous Invasive-Echocardiographic Study. Circulation 135 : 825-838, 2017.
PubMed
14) Kramann R, et al : Speckle tracking echocardiography detects uremic cardiomyopathy early and predicts cardiovascular mortality in ESRD. J Am Soc Nephrol 25 : 2351-2365, 2014.
PubMed
15) Hassanin N, Alkemary A : Early Detection of Subclinical Uremic Cardiomyopathy Using Two-Dimensional Speckle Tracking Echocardiography. Echocardiography 33 : 527-536. 2016.
PubMed
16) Stewart GA, et al : Echocardiography overestimates left ventricular mass in hemodialysis patients relative to magnetic resonance imaging. Kidney Int 56 : 2248-2253, 1999.
PubMed
17) Edwards NC, et al : Defining the natural history of uremic cardiomyopathy in chronic kidney disease : the roie of cardiovascular magnetic resonance. JACC Cardiovasc Imaging 7 : 703-714, 2014.
 
18) 日本腎臓学会 (編) : エビデンスに基づくCKD診療ガイドライン 2018, 東京医学社, 2018.
 
19) Culleton BF, et al : Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life : a randomized controlled trial. JAMA 298 : 1291-1299, 2007.
PubMed
20) FHN Trial Group, et al : In-center hemodialysis six times per week versus three times per week. N Engl J Med 363 : 2287-2300, 2010.
PubMed
P.265 掲載の参考文献
1) 山田章吾, ほか : 食道表在癌に対する標準的放射線治療法. 日本放射線腫瘍学会誌 12 : 169-176, 2000.
 
2) Ishikura S, et al : Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol 21 : 2697-2702, 2003.
PubMed
3) Jingu K, et al : [A case of high FDG-uptake into the myocardium after radiotherapy for esophageal cancer]. Nihon Igaku Hoshasen Gakkai Zasshi 65 : 266-269, 2005.
PubMed
4) Gladstone DJ, et al : Radiation-induced cardiomyopathy as a function of radiation beam gating to the cardiac cycle. Phys Med Biol 49 : 1475-1484, 2004.
 
5) Weintraub NL, et al : Understanding radiation-induced vascular disease. J Am Coll Cardiol 55 : 1237-1239, 2010.
PubMed
6) Umezawa R, et al : Evaluation of radiation-induced myocardial damage using iodine-123 β-methyl-iodophenyl pentadecanoic acid scintigraphy. J Radiat Res 54 : 880-889, 2013.
 
7) Gyenes G, et al : Long-term cardiac morbidity and mortality in a randomized trial of pre- and postoperative radiation therapy versus surgery alone in prirnary breast cancer. Radiother Oncol 48 : 185-190, 1998.
 
8) Taylor C, et al : Estimating the Risks of Breast Cancer Radiotherapy : Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. J Clin Oncol 35 : 1641-1649, 2017.
 
9) Kim DY, et al. Cardiovascular outcome of breast cancer patients with concomitant radiotherapy and chemotherapy : A 10-year multicenter cohort study. J Cardiol 74 : 175-181, 2019.
PubMed
10) Chang JS, et al : Risk of cardiac disease after adjuvant radiation therapy among breast cancer survivors. Breast 43 : 48-54, 2019.
PubMed
11) Pierce LJ, et al : Recent Time Trends and Predictors of Heart Dose From Breast Radiation Therapy in a Large Quality Consortium of Radiation Oncology Practices. Int J Radiat Oncol Biol Phys 99 : 1154-1161, 2017.
 
12) Jingu K, et al : Temporal change in brain natriuretic Peptide after radiotherapy for thoracic esophageal cancer. Int J Radiat Oncol Biol Phys 69 : 1417-1423, 2007.
PubMed
13) Palumbo I, et al : Brain natriuretic peptide as a cardiac marker of transient radiotherapy-related damage in left-sided breast cancer patients : A prospective study. Breast 25 : 45-50, 2016.
PubMed
14) Jingu K, et al : Radiation-induced heart disease after treatment for esophageal cancer. Esophagus 14 : 215-220, 2017.
 
P.269 掲載の参考文献
1) Wilkoff BL, et al : Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator : the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA 288 : 3115-3123, 2002.
 
2) Sweeney MO, et al : Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation 107 : 2932-2937, 2003.
 
3) Sharma AD, et al : Percent right ventricular pacing predicts outcomes in the DAVID trial. Heart Rhythm 2 : 830-834, 2005.
PubMed
4) Khurshid S, et al : Incidence and predictors of right ventricular pacing-induced cardiomyopathy. Heart Rhythm 11 : 1619-1625, 2014.
PubMed
5) Kim JH, et al : Major determinant of the occurrence of pacing-induced cardiomyopathy in complete atrioventricular block : a multicentre, retrospective analysis over a 15-year period in South Korea. BMJ Open 8 : e019048, 2018.
 
6) Yu CM, et al : Biventricular pacing in patients with bradycardia and normal ejection fraction. N Engl J Med 361 : 2123-2134, 2009.
PubMed
7) Yu CM, et al : Long-term follow-up results of the pacing to avoid cardiac enlargement (PACE) trial. Eur J Heart Fail 16 : 1016-1025, 2014.
PubMed
8) Lee SA, et al : Paced QRS duration and myocardial scar amount : predictors of long-term outcome of right ventricular apical pacing. Heart Vessels 31 : 1131-1139, 2016.
PubMed
9) Nahlawi M, et al : Left ventricular function during and after right ventricular pacing. J Am Coll Cardiol 44 : 1883-1888, 2004.
PubMed
10) Khurshid S, et al : Longer Paced QRS Duration is Associated With Increased Prevalence of Right Ventricular Pacing-Induced Cardiomyopathy. J Cardiovasc Electrophysiol 27 : 1174-1179, 2016.
PubMed
11) Kiehl EL, et al : Incidence and predictors of right ventricular pacing-induced cardiomyopathy in patients with complete atrioventricular block and preserved left ventricular systolic function. Heart Rhythm 13 : 2272-2278, 2016.
PubMed
12) Shimony A, et al : Beneficial effects of right ventricular non-apical vs. apical pacing : a systematic review and meta-analysis of randomized-controlled trials. Europace 14 : 81-91, 2012.
PubMed
13) Kaye GC, et al : Effect of right ventricular pacing lead site on left ventricular function in patients with high-grade atrioventricular block : results of the Protect-Pace study. Eur Heart J 36 : 856-862, 2015.
PubMed
14) Shurrab M, et al : Reduction in unnecessary ventricular pacing fails to affect hard clinical outcomes in patients with preserved left ventricular function : a meta-analysis. Europace 19 : 282-288, 2017.
 
15) Curtis AB, et al : Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med 368 : 1585-1593, 2013.
PubMed
P.274 掲載の参考文献
1) Richardson P, et al : Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 93 : 841-842, 1996.
PubMed
2) Elliott P, et al : Classification of the cardiomyopathies : a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 29 : 270-276, 2008.
 
3) Kostareva A, et al : Genetic Spectrum of Idiopathic Restrictive Cardiomyopathy Uncovered by Next-Generation Sequencing. PLoS ONE 11 : e0163362, 2016.
PubMed
4) Carroll JD, et al : Amyloid cardiomyopathy : characterization by a distinctive voltage/mass relation. Am J Cardiol 49 : 9-13, 1982.
PubMed
5) Reddy PR, et al : Utility of BNP in differentiating constrictive pericarditis from restrictive cardiomyopathy in patients with renal insufficiency. J Card Fail 13 : 668-671, 2007.
PubMed
6) Butz T, et al : Diagnostic superiority of a combined assessment of the systolic and early diastolic mitral annular velocities by tissue Doppler imaging for the differentiation of restrictive cardiomyopathy from constrictive pericarditis. Clin Res Cardiol 99 : 207-215, 2010.
PubMed
7) Mahmoud A, et al : New Cardiac Imaging Algorithms to Diagnose Constrictive Pericarditis Versus Restrictive Cardiomyopathy. Curr Cardiol Rep 19 : 43, 2017.
 
8) Ammash NM, et al : Clinical profile and outcome of idiopathic restrictive cardiomyopathy. Circulation 101 : 2490-2496, 2000.
PubMed
P.279 掲載の参考文献
1) Maron BJ, et al : Contemporary definitions and classification of the cardiomyopathies : an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee ; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups ; and Council on Epidemiology and Prevention. Circulation 113 : 1807-1816, 2006.
PubMed
2) Chin TK, et al : Isolated noncompaction of left ventricular myocardium. A study of eight cases. Circulation 82 : 507-513, 1990.
PubMed
3) Ichida F, et al : Clinical features of isolated noncompaction of the ventricular myocardium : long-term clinical course, hemodynamic properties, and genetic background. J Am Coll Cardiol 34 : 233-240, 1999.
PubMed
4) Oechslin EN, et al : Long-term follow-up of 34 adu1ts with isolated left ventricular noncompaction : a distinct cardiomyopathy with poor prognosis. J Am Coll Cardiol 36 : 493-500, 2000.
 
5) Mitani Y, et al : Circurnstances and outcomes of out-of-hospital cardiac arrest in elementary and middle school students in the era of public-access defibrillation. Circ J 78 : 701-707, 2014.
PubMed
6) Nomura Y, et al : A novel MYH7 gene mutation in a fetus with left ventricular noncompaction. Can J Cardiol 31 : 103. e1-3, 2015.
 
7) Gati S, et al : Adult left ventricular noncompaction : reappraisal of current diagnostic imaging modalities. JACC Cardiovasc Imaging 7 : 1266-1275, 2014.
PubMed
8) Wang C, et al : A Wide and Specific Spectrum of Genetic Variants and Genotype-Phenotype Correlations Revealed by Next-Generation Sequencing in Patients with Left Ventricular Noncompaction. J Am Heart Assoc 6. pii : e006210, 2017.
 
9) Jefferies JL, et al : Cardiomyopathy Phenotypes and Outcomes for Children With Left Ventricular Myocardial Noncompaction : Results From the Pediatric Cardiomyopathy Registry. J Card Fail 21 : 877-884, 2015.
PubMed
10) Ichida F : Left ventricular noncompaction. Circ J 73 : 19-26, 2009.
 
11) Kohli SK, et al : Diagnosis of left-ventricular non-compaction in patients with left-ventricular systolic dysfunction : time for a reappraisal of diagnostic criteria? Eur Heart J 29 : 89-95, 2008.
PubMed
12) Wang C, et al : Long-Term Prognosis of Patients With Left Ventricular Noncompaction-Comparison Between Infantile and Juvenile Types. Circ J 81 : 694-700, 2017.
 
13) Cetin MS, et al : Usefulness of Fragmented QRS Complex to Predict Arrhythmic Events and Cardiovascular Mortality in Patients With Noncompaction Cardiomyopathy. Am J Cardiol 117 : 1516-1523, 2016.
PubMed
14) Ichida F, et al : Novel gene mutations in patients with left ventricular noncompaction or Barth syndrome. Circulation 103 : 1256-1263, 2001.
 
15) Hirono K, et al : Clinical and Echocardiographic Impact of Tafazzin Variants on Dilated Cardiomyopathy Phenotype in Left Ventricular Non-Compaction Patients in Early Infancy. Circ J 82 : 2609-2618, 2018.
PubMed
16) Saito K, et al : Successful cardiac resynchronization therapy in a 3-year-old girl with isolated left ventricular non-compaction and narrow QRS complex : acase report. Circ J 73 : 2173-2177, 2009.
 
P.283 掲載の参考文献
1) 日本循環器学会 : 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告). 急性および慢性心筋炎の診断・治療に関するガイドライン (2009年改訂版), 2009. [http://www.j-circ.or.jp/guideline/pdf/JCS2009_izumi_h.pdf] (2019年6月閲覧)
 
2) Caforio ALP, et al : Myocarditis : A Clinical Overview. Curr Cardiol Rep 19 : 63, 2017.
 
3) Faber V, Fischer S : Acute idiopathic myocarditis. Acta Med Scand 154 : 135-138, 1956.
PubMed
4) Take M, et al : Early clinical profiles of cases with histopathologically proven acute idiopathic myocarditis and a proposal for diagnostic criteria. Jpn Circ J 45 : 1415-1420, 1981.
 
5) Pankuweit S, et al : Prevalence of the parvovirus B19 genome in endomyocardial biopsy specimens. Hum Pathol 34 : 497-503, 2003.
PubMed
6) Caforio AL, et al : Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis : a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34 : 2636-2648, 2648a-2648d, 2013.
 
7) Montera MW, et al : I Brazilian guidelines on myocarditis and pericarditis. Arq Bras Cardiol 100 (4 Suppl 1) : 1-36, 2013.
 
8) Kindermann I, et al : Update on myocarditis. J Am Coll Cardiol 59 : 779-792, 2012.
PubMed
9) Yamaguchi S, et al : Late-Onset Fulminant Myocarditis With Immune Checkpoint Inhibitor Nivolumab. Can J Cardiol 34 : 812. e1-812. e3, 2018.
 
10) 日本循環器学会 : 2016年版 心臓サルコイドーシスの診療ガイドライン, 2016. [http://www.j-circ.or.jp/guideline/pdf/JCS2016_terasaki_h.pdf (2019年6月閲覧)]
 
11) Lee CC, et al : Dobutamine-induced fever and isolated eosinophilic myocarditis in a 66-year-old male awaiting heart transplantation : a case report. Transplant Proc 46 : 2464-2466, 2014.
 
12) Ammirati E, et al : Survival and Left Ventricular Function Changes in Fulminant Versus Nonfulminant Acute Myocarditis. Circulation 136 : 529-545, 2017.
PubMed
13) Sawamura A, et al : Prognostic Value of Electrocardiography in Patients With Fulminant Myocarditis Supported by Percutaneous Venoarterial Extracorporeal Membrane Oxygenation-Analysis From the CHANGE PUMP Study. Circ J 82 : 2089-2095, 2018.
PubMed
14) Kondo T, et al : Promising method for management of venoarterial extracorporeal membrane oxygenation : A case of severe heart failure successfully stabilized by "high-flow/vasodilation method". J Cardiol Cases 18 : 81-84, 2018.
 
15) Spillmann F, et al : Mode-of-action of the PROPELLA concept in fulminant myocarditis. Eur Heart J 40 : 2164-2169, 2019.
PubMed
16) 日本循環器学会 : 日本循環器学会/日本心不全学会合同ガイドライン. 急性・慢性心不全診療ガイドライン (2017年改訂版), 2018. [http://www.j-circ.or.jp/guideline/pdf/JCS2017_tsutsui_h.pdf] (2019年6月閲覧)
 
17) van Diepen S, et al : Contemporary Management of Cardiogenic Shock : A Scientific Statement From the American Heart Association. Circulation 136 : e232-e268, 2017.
PubMed
18) Schultheiss HP, et al : The management of myocarditis. Eur Heart J 32 : 2616-2625, 2011.
PubMed
19) Frustaci A, Chimenti C : Immunosuppressive therapy in myocarditis. Circ J 79 : 4-7, 2015.
PubMed
20) Brambatti M, et al : Eosinophilic Myocarditis : Characteristics, Treatment, and Outcomes. J Am Coll Cardiol 70 : 2363-2375, 2017.
PubMed
21) Luyt CE, et al : What's new in myocarditis? Intensive Care Med 42 : 1055-1057, 2016.
 
22) Heymans S, et al : The Quest for New Approaches in Myocarditis and Inflammatory Cardiomyopathy. J Am Coll Cardiol 68 : 2348-2364, 2016.
PubMed
23) Veronese G, et al : Fulminant myocarditis : Characteristics, treatment, and outcomes. Anatol J Cardiol 19 : 279-286, 2018.
 
24) Samuelsson A, et al : Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291 : 484-486, 2001.
PubMed
25) Kato S, et al : Successful high-dose intravenous immunoglobulin therapy for a patient with fulminant myocarditis. Heart Vessels 22 : 48-51, 2007.
PubMed
P.289 掲載の参考文献
1) 日本循環器学会, ほか : 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告). 急性および慢性心筋炎の診断・治療に関するガイドライン (2009年改訂版), 2009. [http://www.j-circ.or.jp/guideline/pdf/JCS2009_izumi_h.pdf] (2019年7月閲覧)
 
2) 岡田了三, ほか : 心筋生検によるウイルス性ないし特発性心筋炎の病理診断基準. 厚生省特発性心筋症調査研究班, 昭和63年度研究報告集, p181-183, 1989.
 
3) 河村慧四郎, ほか ; 病因分科会 : ウイルス性あるいは特発性心筋炎に関する全国アンケート調査. 厚生省特定疾患特発性心筋症調査研究班, 昭和60年度研究報告集, p23-36, 1986.
 
4) Katano H, et al : A novel real-time PCR system for simultaneous detection of human viruses in clinical samples from patients with uncertain diagnoses. J Med Virol 83 : 322-330, 2011.
PubMed
5) Kotani O, et al : Establishment of a panel of in-house polyclonal antibodies for the diagnosis of enterovirus infections. Neuropathology 35 : 107-121, 2015.
PubMed
P.292 掲載の参考文献
1) 日本循環器学会, ほか : 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告). 急性および慢性心筋炎の診断・治療に関するガイドライン (2009年改訂版), 2009.
 
2) Caforio ALP, et al : Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis : a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34 : 2636-2648, 2648a-2648d, 2013.
 
3) 診断モダリティとしての心筋病理 (心筋生検研究会編), p78-93, 南江堂, 2017.
 
4) Caforio ALP, et al : Clinical presentation and diagnosis of myocarditis. Heart 101 : 1332-1344, 2015.
PubMed
5) Mahfoud F, et al : Virus serology in patients with suspected myocarditis : utility or futility? Eur Heart J 32 : 897-903, 2011.
PubMed
6) Fung G, et al : Myocarditis. Circ Res 118 : 496-514, 2016.
PubMed
7) Leone O, et al : 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol 21 : 245-274, 2012.
 
P.298 掲載の参考文献
1) Carapetis JR, et al : Acute rheumatic fever. Lancet 366 : 155-168, 2005.
PubMed
2) Gordis L : The virtual disappearance of rheumatic fever in the United States : lessons in the rise and fall of disease. T. Duckett Jones memorial lecture. Circulation 72 : 1155-1162, 1985.
 
3) Markowitz M : The decline of rheumatic fever : role of medical intervention. Lewis W. Wannamaker Memorial Lecture. J Pediatr 106 : 545-550, 1985.
 
4) 市田蕗子, ほか : 平成21年度稀少疾患サーベイランス調査結果. 日本小児循環器学会雑誌 26 : 348-350, 2010.
 
5) Carapetis JR, et al : Acute rheumatic fever and rheumatic heart disease. Nat Rev Dis Primers 2 : 15084, 2016.
PubMed
6) Gewitz MH, et al : Revision of the Jones Criteria for the diagnosis of acute rheumatic fever in the era of Doppler echocardiography : a scientific statement from the American Heart Association. Circulation 131 : 1806-1818, 2015.
 
7) Seckeler MD, Hoke TR : The worldwide epidemiology of acute rheumatic fever and rheumatic heart disease. Clin Epidemiol 3 : 67-84, 2011.
PubMed
8) Marijon E, et al : Rheumatic heart disease. Lancet 379 : 953-964, 2012.
PubMed
9) Oba Y, et al : A Case of Adult-Onset Acute Rheumatic Fever With Long-Lasting Atrioventricular Block Requiring Permanent Pacemaker Implantation. Int Heart J 56 : 664-667, 2015.
PubMed
10) Gerber MA, et al : Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis : a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research : endorsed by the American Academy of Pediatrics. Circulation 119 : 1541-1551, 2009.
 
11) Albert DA, et al : The treatment of rheumatic carditis : a review and meta-analysis. Medicine (Baltimore) 74 : 1-12, 1995.
PubMed
12) Cilliers A, et al : Anti-inflammatory treatment for carditis in acute rheumatic fever. Cochrane Database Syst Rev (5) : CC003176, 2015.
PubMed
P.302 掲載の参考文献
1) Sanchez-Vargas FM, Gomez-Duarte OG : Mycoplasma pneumoniae-an emerging extrapulmonary pathogen. Clin Microbiol Infect 14 : 105-115, 2008.
PubMed
2) Paz A, Potasman I. : Mycoplasma-associated carditis. Case reports and review. Cardiology 97 : 83-88, 2002.
PubMed
3) 井上林太郎, ほか : 急性心膜心筋炎および急性腎炎を併発したマイコプラズマ肺炎の一例. 感染症学雑誌 57 : 333-338, 1983.
 
4) 東京都感染症情報センター : 東京都感染症マニュアル 2018. (14) マイコプラズマ肺炎, p318-319. [http://idsc.tokyo-eiken.go.jp/assets/survey/kobetsu/j2023.pdf] (2019年6月閲覧)
 
5) Takahashi T, et al : Prolonged Mycoplasma pneumoniae infection in an elderly patient with community-acquired pneumonia. J Infect Chemother 15 : 243-247, 2009.
 
6) Takei T, et al : Clinical features of Mycoplasma pneumoniae infections in the 2010 epidemic season : report of two cases with unusual presentations. Pediatr Neonatol 54 : 402-405, 2013.
PubMed
7) 泉幸雄 : 小児の感染性心内膜炎・心筋炎・心膜炎の実態調査成績. 感染症学雑誌 58 : 400-407, 1984.
 
8) Levy PY, et al : Etiologic diagnosis of 204 pericardial effusions. Medicine (Baltimore) 82 : 385-391, 2003.
PubMed
9) Hofner G, et al : [Intrapericardial hemorrhage as a manifestation of mycoplasrna pneumoniae infection]. Z Kardiol 86 : 423-426, 1997.
PubMed
10) Szymanski M, et al : Mycoplasma pneumoniae pericarditis demonstrated by polymerase chain reaction and electron microscopy. Clin Infect Dis 34 : E16-17, 2002.
PubMed
11) Hawkins S, et al : Constrictive pericarditis secondary to infection with Mycoplasma pneumoniae. Curr Opin Pediatr 23 : 126-129, 2011.
PubMed
12) 中村豪, ほか : マイコプラズマ心筋炎の1例. 心臓 13 : 1394-1400, 1981.
 
13) 日本循環器学会, ほか : 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告). 急性および慢性心筋炎の診断・治療に関するガイドライン (2009年改訂版). I 急性心筋炎の分類と診断・治療, p3-4, 2009. [http://www.j-circ.or.jp/guideline/pdf/JCS2009_izumi_h.pdf] (2019年6月閲覧)
 
14) Zhou Y, et al : More complications occur in macrolide-resistant than in macrolide-sensitive Mycoplasma pneumoniae pneumonia. Antimicrob Agents Chemother 58 : 1034-1038, 2014.
PubMed
15) Vijay A, et al : Mycoplasma pneumoniae pericarditis. Am J Cardiol 123 : 1383-1384, 2019.
PubMed
P.306 掲載の参考文献
1) 荒川創一, ほか : 梅毒診療ガイド, 日本性感染症学会梅毒委員会梅毒診療ガイド作成小委員会, 2018.
 
2) Girardi LN : Syphilitic aortitis : The bigger picture. J Thorac Cardiovasc Surg 154 : e27-e28, 2017.
PubMed
3) Silvestri V, et al : Many Different Patterns under a Common Flag : Aortic Pathology in HIV-A Review of Case Reports in Literature. Ann Vasc Surg, 2019. [Epub ahead of print]
 
4) Golden MR, et al : Update on syphilis : resurgence of an old problem. JAMA 290 : 1510-1514, 2003.
PubMed
5) Chino M, et al : Ruptured ventricular aneurysm in secondary syphilis. Lancet 342 : 935-936, 1993.
PubMed
6) Maleszewski JJ : Inflammatory ascending aortic disease : Perspectives from pathology. J Thorac Cardiovasc Surg 149 (2 Suppl) : S176-Sl83, 2015.
 
7) Roberts WC, et al : Syphilis as a Cause of Thoracic Aortic Aneurysm. Am J Cardiol 116 : 1298-1303, 2015.
PubMed
8) Roberts WC, et al : Natural history of syphilitic aortitis. Am J Cardiol 104 : 1578-1587, 2009.
PubMed
9) Del Re F, et al : Syphilitic Aortic Aneurysm in the Third Millennium. Aorta (Stamford) 6 : 118-119, 2018.
PubMed
P.311 掲載の参考文献
1) 日本循環器学会, ほか : 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告 : 班長和泉徹), 急性および慢性心筋炎の診断・治療に関するガイドライン (2009年改訂版), 2009. [http://www.j-circ.or.jp/guideline/pdf/JCS2009_izumi_h.pdf] (2019年6月閲覧)
 
2) Cooper LT, et al : Idiopathic giant-cell myocarditis-natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N Engl J Med 336 : 1860-1866, 1997.
 
3) Cooper LT, et al : Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol 102 : 1535-1539, 2008.
PubMed
4) Okura Y, et al : A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis. J Am Coll Cardiol 41 : 322-329, 2003.
PubMed
5) Blauwet LA, Cooper LT : Idiopathic giant cell myocarditis and cardiac sarcoidosis. Heart Fail Rev 18 : 733-746, 2013.
PubMed
6) Davidoff R, et al : Giant cell versus lymphocytic myocarditis. A comparison of their clinical features and long-term outcomes. Circulation 83 : 953-961, 1991.
PubMed
7) Kodama M, et al : Early and long-term mortality of the clinical subtypes of myocarditis. Jpn Circ J 65 : 961-964, 2001.
PubMed
8) Ammirati E, et al : Survival and Left Ventricular Function Changes in Fulminant Versus Nonfulminant Acute Myocarditis. Circulation 136 : 529-545, 2017.
PubMed
9) Shields RC, et al : The role of right ventricular endomyocardial biopsy for idiopathic giant cell myocarditis. J Card Fail 8 : 74-78, 2002.
PubMed
10) Kandolin R, et al : Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression. Circ Heart Fail 6 : 15-22, 2013.
PubMed
11) Montero S, et al : Fulminant giant-cell myocarditis on mechanical circulatory support : Management and outcomes of a French multicentre cohort. Int J Cardiol 253 : 105-112, 2018.
PubMed
12) Ekstrom K, et al : Long-term outcome and its predictors in giant cell myocarditis. Eur J Heart Fail 18 : 1452-1458, 2016.
PubMed
13) Maleszewski JJ, et al : Long-term risk of recurrence, morbidity and mortality in giant cell myocarditis. Am J Cardiol 115 : 1733-1738, 2015.
PubMed
P.315 掲載の参考文献
1) 日本循環器学会 : 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告, 班長 : 和泉徹). 急性および慢性心筋炎の診断・治療に関するガイドライン (2009年改訂版), 2009. [http://www.j-circ.or.jp/guideline/pdf/JCS2009_izumi_h.pdf] (2019年6月閲覧)
 
2) Brambatti M, et al : Eosinophilic Myocarditis : Characteristics, Treatment, and Outcomes. J Am Coll Cardiol 70 : 2363-2375, 2017.
PubMed
3) 吉澤佐恵子, ほか : 過敏性心筋炎の病態と病理. 東京女子医科大学雑誌 84 (臨時増刊 2号) : E250-E256, 2014.
 
4) 大郷恵子, ほか : 救命しえた劇症型好酸球性心筋炎の1例. 心臓 39 (Suppl 3) : 112-117, 2007.
 
5) Tai PC, et al : Deposits of eosinophil granule proteins in cardiac tissues of patients with eosinophilic endomyocardial disease. Lancet 1 : 643-647, 1987.
PubMed
6) Kontani M, et al : Survival after acute necrotizing eosinophilic myocarditis complicating a massive left ventricular mural thrombus : a case report. J Cardiol 50 : 127-133, 2007.
PubMed
7) Morimoto S, et al : Changes in the peripheral eosinophil count in patients with acute eosinophilic myocarditis. Heart Vessels 18 : 193-196, 2003.
PubMed
8) Fozing T, et al : Management of a patient with eosinophilic myocarditis and normal peripheral eosinophil count : case report and literature review. Circ Heart Fail 7 : 692-694, 2014.
PubMed
9) Arima M, et al : Serum levels of eosinophil cationic protein in patients with eosinophilic myocarditis. Int J Cardiol 84 : 97-99, 2002.
PubMed
10) 猪又孝元 : 好酸球性心筋炎. 診断と治療 103 : 677-680, 2015.
Medical*Online
11) Watanabe N, et al : Acute necrotizing eosinophilic myocarditis successfully treated by high dose methylprednisolone. Jpn Circ J 65 : 923-926, 2001.
PubMed
12) 鈴木佑一, ほか : 心筋障害残存の有無からみた好酸球性心筋炎の2症例の対比. 心臓 49 : 1031-1038, 2017.
Medical*Online
13) Yanagisawa T, et al : Clinical significance of corticosteroid therapy for eosinophilic myocarditis. Int Heart J 52 : 110-113, 2011.
PubMed
P.321 掲載の参考文献
1) Fiedler A : Ueber akute interstitielle Myokarditis. In : Festschrift zur Feier des funfzigjahrige Bestehens des Stadtkrankenhauses zu Dresden-Friedrichstadt, part 2, p3-24, Baensch, Dresden, 1899.
 
2) Veronese G, et al : Fulminant myocarditis : Characteristics, treatment, and outcomes. Anatol J Cardiol 19 : 279-286, 2018.
 
3) Lieberman EB, et al : Clinicopathologic description of myocarditis. J Am Coll Cardiol 18 : 1617-1626, 1991.
PubMed
4) Ginsberg F, Parrillo JE : Fulminant myocarditis. Crit Care Clin 29 : 465-483, 2013.
PubMed
5) Ammirati E, et al : Survival and Left Ventricular Function Changes in Fulminant Versus Nonfulminant Acute Myocarditis. Circulation 136 : 529-545, 2017.
PubMed
6) 日本循環器学会 : 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告). 急性および慢性心筋炎の診断・治療に関するガイドライン (2009年改訂版), 2009. [http://www.j-circ.or.jp/guideline/pdf/JCS2009_izumi_h.pdf] (2019年6月閲覧)
 
7) McCarthy RE 3rd, et al : Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 342 : 690-695, 2000.
PubMed
8) Chang JJ, et al : Heart Failure and Mortality of Adult Survivors from Acute Myocarditis Requiring Intensive Care Treatment-A Nationwide Cohort Study. Int J Med Sci 14 : 1241-1250, 2017.
PubMed
9) Sawamura A, et al : Early Prediction Model for Successful Bridge to Recovery in Patients With Fulminant Myocarditis Supported With Percutaneous Venoarterial Extracorporeal Membrane Oxygenation-Insights From the CHANGE PUMP Study. Circ J 82 : 699-707, 2018.
PubMed
10) Sawamura A, et al : Prognostic Value of Electrocardiography in Patients With Fulminant Myocarditis Supported by Percutaneous Venoarterial Extracorporeal Membrane Oxygenation-Analysis From the CHANGE PUMP Study. Circ J 82 : 2089-2095, 2018.
PubMed
11) 心筋生検研究会 (編) : 診断モダリティとしての心筋病理, p78-93, 南江堂, 2017.
 
12) Aoyama N, et al : National survey of fulminant myocarditis in Japan : therapeutic guidelines and long-term prognosis of using percutaneous cardiopulmonary support for fulminant myocarditis (special report from a scientific committee). Circ J 66 : 133-144, 2002.
PubMed
13) Kato S, et al : Risk factors for patients developing a fulminant course with acute myocarditis. Circ J 68 : 734-739, 2004.
PubMed
14) Chen YS, et al : Experience and result of extracorporeal membrane oxygenation in treating fulminant myocarditis with shock : what mechanical support should be considered first? J Heart Lung Transplant 24 : 81-87, 2005.
 
15) Hiramitsu S. et al : Significance of transient left ventricular wall thickening in acute lymphocytic myocarditis. Heart Vessels 22 : 25-29, 2007.
PubMed
16) Kondo T, et al : Hemodynamics of cardiac tamponade during extracorporeal membrane oxygenation support in a patient with fulminant myocarditis. J Cardiol Cases 19 : 22-24, 2019.
 
17) Kondo T, et al : Promising method for management of venoarterial extracorporeal membrane oxygenation : A case of severe heart failure stlccessfully stabilized by "high-flow/vasodilation method". J Cardiol Cases 18 : 81-84, 2018.
 
18) Schultheiss HP, et al : The management of myocarditis. Eur Heart J 32 : 2616-2625, 2011.
PubMed
19) Frustaci A, Chimenti C : Immunosuppressive therapy in myocarditis. Circ J 79 : 4-7, 2015.
PubMed
20) Brambatti M, et al : Eosinophilic Myocarditis : Characteristics, Treatment, and Outcomes. J Am Coll Cardiol 70 : 2363-2375, 2017.
PubMed
21) Caforio AL, et al : Current state of knowledge on aetiology, diagnosis. management, and therapy of myocarditis : a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34 : 2636-2648, 2648a-2648d, 2013.
 
22) Luyt CE, et al : What's new in myocarditis? Intensive Care Med 42 : 1055-1057, 2016.
 
23) Heymans S, et al : The Quest for New Approaches in Myocarditis and Inflammatory Cardiomyopathy. J Am Coll Cardiol 68 : 2348-2364, 2016.
PubMed
24) Samuelsson A, et al : Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291 : 484-486, 2001.
PubMed
25) Robinson JL, et al : A systematic review of intravenous gamma globulin for therapy of acute myocarditis. BMC Cardiovasc Disord 5 : 12, 2005.
PubMed
26) Kato S, et al : Successful high-dose intravenous immunoglobulin therapy for a patient with fulminant myocarditis. Heart Vessels 22 : 48-51, 2007.
PubMed
P.326 掲載の参考文献
1) 日本循環器学会 : 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告). 急性および慢性心筋炎の診断・治療に関するガイドライン (2009年改訂版), 2009.
 
2) 日本循環器学会 : 日本循環器学会/日本心不全学会合同ガイドライン. 心筋症診療ガイドライン (2018年改訂版), 2019.
 
3) Aretz HT : Myocarditis : the Dallas criteria. Hum Pathol 18 : 619-624, 1987.
PubMed
4) Trachtenberg BH, Hare JM : Inflammatory Cardiomyopathic Syndromes. Circ Res 121 : 803-818, 2017.
PubMed
5) Caforio AL, et al : Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis : a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34 : 2636-2648, 2648a-2648d, 2013.
 
6) Klingel K, et al : Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection : quantitative analysis of virus replication, tissue damage, and inflammation. Proc Natl Acad Sci USA 89 : 314-318, 1992.
PubMed
7) Dominguez F, et al : Update on Myocarditis and Inflammatory Cardiomyopathy : Reemergence of Endomyocardial Biopsy. Rev Esp Cardiol (Engl Ed) 69 : 178-187, 2016.
PubMed
8) Otsuka K, et al : Suppression of inflammation in rat autoimmune myocarditis by S100A8/A9 through modulation of the proinflammatory cytokine network. Eur J Heart Fail 11 : 229-237, 2009.
 
9) Sotiriou E, et al : Therapeutic implications of a combined diagnostic workup including endomyocardial biopsy in an all-comer population of patients with heart failure : aretrospective analysis. ESC Heart Fail 5 : 630-641, 2018.
 
10) Friedrich MG, et al ; International Consensus Group on Cardiovascular Magnetic Resonance in Myocarditis : Cardiovascular magnetic resonance in myocarditis : AJACC White Paper. J Am Coll Cardiol 53 : 1475-1487, 2009.
 
11) Krejci J, et al : Inflammatory Cardiomyopathy : A Current View on the Pathophysiology, Diagnosis, and Treatment. Biomed Res Int 2016 : 4087632, 2016.
PubMed
12) Grun S, et al : Long-term follow-up of biopsy-proven viral myocarditis : predictors of mortality and incomplete recovery. J Am Coll Cardiol 59 : 1604-1615, 2012.
 
P.332 掲載の参考文献
1) 藤山幹子 : DIHSの臨床的特徴と診断基準. 薬疹診療のフロントライン (相原道子編), p111-115, 中山書店, 2011.
 
2) Garcia-Ferrer L, et al : Myocarditis by mesalazine with cardiac magnetic resonance imaging. Eur Heart J 30 : 1015, 2009.
PubMed
3) 日本循環器学会, ほか : 薬剤性心筋炎. 循環器病の診断と治療に関するガイドライン (2008年度合同研究斑報告). 急性および慢性心筋炎の診断・治療に関するガイドライン (2009年改訂版) (班長 : 和泉徹), p28-29, 2009. [http://www.j-circ.or.jp/guideline/pdf/JCS2009_izumi_h.pdf] (2019年7月閲覧)
 
4) 増谷学 : 潰瘍性大腸炎に対するmesalazine投与により急性心筋炎を発症した1例. 日本消化器病学会雑誌 96 : 524-529, 1999.
Medical*Online
5) Habal FM, Greenberg GR : Treatment of ulcerative colitis with oral 5-aminosalicylic acid including patients with adverse reactions to sulfasalazine. Am J Gastroenterol 83 : 15-19, 1988.
PubMed
6) 庄司涼子 : 潰瘍性大腸炎に対して投与した5-ASA製剤により心筋炎を発症した1例. 旭中央病院医報 26 : 150-153, 2004.
 
7) Agnholt J, et al : Cardiac hypersensitivity to 5-aminosalicylic acid. Lancet 1 : 1135, 1989.
PubMed
8) Fenoglio JJ Jr, et al : Drug related myocarditis. I. Hypersensitivity myocarditis. Hum Pathol 12 : 900-907, 1981.
PubMed
P.336 掲載の参考文献
1) Hammond EH, et al : Vascular rejection and its relationship to allograft coronary artery disease. J Heart Lung Transplant 11 : S111-119, 1992.
PubMed
2) Chin C, et al : Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J Heart Lung Transplant 30 : 158-163, 2011.
PubMed
3) Clerkin KJ, et al : Donor-specific anti-HLA antibodies with antibody-mediated rejection and long-term outcomes following heart transplantation. J Heart Lung Transplant 36 : 540-545, 2017.
PubMed
4) Billingham ME, et al : A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection : Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 9 : 587-593, 1990.
 
5) Stewart S, et al : Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 24 : 1710-1720, 2005.
PubMed
6) Angelini A, et al : A web-based pilot study of inter-pathologist reproducibility using the ISHLT 2004 working formulation for biopsy diagnosis of cardiac allograft rejection : the European experience. J Heart Lung Transplant 30 : 1214-1220, 2011.
PubMed
7) Berry GJ, et al : The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 32 : 1147-1162, 2013.
PubMed
8) Colvin MM, et al : Antibody-mediated rejection in cardiac transplantation : emerging knowledge in diagnosis and management : a scientific statement from the American Heart Association. Circulation 131 : 1608-1639, 2015.
PubMed
9) Tambur AR, et al : Flow cytometric detection of HLA-specific antibodies as a predictor of heart allograft rejection. Transplantation 70 : 1055-1059, 2000.
PubMed
10) Kubo SH, et al : Risk factors for late recurrent rejection after heart transplantation : a multiinstitutional, multivariable analysis. Cardiac Transplant Research Database Group. J Heart Lung Transplant 14 : 409-418, 1995.
 
11) Crespo-Leiro MG, et al : Clinical usefulness of gene-expression profile to rule out acute rejection after heart transplantation : CARGO II. Eur Heart J 37 : 2591-2601, 2016.
PubMed

III 弁膜症

P.342 掲載の参考文献
1) 大門雅夫 : 心不全患者の失敗しない弁膜症治療, p2-5, 文光堂, 2017.
 
2) Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery ; Shimizu H, et al : Thoracic and cardiovascular surgery in Japan during 2015 : Annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg 66 : 581-615, 2018.
PubMed
3) 日本循環器学会, ほか : 循環器病の診断と治療に関するガイドライン (2011年度合同研究班報告). 弁膜疾患の非薬物治療に関するガイドライン (2012年改訂版), p3-27, 2012.
 
P.347 掲載の参考文献
1) Sievers HH, Schmidtke C : A classification system for the bicuspid aortic valve from 304 surgical specimens. J Thorac Cardiovasc Surg 133 : 1226-1233, 2007.
PubMed
2) Otto CM, et al : Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 90 : 844-853, 1994.
PubMed
3) Ross J Jr, Braunwald E : Aortic stenosis. Circulation 38 : 61-67, 1968.
PubMed
4) Bourguignon T, et al : Very long-term outcomes of the Carpentier-Edwards Perimount valve in aortic position. Ann Thorac Surg 99 : 831-837, 2015.
PubMed
5) Johnson S, et al : Thirty-year experience with a bileaflet mechanical valve prosthesis. J Thorac Cardiovasc Surg 157 : 213-222, 2019.
PubMed
6) Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery ; Shimizu H, et al : Thoracic and cardiovascular surgery in Japan in 2016 : Annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg 67 : 377-411, 2019.
PubMed
7) Leon MB, et al : Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med 374 : 1609-1620, 2016.
 
8) Thourani VH, et al : Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients : a propensity score analysis. Lancet 387 : 2218-2225, 2016.
PubMed
9) Reardon MJ, et al : Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med 376 : 1321-1331, 2017.
 
10) Baumgartner H, et al : 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 38 : 2739-2791, 2017.
PubMed
11) Nishimura RA, et al : 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 70 : 252-289, 2017.
 
12) Mack MJ, et al : Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med 380 : 1695-1705, 2019.
PubMed
13) Popma JJ, et al : Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med 380 : 1706-1715, 2019.
PubMed
14) Yamamoto M, et al : Transcatheter aortic valve replacement outcomes in Japan : Optimized CathEter vAlvular iNtervention (OCEAN) Japanese multicenter registry. Cardiovasc Revasc Med, 2018. [Epub ahead of print]
 
P.353 掲載の参考文献
1) Zoghbi WA, et al : Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 16 : 777-802, 2003.
PubMed
2) Nishimura RA, et al : 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129 : e521-643, 2014.
 
3) Daimon M, et al : Normal values of echocardiographic parameters in relation to age in a healthy Japanese population : the JAMP study. Circ J 72 : 1859-1866, 2008.
 
4) He GW, et al : Aortic valve replacement : determinants of operative mortality. Ann Thorac Surg 57 : 1140-1146, 1994.
PubMed
5) Klodas E, et al : Surgery for aortic regurgitation in women. Contrasting indications and outcomes compared with men. Circulation 94 : 2472-2478, 1996.
PubMed
6) Dujardin KS, et al : Mortality and morbidity of aortic regurgitation in clinical practice. A long-term follow-up study. Circulation 99 : 1851-1857, 1999.
PubMed
7) Sambola A, et al : Prognostic value of preoperative indexed end-systolic left ventricle diameter in the outcome after surgery in patients with chronic aortic regurgitation. Am Heart J 155 : 1114-1120, 2008.
PubMed
8) Okita Y, et al : Direct visualization of the aortic cusp from the left ventricle during aortic root reimplantation. J Thorac Cardiovasc Surg 144 : 981-982, 2012.
PubMed
9) Boodhwani M, et al : Repair-oriented classification of aortic insufficiency : impact on surgical techniques and clinical outcomes. J Thorac Cardiovasc Surg 137 : 286-294, 2009.
PubMed
10) Schafers HJ, et al : Cusp height in aortic valves. J Thorac Cardiovasc Surg 146 : 269-274, 2013.
PubMed
11) Malas T, et al : Is Aortic Valve Repair Reproducible? Analysis of the Learning Curve for Aortic Valve Repair. Can J Cardiol 31 : 1497. e15-22, 2015.
 
P.358 掲載の参考文献
1) Sun BJ, et al : Performance of a Simplified Dichotomous Phenotypic Classification of Bicuspid Aortic Valve to Predict Type of Valvulopathy and Combined Aortopathy. J Am Soc Echocardiogr 30 : 1152-1161, 2017.
PubMed
2) Sievers HH, Schmidtke C : Aclassification system for the bicuspid aortic valve from 304 surgical specimens. J Thorac Cardiovasc Surg 133 : 1226-1233, 2007.
 
3) Michelena HI, et al : Natural history of asymptomatic patients with normally functioning or minimally dysfunctional bicuspid aortic valve in the community. Circulation 117 : 2776-2784, 2008.
PubMed
4) Kong WK, et al : Prognostic Implications of Raphe in Bicuspid Aortic Valve Anatomy. JAMA Cardiol 2 : 285-292, 2017.
PubMed
P.362 掲載の参考文献
1) Martin PS, et al : Embryonic Development of the Bicuspid Aortic Valve. J Cardiovasc Dev Dis 2 : 248-272, 2015.
PubMed
2) Azhar M, et al : Ligand-specific function of transforming growth factor beta in epithelialmesenchymal transition in heart development. Dev Dyn 238 : 431-442, 2009.
PubMed
3) Siu SC, Silversides CK : Bicuspid aortic valve disease. J Am Coll Cardiol 55 : 2789-2800, 2010.
PubMed
4) Yuan SM : Quadricuspid Aortic Valve : A Comprehensive Review. Braz J Cardiovasc Surg 31 : 454-460, 2016.
PubMed
5) Mitchell MB, Goldberg SP : Supravalvar aortic stenosis in infancy. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 14 : 85-91, 2011.
PubMed
6) Devabhaktuni SR, et al : Subvalvular aortic stenosis : a review of current literature. Clin Cardiol 41 : 131-136, 2018.
PubMed
7) Hakuno D, et al : Molecular mechanisms underlying the onset of degenerative aortic valve disease. J Mol Med 87 : 17-24, 2009.
PubMed
8) Hulin A, et al : Emerging pathogenic mechanisms in human myxomatous mitral valve : lessons from past and novel data. Cardiovasc Pathol 22 : 245-250, 2013.
PubMed
9) Karci AC, et al : Matrix metalloproteinase 2 (MMP-2) levels are increased in active acromegaly patients. Endocrine 57 : 148-155, 2017.
PubMed
10) Labeur M, et al : Pituitary tumors : cell type-specific roles for BMP-4. Mol Cell Endocrinol 326 : 85-88, 2010.
PubMed
P.367 掲載の参考文献
1) Iung B, et al : A prospective survey of patients with valvular heart disease in Europe : The Euro Heart Survey on Valvular Heart Disease. Eur Heart J 24 : 1231-1243, 2003.
PubMed
2) Baumgartner H, et al : Echocardiographic assessment of valve stenosis : EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr 22 : 1-23, 2009.
PubMed
3) 日本循環器学会 : 循環器病の診断と治療に関するガイドライン (2011年度合同研究班報告). 弁膜疾患の非薬物治療に関するガイドライン (2012年改訂版), 2012. [http://www.j-circ.or.jp/guideline/index.htm] (2019年8月閲覧)
 
4) Nishimura RA, et al : 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease : executive summary : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129 : 2440-2492, 2014.
 
5) Baumgartner H, et al : 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 38 : 2739-2791, 2017.
PubMed
6) Inoue K, et al : Clinical application of transvenous mitral commissurotomy by a new balloon catheter. J Thorac Cardiovasc Surg 87 : 394-402, 1984.
PubMed
7) Wilkins GT, et al : Percutaneous balloon dilatation of the mitral valve : an analysis of echocardiographic variables related to outcome and the mechanism of dilatation. Br Heart J 60 : 299-308, 1988.
PubMed
8) Hernandez R, et al : Long-term clinical and echocardiographic follow-up after percutaneous mitral valvuloplasty with the Inoue balloon. Circulation 99 : 1580-1586, 1999.
PubMed
9) Palacios IF, et al : Which patients benefit from percutaneous mitral balloon vaivuloplasty? Prevalvuloplasty and postvalvuloplasty variables that predict long-term outcome. Circulation 105 : 1465-1471, 2002.
PubMed
10) Fatkin D, et al : Percutaneous balloon mitral valvotomy with the Inoue single-balloon catheter : commissural morphology as a determinant of outcome. J Am Coll Cardiol 21 : 390-397, 1993.
PubMed
11) Meneguz-Moreno RA, et al : Very long term follow-up after percutaneous balloon mitral valvuloplasty. JACC Cardiovasc Interv 11 : 1945-1952, 2018.
PubMed
P.373 掲載の参考文献
1) Bursi F, et al : Mitral regurgitation after myocardia川nfarction : a review. Am J Med 119 : 103-112, 2006.
 
2) Otsuji Y, et ai : Insights from three-dimensional echocardiography into the mechanism of functional mitral regurgitation : direct in vivo demonstration of altered leaflet tethering geometry. Circulation 96 : 1999-2008, 1997.
 
3) Otsuji Y, et al : Mechanism of ischemic mitral regurgitation with segmental left ventricular dysfunction : three-dimensional echocardiographic studies in models of acute and chronic progressive regurgitation. J Am Coll Cardiol 37 : 641-648, 2001.
PubMed
4) Kaul S, et al : Mechanism of ischemic mitral regurgitation. An experimental evaluation. Circulation 84 : 2167-2180, 1991.
PubMed
5) Kumanohoso T, et al : Mechanism of higher incidence of ischemic mitral regurgitation in patients with inferior myocardial infarction : quantitative analysis of left ventricular and mitral valve geometry in 103 patients with prior myocardial infarction. J Thorac Cardiovasc Surg 125 : 135-143, 2003.
PubMed
6) Lopez-Perez M, et al : Long-term prognostic value of mitral regurgitation in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention. Am J Cardiol 113 : 907-912, 2014.
PubMed
7) Nishino S, et al : Acute Versus Chronic Ischemic Mitral Regurgitation : An Echocardiographic Study of Anatomy and Physiology. Circ Cardiovasc Imaging 11 : e007028, 2018.
PubMed
8) Dal-Bianco JP, et al : Active adaptation of the tethered mitral valve : insights into a compensatory mechanism for functional mitral regurgitation. Circulation 120 : 334-342, 2009.
PubMed
9) Dal-Bianco JP, et al : Myocardial Infarction Alters Adaptation of the Tethered Mitral Valve. J Am Coll Cardiol 67 : 275-287, 2016.
PubMed
10) Watanabe N, et al : Mitral annulus flattens in ischemic mitral regurgitation : geometric differences between inferior and anterior myocardial infarction : a real-time 3-dimensional echocardiographic study. Circulation 112 : I458-462, 2005.
PubMed
11) Watanabe N, et al : Geometric differences of the mitral valve tenting between anterior and inferior myocardial infarction with significant ischemic mitral regurgitation : quantitation by novel software system with transthoracic real-time three-dimensional echocardiography. J Am Soc Echocardiogr 19 : 71-75, 2006.
 
12) Watanabe N, et al : Dynamics of Mitral Complex Geometry and Functional Mitral Regurgitation During Heart Failure Treatment-Real-time Three-dimensional Echocardiographic Study-. J Echocardiogr 4 : 51-58, 2006.
 
13) Toida R, et al : Prognostic Implication of Three-Dimensional Mitral Valve Tenting Geometry in Dilated Cardiomyopathy. J Heart Valve Dis 24 : 577-585, 2015.
PubMed
14) Baumgartner H, et al : 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 38 : 2739-2791, 2017.
PubMed
15) Grigioni F, et al : Contribution of ischemic mitral regurgitation to congestive heart failure after myocardial infarction. J Am Coll Cardiol 45 : 260-267, 2005.
PubMed
16) Nishino S, et al : The Course of Ischemic Mitral Regurgitation in Acute Myocardial Infarction After Primary Percutaneous Coronary Intervention : From Emergency Room to Long-Term Follow-Up. Circ Cardiovasc Imaging 9 : e004841, 2016.
 
17) Stone GW, et al : Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med 379 : 2307-2318, 2018.
PubMed
18) Obadia JF, et al : Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. N Engl J Med 379 : 2297-2306, 2018.
 
P.379 掲載の参考文献
1) 日本循環器学会 : 循環器病の診断と治療に関するガイドライン (2011年度合同研究班報告). 弁膜疾患の非薬物治療に関するガイドライン (2012年改訂版), 2012. [http://www.j-circ.or.jp/guideline/pdf/JCS2012_ookita_h.pdf] (2019年7月閲覧)
 
2) Nishimura RA, et al : 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 135 : e1159-e1195, 2017.
 
3) Nishimura RA, et al : 2014 AHA/ACC guideline for the management of patients with valvular heart disease : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 : e57-185, 2014.
 
4) Delling FN, et al : Epidemiology and pathophysiology of mitral valve prolapse : new insights into disease progression, genetics, and molecular basis. Circulation 129 : 2158-2170, 2014.
PubMed
5) Adams DH, et al : Degenerative mitral valve regurgitation : best practice revolution. Eur Heart J 31 : 1958-1966, 2010.
PubMed
6) Deferm S, et al : Atrial Functional Mitral Regurgitation : JACC Review Topic of the Week. J Am Coll Cardiol 73 : 2465-2476, 2019.
 
7) Boudoulas KD, et al : Floppy mitral valve (FMV) /mitral valve prolapse (MVP) and the FMV/MVP syndrome : pathophysiologic mechanisms and pathogenesis of symptoms. Cardiology 126 : 69-80, 2013.
PubMed
8) Yoshida K, et al : Value of acceleration flows and regurgitant jet direction by color Doppler flow mapping in the evaluation of mitral valve prolapse. Circulation 81 : 879-885, 1990.
PubMed
9) Zoghbi WA, et al : Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation : A Report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr 30 : 303-371, 2017.
 
10) Sriram CS, et al : Malignant bileaflet mitral valve prolapse syndrome in patients with otherwise idiopathic out-of-hospital cardiac arrest. J Am Coll Cardiol 62 : 222-230, 2013.
PubMed
11) Basso C, et al : Arrhythmic Mitral Valve Prolapse and Sudden Cardiac Death. Circulation 132 : 556-566, 2015.
PubMed
12) Narayanan K, et al : Mitral valve prolapse and sudden cardiac arrest in the community. Heart Rhythm 13 : 498-503, 2016.
PubMed
13) Nordhues BD, et al : Bileaflet Mitral Valve Prolapse and Risk of Ventricular Dysrhythmias and Death. J Cardiovasc Electrophysiol 27 : 463-468, 2016.
 
P.384 掲載の参考文献
1) Abe Y, et al : Prevalence and Prognostic Significance of Functional Mitral and Tricuspid Regurgitation Despite Preserved Left Ventricular Ejection Fraction in Atrial Fibrillation Patients. Circ J 82 : 1451-1458, 2018.
PubMed
2) Gertz ZM, et al : Evidence of atrial functional mitral regurgitation due to atrial fibrillation : reversal with arrhythmia control. J Am Coll Cardiol 58 : 1474-1481, 2011.
PubMed
3) Takahashi Y, et al : Mitral valve repair for atrial functional mitral regurgitation in patients with chronic atrial fibrillation. Interact Cardiovasc Thorac Surg 21 : 163-168, 2015.
PubMed
4) Ito K, et al : Mechanism of atrial functional mitral regurgitation in patients with atrial fibrillation : A study using three-dimensional transesophageal echocardiography. J Cardiol 70 : 584-590, 2017.
PubMed
5) Machino-Ohtsuka T, et al : Novel Mechanistic Insights Into Atrial Functional Mitral Regurgitation-3-Dimensional Echocardiographic Study. Circ J 80 : 2240-2248, 2016.
PubMed
6) Kagiyama N, et al : Insufficient Leaflet Remodeling in Patients With Atrial Fibrillation : Association With the Severity of Mitral Regurgitation. Circ Cardiovasc Imaging 10. pii : e005451, 2017.
 
7) Kim DH, et al : Mitral Valve Adaptation to Isolated Annular Dilation : Insights Into the Mechanism of Atrial Functional Mitral Regurgitation. JACC Cardiovasc Imaging 12 : 665-677, 2019.
PubMed
8) Netter FH : The CIBA Collection of Medical Illustrations, Volume 5 : Heart, CIBA, Summit, 1969.
 
9) Silbiger JJ : Novel pathogenetic mechanisms and structural adaptations in ischemic mitral regurgitation. J Am Soc Echocardiogr 26 : 1107-1117, 2013.
PubMed
10) Nagaura T, et al : Percutaneous Edge-to-Edge Repair for Atrial Functional Mitral Regurgitation : A Real-Time 3-Dimensional Transesophageal Echocardiography Study. JACC Cardiovasc Imaging, 2019. [Epub ahead of print]
 
P.388 掲載の参考文献
1) Barlow JB, Bosman CK : Aneurysmal protrusion of the posterior leaflet of the mitral valve. An auscultatory-electrocardiographic syndrome. Am Heart J 71 : 166-178, 1966,
PubMed
2) Perspectives on the Mitral Valve (ed by Barlow JB), FA Davis Company, Philadelphia, 1987.
 
3) Hjortnaes J, et al : Comparative histopathological analysis of mitral valves in Barlow disease and fibroelastic deficiency. Semin Thorac Surg 28 : 757-767, 2016.
PubMed
4) Matsumaru I, et al : Clinical and pathological features of degenerative mitral valve disease : billowing mitral leaflet versus fibroelastic deficiency. Ann Thorac Cardiovasc Surg 20 : 987-994, 2014.
PubMed
5) Adams DH, et al : Degenerative mitral valve regurgitation : best practice revolution. Eur Heart J 31 : 1958-1966, 2010.
PubMed
6) Barlow JB, Pocock WA : Billowing, floppy, prolapsed or flail mitral valves? Am J Cardiol 55 : 501-502, 1985.
PubMed
7) Chandra S, et al : Characterization of degenerative mitral valve disease using morphologic analysis of real-time three-dimensional echocardiographic images : objective insight into complexity and planning of mitral valve repair. Circ Cardiovasc Imaging 4 : 24-32, 2011.
PubMed
8) Manabe S, et al : Influence of left ventricular function on development of systolic anterior motion after mitral valve repair. J Thorac Cardiovasc Surg 146 : 291-295. e1, 2013.
 
9) Maslow AD, et al : Echocardiographic predictors of left ventricular outflow tract obstruction and systolic anterior motion of the mitral valve after mitral valve reconstruction for myxomatous valve disease. J Am Coll Cardiol 34 : 2096-2104, 1999.
 
10) Carpentier A, et al : Carpentier's Reconstructive Valve Surgery, p267-278, Saunders Elsevier, Maryland Heights, 2010.
 
11) Lawrie GM : Barlow disease : simple and complex. J Thorac Cardiovasc Surg 150 : 1078-1081, 2015.
PubMed
12) Borger MA, et al : Minimally invasive mitral valve repair in Barlow's disease : early and long-term results. J Thorac Cardiovasc Surg 148 : 1379-1385, 2014.
 
13) da Rocha E Silva JG, et al : Barlow's mitral valve disease : a comparison of neochordal (loop) and edge-to-edge (Alfieri) minimally invasive repair techniques. Ann Thorac Surg 100 : 2127-2133 ; discussion 2133-2135, 2015.
 
14) Ben Zekry S, et al : Simple repair approach for mitral regurgitation in Barlow disease. J Thorac Cardiovasc Surg 150 : 1071-1077. el, 2015.
 
15) Adams DH, et al : Large annuloplasty rings facilitate mitral valve repair in Barlow's disease. Ann Thorac Surg 82 : 2096-2100 ; discussion 2101, 2006.
 
P.392 掲載の参考文献
1) Prieto LR, Laston LA : Pulmonary stenosis. In : Moss and Adams' Heart Disease in Infants, Children, and Adolescents : Including the Fetus and Young Adult, 9th ed (ed by Allen HD, et al), p983-1007, Lippincott Williams & Wilkins, Philadelphia, 2016.
 
2) Prendiville TW, et al : Cardiovascular disease in Noonan syndrome. Arch Dis Child 99 : 629-634, 2014.
PubMed
3) Oster ME, et al : An update on cardiovascular malformations in congenital rubella syndrome. Birth Defects Res Part A Clin Mol Teratol 88 : 1-8, 2010.
 
4) Drossner DM, Mahle WT : A management strategy for mild valvar pulmonary stenosis. Pediatr Cardiol 29 : 649-652, 2008.
PubMed
5) Kreibich M, et al : Aneurysms of the pulmonary artery. Circulation 131 : 310-316, 2015.
PubMed
6) Rowland DG, et al : Natural course of isolated pulmonary valve stenosis in infants and children utilizing Doppler echocardiography. Am J Cardiol 79 : 344-349, 1997.
PubMed
7) 富松宏文 : 肺動脈弁狭窄症. エコーで診る先天性心疾患, p185-189, アトムス, 2018.
 
8) Kan JS, et al : Percutaneous balloon valvuloplasty : a new method for treating congenital pulmonary-valve stenosis. N Engl J Med 307 : 540-542, 1982.
PubMed
9) Peterson C, et al : Comparative long-term results of surgery versus balloon valvuloplasty for pulmonary valve stenosis in infants and children. Ann Thorac Surg 76 : 1078-1082 ; discussion 1082-1083, 2003.
 
10) Ferraz Cavalcanti PE, et al : Pulmonary valve replacement after operative repair of tetralogy of Fallot : meta-analysis and meta-regression of 3,118 patients from 48 studies. J Am Coll Cardiol 62 : 2227-2243, 2013.
PubMed
11) Babu-Narayan SV, et al : Clinical outcomes of surgical pulmonary valve replacement after repair of tetralogy of Fallot and potential prognostic value of preoperative cardiopulmonary exercise testing. Circulation 129 : 18-27, 2014.
PubMed
P.398 掲載の参考文献
1) Zoghbi WA, et al : Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation : A Report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr 30 : 303-371, 2017.
 
2) Lang RM, et al : Recommendations for cardiac chamber quantification by echocardiography in adults : an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 28 : 1-39. e14, 2015.
 
3) Rudski LG, et al : Guidelines for the echocardiographic assessment of the right heart in adults : a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 23 : 685-713 ; quiz 786-788, 2010.
 
4) Nishimura RA, et al : 2014 AHA/ACC guideline for the management of patients with valvular heart disease : executive summary : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 : 2438-2488, 2014.
 
5) Baumgartner H, et al : 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 38 : 2739-2791, 2017.
PubMed
6) Lang RM, et al : EAE/ASE recommendations for image acquisition and display using three-dimensional echocardiography. J Am Soc Echocardiogr 25 : 3-46, 2012.
PubMed
7) Watanabe K, et al : Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure. J Cardiol 60 : 462-469, 2012.
PubMed
8) Messika-Zeitoun D, et al : Medical and surgical outcome of tricuspid regurgitation caused by flail leaflets. J Thorac Cardiovasc Surg 128 : 296-302, 2004.
PubMed
9) Takahashi Y, et al : Actual management and prognosis of severe isolated tricuspid regurgitation associated with atrial fibrillation without structural heart disease. Int J Cardiol 243 : 251-257, 2017.
PubMed
10) Izumi C, et al : Progression of isolated tricuspid regurgitation late after mitral valve surgery for rheumatic mitral valve disease. J Heart Valve Dis 11 : 353-356, 2002.
 
11) Jeganathan R, et al : The risk and outcomes of reoperative tricuspid valve surgery. Ann Thorac Surg 95 : 119-124, 2013.
PubMed
12) Baumgartner H, et al : Echocardiographic assessment of valve stenosis : EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr 22 : 1-23 : quiz 101-102, 2009.
 
P.402 掲載の参考文献
1) Marijon E, et al : Rheumatic heart disease. Lancet 379 : 953-964, 2012.
PubMed
2) Essop MR, Peters F : Contemporary issues in rheumatic fever and chronic rheumatic heart disease. Circulation 130 : 2181-2188, 2014.
PubMed
3) Marijon E, et al : Rheumatic heart disease screening by echocardiography : the inadequacy of World Health Organization criteria for optimizing the diagnosis of subclinical disease. Circulation 120 : 663-668, 2009.
PubMed
4) WHO Technical Report Series 923. Rheumatic Fever and Rheumatic Heart Disease : Report of a WHO Expert Consultation, Geneva, 29 October-1 November 2001. World Health Organization, Geneva, 2004.
 
P.406 掲載の参考文献
1) Hamirani YS, et al : Relation of mitral annular calcium and coronary calcium (from the Multi-Ethnic Study of Atherosclerosis [MESA]). Am J Cardiol 107 : 1291-1294, 2011.
 
2) Kanjanauthai S, et al : Relationships of mitral annular calcification to cardiovascular risk factors : the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 213 : 558-562, 2010.
PubMed
3) Adler Y, et al : Mitral annulus calcification-a window to diffuse atherosclerosis of the vascular system. Atherosclerosis 155 : 1-8, 2001.
PubMed
4) Barasch E, et al : Clinical significance of calcification of the fibrous skeleton of the heart and aortosclerosis in community dwelling elderly. The Cardiovascular Health Study (CHS). Am Heart J 151 : 39-47, 2006.
PubMed
5) Silbiger JJ : Anatomy, mechanics, and pathophysiology of the mitral annulus. Am Heart J 164 : 163-176, 2012.
PubMed
6) Fox CS, et al : Mitral annular calcification predicts cardiovascular morbidity and mortality : the Framingrham Heart Study. Circulation 107 : 1492-1496, 2003.
PubMed
7) Atar S, et al : Mitral annular calcification : a marker of severe coronary artery disease in patients under 65 years old. Heart 89 : 161-164, 2003.
PubMed
8) Benjamin EJ, et al : Mitral annular calcification and the risk of stroke in an elderly cohort. N Engl J Med 327 : 374-379, 1992.
 
9) Takamoto T, Popp RL : Conduction disturbances related to the site and severity of mitral anular calcification : a 2-dimensional echocardiographic and electrocardiographic correlative study. Am J Cardiol 51 : 1644-1649, 1983.
 
10) Fox CS, et al : Mitral annular calcification is a predictor for incident atrial fibrillation. Atherosclerosis 173 : 291-294, 2004.
PubMed
11) O'Neal WT, et al : Mitral annular calcification and incident atrial fibrillation in the Multi-Ethnic Study of Atherosclerosis. Europace 17 : 358-363, 2015.
PubMed
12) Okada Y : Surgical management of mitral annular calcification. Gen Thorac Cardiovasc Surg 61 : 619-625, 2013.
PubMed
13) Cheng R, et al : Mitral annular calcification is not associated with decreased procedural success, durability of repair, or left ventricular remodelling in percutaneous edge-to-edge repair of mitral regurgitation. EuroIntervention 12 : 1176-1184, 2016.
 
14) Deluca G, et al : The incidence and clinical course of caseous calcification of the mitral annulus : a prospective echocardiographic study. J Am Soc Echocardiogr 21 : 828-833, 2008.
PubMed
15) Pomerance A : Pathological and clinical study of calcification of the mitral valve ring. J Clin Pathol 23 : 354-361, 1970.
 
P.411 掲載の参考文献
1) Wang A, et al : Contemporary clinical profile and outcome of prosthetic valve endocarditis. JAMA 297 : 1354-1361, 2007.
PubMed
2) Lopez J, et al : Age-dependent profile of left-sided infective endocarditis : a 3-center experience. Circulation 121 : 892-897, 2010.
PubMed
3) Ohara T, et al : Clinical predictors of in-hospital death and early surgery for infective endocarditis : results of CArdiac Disease REgistration (CADRE), a nation-wide survey in Japan. Int J Cardiol 167 : 2688-2694, 2013.
PubMed
4) Nakatani S, et al : Recent picture of infective endocarditis in Japan-lessons from Cardiac Disease Registration (CADRE-IE). Circ J 77 : 1558-1564, 2013.
PubMed
5) Graupner C, et al : Periannular extension of infective endocarditis. J Am Coll Cardiol 39 : 1204-1211, 2002.
PubMed
6) Durante-Mangoni E, et al : Current features of infective endocarditis in elderly patients : results of the International Collaboration on Endocarditis Prospective Cohort Study. Arch Intern Med 168 : 2095-2103, 2008.
PubMed
7) Li JS, et al : Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 30 : 633-638, 2000.
 
8) 日本循環器学会, ほか (班長 : 中谷敏) : 感染性心内膜炎の予防と治療に関するガイドライン (2017年改訂版), 2018. [http://www.j-circ.or.jp/guideline/pdf/JCS2017_nakatani_h.pdf] (2019年7月閲覧)
 
9) Habib G, et al : 2015 ESC Guidelines for the management of infective endocarditis : The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by : European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 36 : 3075-3128, 2015.
 
10) Lalani T, et al : Analysis of the impact of early surgery on in-hospital mortality of native valve endocarditis : use of propensity score and instrumental variable methods to adjust for treatment-selection bias. Circulation 121 : 1005-1013, 2010.
PubMed
11) San Roman JA, et al : Prognostic stratification of patients with left-sided endocarditis determined at admission. Am J Med 120 : 369. e1-7, 2007.
 
12) Olmos C, et al : Risk score for cardiac surgery in active left-sided infective endocarditis. Heart 103 : 1435-1442, 2017.
PubMed
P.415 掲載の参考文献
1) 日本循環器学会, ほか : 循環器病の診断と治療に関するガイドライン (2011年度合同研究班報告). 弁膜疾患の非薬物治療に関するガイドライン (2012年度改訂版). 2012. [http://www.j-circ.or.jp/guideline/pdf/JCS2012_ookita_h.pdf] (2019年7月閲覧)
 
2) Vahanian A, et al : Guidelines on the management of valvular heart disease (version 2012) : the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg 42 : S1-44, 2012.
 
3) Nishimura RA, et al : 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease : executive summary : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129 : 2440-2492, 2014.
 
4) Nishimura RA, et al : 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 135 : e1159-e1195, 2017.
 
5) 南方謙二 : 人工弁選択-最新の基準-. 心臓 48 : 594-601, 2016.
Medical*Online
6) Tanaka K, et al : Early and late outcomes of aortic valve replacement in dialysis patients. Ann Thorac Surg 89 : 65-70, 2010.
PubMed
P.420 掲載の参考文献
1) Zoghbi WA, et al : Recommendations for evaluation of prosthetic valves with echocardiography and doppler ultrasound : a report From the American Society of Echocardiography's Guidelines and Standards Committee and the Task Force on Prosthetic Valves, developed in conjunction with the American College of Cardiology Cardiovascular Imaging Committee, Cardiac Imaging Committee of the American Heart Association, the European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography and the Canadian Society of Echocardiography, endorsed by the American College of Cardiology Foundation, American Heart Association, European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography, and Canadian Society of Echocardiography. J Am Soc Echocardiogr 22 : 975-1014 ; quiz 1082-1084, 2009.
 
2) Ben Zekry S, et al : Flow acceleration time and ratio of acceleration time to ejection time for prosthetic aortic valve function. JACC Cardiovasc Imaging 4 : 1161-1170, 2011.
PubMed
3) Head SJ, et al : The impact of prosthesis-patient mismatch on long-term survival after aortic valve replacement : a systematic review and meta-analysis of 34 observational studies comprising 27 186 patients with 133 141 patient-years. Eur Heart J 33 : 1518-1529, 2012.
PubMed
4) Fernandes V, et al : Peak early diastolic velocity rather than pressure half-time is the best index of mechanical prosthetic mitral valve function. Am J Cardiol 89 : 704-710, 2002.
PubMed
5) Olmos L, et al : Usefulness of transthoracic echocardiography in detecting significant prosthetic mitral valve regurgitation. Am J Cardiol 83 : 199-205, 1999.
PubMed
6) Kronzon I, et al : Real-time 3-dimensional transesophageal echocardiography in the evaluation of post-operative mitral annuloplasty ring and prosthetic valve dehiscence. J Am Coll Cardiol 53 : 1543-1547, 2009.
PubMed
7) Kappetein AP, et al : Updated standardized endpoint definitions for transcatheter aortic valve implantation : the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol 60 : 1438-1454, 2012.
 
8) Zoghbi WA, et al : Guidelines for the Evaluation of Valvular Regurgitation After Percutaneous Valve Repair or Replacement : A Report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Angiography and Interventions, Japanese Society of Echocardiography, and Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr 32 : 431-475, 2019.
PubMed
P.424 掲載の参考文献
1) Habib G, et al : 2015 ESC Guidelines for the management of infective endocarditis : The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by : European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 36 : 3075-3128, 2015.
 
2) Wang A, et al : Contemporary clinical profile and outcome of prosthetic valve endocarditis. JAMA 297 : 1354-1361, 2007.
PubMed
3) Ohara T, et al : Clinical predictors of in-hospital death and early surgery for infective endocarditis : results of CArdiac Disease REgistration (CADRE), a nation-wide survey in Japan. Int J Cardiol 167 : 2688-2694, 2013.
PubMed
4) Ostergaard L, et al : Incidence of infective endocarditis among patients considered at high risk. Eur Heart J 39 : 623-629, 2018.
PubMed
5) Luciani N, et al : Prosthetic valve endocarditis : predictors of early outcome of surgical therapy. A multicentric study. Eur J Cardiothorac Surg 52 : 768-774, 2017.
PubMed
6) Lalani T, et al : In-hospital and 1-year mortality in patients undergoing early surgery for prosthetic valve endocarditis. JAMA Intern Med 173 : 1495-1504, 2013.
PubMed
7) Hammermeister K, et al : Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve : final report of the Veterans Affairs randomized trial. J Am Coll Cardiol 36 : 1152-1158, 2000.
 
8) Lopez J, et al : Definition, clinical profile, microbiological spectrum, and prognostic factors of early-onset prosthetic valve endocarditis. Eur Heart J 28 : 760-765, 2007.
PubMed
9) Antoniadou A, Giamarellou H : Infectious endocarditis. In : Textbook of Critical Care, 7th ed (ed by Vincent JL, et al), p896-899, Elsevier, Philadelphia, 2017.
 
10) Ivanovic B, et al : Prosthetic valve endocarditis-A trouble or a challenge? J Cardiol 73 : 126-133, 2019.
PubMed
11) Saby L, et al : Positron emission tomography/computed tomography for diagnosis of prosthetic valve endocarditis : increased valvular 18F-fluorodeoxyglucose uptake as a novel major criterion. J Am Coll Cardiol 61 : 2374-2382, 2013.
PubMed
12) 日本循環器学会, ほか : 感染性心内膜炎の予防と治療に関するガイドライン (2017年改訂版), 2018.
 
13) Tornos P, et al : Infective endocarditis in Europe : lessons from the Euro heart survey. Heart 91 : 571-575, 2005.
PubMed
14) Akowuah EF, et al : Prosthetic valve endocarditis : early and late outcome following medical or surgical treatment. Heart 89 : 269-272, 2003.
 
15) Mihos CG, et al : Surgical Versus Medical Therapy for Prosthetic Valve Endocarditis : A Meta-Analysis of 32 Studies. Ann Thorac Surg 103 : 991-1004, 2017.
PubMed
P.429 掲載の参考文献
1) Iung B, Vahanian A : Epidemiology of valvular heart disease in the adult. Nat Rev Cardiol 8 : 162-172, 2011.
PubMed
2) Nishimura RA, et al : 2014 AHA/ACC guideline for the management of patients with valvular heart disease : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [Published correction appears in J Am Coll Cardiol 2014 ; 63 : 2489]. J Am Coll Cardiol 63 : e57-185, 2014.
 
3) Roudaut R, et al : Thrombosis of prosthetic heart valves : diagnosis and therapeutic considerations. Heart 93 : 137-142, 2007.
PubMed
4) Lin SS, et al : Prediction of thrombus-related mechanical prosthetic valve dysfunction using transesophageal echocardiog-raphy. Am J Cardiol 86 : 1097-1101, 2000.
 
5) Laplace G, et al : Clinical significance of early thrombosis after prosthetic mitral valve replacement : a postoperative monocentric study of 680 patients. J Am Coll Cardiol 43 : 1283-1290, 2004.
PubMed
6) Hansson NC, et al : Transcatheter Aortic Valve Thrombosis : Incidence, Predisposing Factors, and Clinical Implications. J Am Coll Cardiol 68 : 2059-2069, 2016.
PubMed
7) Habets J, et al : Diagnostic evaluation of left-sided prosthetic heart valve dysfunction. Nat Rev Cardiol 8 : 466-478, 2011.
PubMed
8) Dangas GD, et al : Prosthetic Heart Valve Thrombosis. J Am Coll Cardiol 68 : 2670-2689, 2016.
PubMed
9) Egbe AC, et al : Bioprosthetic Valve Thrombosis Versus Structural Failure : Clinical and Echocardiographic Predictors. J Am Coll Cardiol 66 : 2285-2294, 2015.
PubMed
10) 日本循環器学会, ほか : 循環器病の診断と治療に関するガイドライン (2011年度合同研究班報告). 弁膜疾患の非薬物治療に関するガイドライン (2012年改訂版), 2012. [http://www.j-circ.or.jp/guideline/pdf/JCS2012_ookita_h.pdf] (2019年8月閲覧)
 
11) Baumgartner H, et al : 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 38 : 2739-2791, 2017.
PubMed
12) Guyatt GH, et al : Executive surnmary : Antithrombotic Therapy and Prevention of Thrombosis, 9th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141 : 7S-47S, 2012.
PubMed
13) Stortecky S, Windecker S : Stroke : an infrequent but devastating complication in cardiovascular interventions. Circulation 126 : 2921-2924, 2012.
PubMed
P.435 掲載の参考文献
1) Eggebrecht H, Mehta RH : Transcatheter aortic valve implantation (TAVI) in Germany : more than 100,000 procedures and now the standard of care for the elderly. EuroIntervention 14 : e1549-e1552, 2019.
PubMed
2) Cesna S, et al : Rapid adoption of transcatheter aortic valve replacement in intermediate- and high-risk patients to treat severe aortic valve stenosis. J Thorac Dis 9 : 1432-1436, 2017.
PubMed
3) Leon MB, et al : Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med 374 : 1609-1620, 2016.
 
4) Thourani VH, et al : Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients : a propensity score analysis. Lancet 387 : 2218-2225, 2016.
PubMed
5) Reardon MJ, et al : Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med 376 : 1321-1331, 2017.
 
6) Mack MJ, et al : Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med 380 : 1695-1705, 2019.
PubMed
7) Popma JJ, et al : Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med 380 : 1706-1715, 2019.
PubMed
8) Kaneko H, et al : Rescue Valve-in-Valve Transcatheter Aortic Valve Replacement for Pure Aortic Regurgitation. JACC Cardiovasc Interv 10 : e23-e24, 2017.
PubMed
9) Yoon SH, et al : Transcatheter Aortic Valve Replacement in Pure Native Aortic Valve Regurgitation. J Am Coll Cardiol 70 : 2752-2763, 2017.
PubMed
10) Nkomo VT, et al : Burden of valvular heart diseases : a population-based study. Lancet 368 : 1005-1011, 2006.
PubMed
11) Mirabel M, et al : What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J 28 : 1358-1365, 2007.
PubMed
12) Feldman T, et al : Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 364 : 1395-1406, 2011.
 
13) Feldman T, et al : Percutaneous mitral repair with the MitraClip system : safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort. J Am Coll Cardiol 54 : 686-694, 2009.
PubMed
14) Boekstegers P, et al : Percutaneous interventional mitral regurgitation treatment using the Mitra-Clip system. Clin Res Cardiol 103 : 85-96, 2014.
PubMed
15) Maisano F, et al : Percutaneous mitral valve interventions in the real world : early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe. J Am Coll Cardiol 62 : 1052-1061, 2013.
 
16) Eggebrecht H, et al : Risk and outcomes of complications during and after MitraClip implantation : Experience in 828 patients from the German TRAnscatheter mitral valve interventions (TRAMI) registry. Catheter Cardiovasc Interv 86 : 728-735, 2015.
PubMed
17) Stone GW, et al : Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med 379 : 2307-2318, 2018.
PubMed
18) Obadia JF, et al : Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. N Engl J Med 379 : 2297-2306, 2018.
 
19) Kaneko H, et al : Impact of residual mitral regurgitation after MitraClip implantation. Int J Cardiol 227 : 813-819, 2017.
PubMed
20) Neuss M, et al : Elevated Mitral Valve Pressure Gradient After MitraClip Implantation Deteriorates Long-Term Outcome in Patients With Severe Mitral Regurgitation and Severe Heart Failure. JACC Cardiovasc Interv 10 : 931-939, 2017.
PubMed
21) Taramasso M, et al : Percutaneous mitral valve repair and replacement : complementary or competitive techniques? EuroIntervention 12 : Y97-Y101, 2016.
 
22) Taramasso M, et al : Percutaneous tricuspid valve therapies : the new frontier. Eur Heart J 38 : 639-647, 2017.
PubMed
P.441 掲載の参考文献
1) Nishimura RA, et al : 2014 AHA/ACC guideline for the management of patients with valvular heart disease : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 : e57-185, 2014.
 
2) Mentias A, et al : Long-Term Outcomes in Patients With Aortic Regurgitation and Preserved Left Ventricular Ejection Fraction. J Am Coll Cardiol 68 : 2144-2153, 2016.
PubMed
3) Brown ML, et al : Indexed left ventricular dimensions best predict survival after aortic valve replacement in patients with aortic valve regurgitation. Ann Thorac Surg 87 : 1170-1175 : discussion 1175-1176, 2009.
 
4) Chaliki HP, et al : Outcomes after aortic valve replacement in patients with severe aortic regurgitation and markedly reduced left ventricular function. Circulation 106 : 2687-2693, 2002.
PubMed
5) Sharma V, et al : Expanding relevance of aortic valve repair-is earlier operation indicated? J Thorac Cardiovasc Surg 147 : 100-107, 2014.
PubMed
6) Wang Y, et al : Aortic valve replacement for severe aortic regurgitation in asymptomatic patients with normal ejection fraction and severe left ventricular dilatation. Interact Cardiovasc Thorac Surg 22 : 425-430, 2016.
PubMed
7) Hiratzka LF, et al : 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. J Am Coll Cardiol 55 : e27-e129, 2010.
 
8) Erbel R, et al : 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases : Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J 35 : 2873-2926, 2014.
 
9) Boodhwani M, et al : Repair-oriented classification of aortic insufficiency : impact on surgical techniques and clinical outcomes. J Thorac Cardiovasc Surg 137 : 286-294, 2009.
PubMed
10) David TE, Feindel CM : An aortic valve-sparing operation for patients with aortic incompetence and aneurysm of the ascending aorta. J Thorac Cardiovasc Surg 103 : 617-621 ; discussion 622, 1992.
PubMed
11) Sarsam MA, Yacoub M : Remodeling of the aortic valve anulus. J Thorac Cardiovasc Surg 105 : 435-438, 1993.
PubMed
12) Schneider U, et al : Suture Annuloplasty in Aortic Valve Repair. Ann Thorac Surg 101 : 783-785, 2016.
PubMed
13) Lansac E, et al : Remodeling root repair with an external aortic ring annuloplasty. J Thorac Cardiovasc Surg 153 : 1033-1042, 2017.
PubMed
14) Mazzitelli D, et al : Geometric ring annuloplasty as an adjunct to aortic valve repair : clinical investigation of the HAART 300 device. Eur J Cardiothorac Surg 49 : 987-993, 2016.
PubMed
15) Schafers HJ, et al : Aortic valve reconstruction in myxomatous degeneration of aortic valves : are fenestrations a risk factor for repair failure? JThorac Cardiovasc Surg 139 : 660-664, 2010.
PubMed
P.445 掲載の参考文献
1) Nishimura RA, et al : 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 70 : 252-289, 2017.
 
2) Baumgartner H, et al : 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 38 : 2739-2791, 2017.
PubMed
3) 日本循環器学会, ほか : 循環器病の診断と治療に関するガイドライン (2011年度合同研究班報告). 弁膜疾患の非薬物治療に関するガイドライン (2012年改訂版), 2012. [http://www.j-circ.or.jp/guideline/pdf/JCS2012_ookita_h.pdf] (2019年7月閲覧)
 
4) Carpentier A : Cardiac valve surgery-the "French correction". J Thorac Cardiovasc Surg 86 : 323-337, 1983.
PubMed
5) Carpentier AF, et al : The "physio-ring" : an advanced concept in mitral valve annuloplasty. Ann Thorac Surg 60 : 1177-1185 ; discussion 1185-1186, 1995.
 
6) Doi K, et al : Annuloplasty Ring Size Determines Exercise-Induced Mitral Stenosis Severity after Valve Repair. J Heart Valve Dis 24 : 744-751, 2015.
PubMed
7) Perier P, et al : Toward a new paradigm for the reconstruction of posterior leaflet prolapse : midterm results of the "respect rather than resect" approach. Ann Thorac Surg 86 : 718-725 ; discussion 718-725, 2008.
 
8) David TE, et al : Long-term results of mitral valve repair for myxomatous disease with and without chordal replacement with expanded polytetrafluoroethylene sutures. J Thorac Cardiovasc Surg 115 : 1279-1285 ; discussion 1285-1286, 1998.
 
9) Chotivatanapong T, et al : Rheumatic mitral valve repair : experience of 221 cases from Central Chest Institute of Thailand. J Med Assoc Thai 95 (Suppl 8) : S51-57, 2012.
 
10) Kitamura N, et al : A new technique for debridement in rheumatic valvular disease : the rasping procedure. Ann Thorac Surg 69 : 121-125, 2000.
PubMed
11) Shomura Y, et al : Late results of mitral valve repair with glutaraldehyde-treated autologous pericardium. Ann Thorac Surg 95 : 2000-2005, 2013.
PubMed
12) Fukunaga N, et al : Mitral Valve Stenosis Progression Due to Severe Calcification on Glutaraldehyde-Treated Autologous Pericardium : Word of Caution for an Attractive Repair Technique. Ann Thorac Surg 99 : 2203-2205, 2015.
PubMed
13) Goldstein D, et al : Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation. N Engl J Med 374 : 344-353, 2016.
PubMed
14) Moscarelli M, et al : The value of adding sub-valvular procedures for chronic ischemic mitral regurgitation surgery : a meta-analysis. Perfusion 32 : 436-445, 2017.
PubMed
15) Nappi F, et al : Papillary Muscle Approximation Versus Restrictive Annuloplasty Alone for Severe Ischemic Mitral Regurgitation. J Am Coll Cardiol 67 : 2334-2346, 2016.
PubMed
P.451 掲載の参考文献
1) Izumi C, et al : Progression of isolated tricuspid regurgitation late after left-sided valve surgery. Clinical features and mechanisms. Circ J 75 : 2902-2907, 2011.
PubMed
2) Nath J, et al : Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol 43 : 405-409, 2004.
PubMed
3) Carpentier A, et al : Carpentier's Reconstructive Valve Surgery, 1st ed, p186, WB Saunders Philadelphia, 2010.
 
4) 日本循環器学会 : 循環器病の診断と治療に関するガイドライン (2011年度合同研究班報告). 弁膜疾患の非薬物治療に関するガイドライン (2012年改訂版), 2012.
 
5) Nishimura RA, et al : 2014 AHA/ACC Guideline for the management of patients with valvular heart disease : A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 : e57-185, 2014.
 
6) Dreyfus GD, et al : Secondary tricuspid regurgitation or dilatation : which shou1d be the criteria for surgical repair? Ann Thorac Surg 79 : 127-132, 2005.
 
7) Vahanian A, et al : Guidelines on the management of valvular heart disease : The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 28 : 230-268, 2007.
 
8) Colombo T, et al : Tricuspid regurgitation secondary to mitral valve disease : tricuspid annulus function as guide to tricuspid valve repair. Cardiovasc Surg 9 : 369-377, 2001.
PubMed
9) Tang GH, et al : Tricuspid valve repair with an annuloplasty ring results in improved long-term outcomes. Circulation 114 : 1577-581, 2006.
 
10) McCarthy PM, et al : Tricuspid valve repair : durability and risk factors for failure. J Thorac Cardiovasc Surg 127 : 674-685, 2004.
PubMed
11) Wang N, et al : Flexible band versus rigid ring annuloplasty for tricuspid regurgitation : a systematic review and meta-analysis. Ann Cardiothorac Surg 6 : 194-203, 2017.
PubMed
12) Dreyfus GD, et al : Tricuspid leaflet augmentation to address severe tethering in functional tricuspid regurgitation. Eur J Cardiothorac Surg 34 : 908-910, 2008.
PubMed
13) Pettinari M, et al : Mid-term results of leaflet augmentation in severe tricuspid functional tethering. Eur J Cardiothorac Surg 50 : 504-508, 2016.
PubMed
14) Lapenna E, et al : The clover technique for the treatment of complex tricuspid valve insufficiency : midterm clinical and echocardiographic results in 66 patients. Eur J Cardiothorac Surg 37 : 1297-1303, 2010.
PubMed
15) Eishi K, et al : Spiral suspension, a novel repair technique for severe functional tricuspid regurgitation. J Thorac Cardiovasc Surg 156 : 649-652, 2018.
PubMed

IV 心内膜疾患

P.458 掲載の参考文献
1) Baddour LM, et al : Infective Endocarditis in Adults : Diagnosis, Antimicrobial Therapy, and Managernent of Cornplications : A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation 132 : 1435-1486, 2015.
 
2) Berlin JA, et al : Incidence of infective endocarditis in the Delaware Valley, 1988-1990. Am J Cardiol 76 : 933-936, 1995.
PubMed
3) Nakatani S, et al : Current characteristics of infective endocarditis in Japan : an analysis of 848 cases in 2000 and 2001. Circ J 67 : 901-905, 2003.
PubMed
4) Nakatani S, et al : Recent picture of infective endocarditis in Japan-Lessons from Cardiac Disease Registration (CADRE-IE). Circ J 77 : 1558-1564, 2013.
PubMed
5) 日本循環器学会, ほか (班長 : 中谷敏) : 感染性心内膜炎の予防と治療に関するガイドライン (2017年改訂版), 2018. [http://www.j-circ.or.jp/guideline/pdf/JCS2017_nakatani_h.pdf] (2019年7月閲覧)
 
6) Habib G, et al : 2015 ESC Guidelines for the management of infective endocarditis : The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by : European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 36 : 3075-3128, 2015.
 
7) Wilson W, et al : Prevention of infective endocarditis : guidelines from the American Heart Association : a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 116 : 1736-1754, 2007.
 
8) Mylonakis E, Calderwood SB : Infective endocarditis in adults. N Engl J Med 345 : 1318-1330, 2001.
PubMed
9) Butt JH, et al : Long-Term Risk of Infective Endocarditis After Transcatheter Aortic Valve Replacement. J Am Coll Cardiol 73 : 1646-1655, 2019.
PubMed
P.463 掲載の参考文献
1) Durack DT, et al : New criteria for diagnosis of infective endocarditis : utilization of specific echocardiographic findings. Duke Endocarditis Service. Am J Med 96 : 200-209, 1994.
PubMed
2) Li JS, et al : Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 30 : 633-638, 2000.
 
3) 日本循環器学会 : 感染性心内膜炎の予防と治療に関するガイドライン (2017年改訂版), p52, 2018.
 
4) Habib G, et al : 2015 ESC Guidelines for the managernent of infective endocarditis : The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by : European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 36 : 3075-3128, 2015.
 
5) Murdoch DR, et al : Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century : the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med 169 : 463-473, 2009.
PubMed
6) Rasmussen RV, et al : Prevalence of infective endocarditis in patients with Staphylococcus aureus bacteraemia : the value of screening with echocardiography. Eur J Echocardiogr 12 : 414-420, 2011.
PubMed
7) Chang FY, et al : A prospective multicenter study of Staphylococcus aureus bacteremia : incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore) 82 : 322-332, 2003.
PubMed
8) 豊田一則 : 心内膜炎による脳卒中. 脳と循環 10 : 27-31, 2005.
Medical*Online
9) Novy E, et al : Neurological complications of infective endocarditis : new breakthroughs in diagnosis and management. Med Mal Infect 43 : 443-450, 2013.
PubMed
10) Habets J, et al : Are novel non-invasive imaging techniques needed in patients with suspected prosthetic heart valve endocarditis? A systematic review and meta-analysis. Eur Radiol 25 : 2125-2133, 2015.
PubMed
11) Baddour LM, et al : Infective Endocarditis in Adults : Diagnosis, Antimicrobial Therapy, and Management of Complications : A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation 132 : 1435-1486, 2015.
PubMed
12) Roberts GJ, et al : Optimum sampling time for detection of dental bacteraemia in children. Int J Cardiol 35 : 311-315, 1992.
PubMed
13) Nakamura Y, et al : Prevalence of periodontitis and optimal timing of dental treatment in patientsundergoing heart valve surgery. Interact Cardiovasc Thorac Surg 12 : 696-700, 2011.
 
P.470 掲載の参考文献
1) Murdoch DR, et al : Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century : the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med 169 : 463-473, 2009.
PubMed
2) Chu VH, et al : Association between surgical indications, operative risk, and clinical outcome in infective endocarditis : a prospective study from the International Collaboration on Endocarditis. Circulation 131 : 131-140, 2015.
PubMed
3) Habib G, et al : 2015 ESC Guidelines for the management of infective endocarditis : The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by : European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 36 : 3075-3128, 2015.
 
4) Yokoyama J, et al : Surgery-first treatment improves clinical results in infective endocarditis complicated with disseminated intravascular coagulation†. Eur J Cardiothorac Surg, 2019. [Epub ahead of print]
 
5) Matsuura R, et al : Effect of the lnitial Strategy for Active Endocarditis Complicated With Acute Heart Failure. Circ J 82 : 2896-2904, 2018.
PubMed
6) Yoshioka D, et al : Impact of early surgical treatment on postoperative neurologic outcome for active infective endocarditis complicated by cerebral infarction. Ann Thorac Surg 94 : 489-495 ; discussion 496, 2012.
PubMed
7) Dickerman SA, et al : The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis : an analysis from the ICE Prospective Cohort Study (ICE-PCS). Am Heart J 154 : 1086-1094, 2007.
PubMed
8) Hubert S, et al : Prediction of symptomatic embolism in infective endocarditis : construction and validation of a risk calculator in a multicenter cohort. J Am Coll Cardiol 62 : 1384-1392, 2013.
 
9) 日本循環器学会, ほか : 「感染性心内膜炎の予防と治療に関するガイドライン (2017年改訂版), 2018.」
 
P.476 掲載の参考文献
1) 日本循環器学会, ほか : 感染性心内膜炎の予防と治療に関するガイドライン (2017年改訂版), 2018. [http://www.j-circ.or.jp/guideline/pdf/JCS2017_nakatani_h.pdf] (2019年6月閲覧)
 
2) Baddour LM, et al : Infective Endocarditis in Adults : Diagnosis, Antimicrobial Therapy, and Management of Complications : A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation 132 : 1435-1486, 2015.
PubMed
3) Habib G, et al : 2015 ESC Guidelines for the management of infective endocarditis : The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by : European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 36 : 3075-3128, 2015.
 
4) JACVSD JapanSCORE. [https://center6.umin.ac.jp/islet/jcvsd/index.html] (2019年6月閲覧)
 
5) STS score. [http://riskcalc.sts.org/stswebriskcalc/calculate] (2019年6月閲覧)
 
6) EuroSCORE. [http://www.euroscore.org/calc.html] (2019年6月閲覧)
 
7) Kang DH, et al : Early surgery versus conventional treatment for infective endocarditis. N Engl J Med 366 : 2466-2473, 2012.
PubMed
8) Sakamoto T, et al : Efficacy of nafamostat mesilate as anticoagulation during cardiopulmonary bypass for early surgery in patients with active infective endocarditis complicated by stroke. J Heart Valve Dis 23 : 744-751, 2014.
PubMed
9) Solari S, et al : Active infective mitral valve endocarditis : is a repair-oriented surgery safe and durable? Eur J Cardiothorac Surg 55 : 256-262, 2019.
PubMed
10) AATS Surgical Treatment of Infective Endocarditis Consensus Guidelines Writing Committee Chairs ; Pettersson GB, et al : 2016 The American Association for Thoracic Surgery (AATS) consensus guidelines : Surgical treatment of infective endocarditis : Executive summary. J Thorac Cardiovasc Surg 153 : 1241-1258. e29, 2017.
 
11) Okita Y, et al : Optimal timing of surgery for active infective endocarditis with cerebral complications : a Japanese multicentre study. Eur J Cardiothorac Surg 50 : 374-382, 2016.
PubMed
12) David TE, et al : Aortic and mitral valve replacement with reconstruction of the intervalvular fibrous body. J Thorac Cardiovasc Surg 114 : 766-771 ; discussion 771-772, 1997.
 
13) Pettersson GB, et al : Reconstruction of fibrous skeleton : technique, pitfalls and results. Multimed Man Cardiothorac Surg 2014. pii : mmu004, 2014.
 
P.481 掲載の参考文献
1) Carrasco F, et al : Clinical features and changes in epidemiology of infective endocarditis on pacemaker devices over a 27-year period (1987-2013). Europace 18 : 836-841, 2016.
 
2) Vieira ML et al : Repeated echocardiographic examinations of patients with suspected infective endocarditis. Heart 90 : 1020-1024, 2004.
PubMed
3) Greenspon AJ, et al : 16-year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States l993 to 2008. J Am Coll Cardiol 58 : 1001-1006, 2011.
 
4) 日本循環器学会, ほか : 感染性心内膜炎の予防と治療に関するガイドライン (2017年改訂版), 2018.
 
5) Ozcan C, et al : Infective endocarditis and risk of death after cardiac implantable electronic device implantation : a nationwide cohort study. Europace 19 : 1007-1014, 2017.
 
6) Hussein AA, et al : Microbiology of Cardiac Implantable Electronic Device Infections. JACC Clin Electrophysiol 2 : 498-505, 2016.
PubMed
7) Kusumoto FM, et al : 2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction. Heart Rhythm 14 : e503-e551, 2017.
PubMed
8) Ye R, et al : Clinical characteristics of septic pulmonary embolism in adults : a systematic review. Respir Med 108 : 1-8, 2014.
PubMed
9) Le KY, et al : Impact of timing of device removal on mortality in patients with cardiovascular implantable electronic device infections. Heart Rhythm 8 : 1678-1685, 2011.
PubMed
10) 日本循環器学会, ほか : 日本循環器学会/日本不整脈心電学会合同ガイドライン. 不整脈非薬物治療ガイドライン (2018年改訂版), 2019.
 
11) Wilkoff BL. et al : Pacemaker lead extraction with the laser sheath : results of the pacing lead extraction with the excimer sheath (PLEXES) trial. J Am Coll Cardiol 33 : 1671-1676, 1999.
 
12) Wazni O, et al : Lead Extraction in the Contemporary Setting : The LExICon Study : An Observational Retrospective Study of Consecutive Laser Lead Extractions. J Am Coll Cardiol 55 : 579-586, 2010.
PubMed
13) Bongiorni MG, et al : Transvenous removal of pacing and implantable cardiac defibrillating leads using single sheath mechanical dilatation and multiple venous approaches : high success rate and safety in more than 2000 leads. Eur Heart J 29 : 2886-2893, 2008.
PubMed
14) Sohail MR, et al : Infective endocarditis complicating permanent pacemaker and implantable cardioverter-defibrillator infection. Mayo Clin Proc 83 : 46-53, 2008.
PubMed
P.486 掲載の参考文献
1) Loffler W : Endocarditis parietalis fibroplastica mit Bluteosinophilie. Ein eigenartige Krankheitshild. Schweiz Med Wochenschr 66 : 817-820, 1936.
 
2) 岡田了三 : Lofler心内膜心筋炎 ; 心内膜疾患. 別冊日本臨牀新領域別症候群シリーズ No. 5 循環器症候群 (第2版) II, p317-321, 日本臨牀社, 2007.
 
3) 岡田了三 : Lofflerの好酸球性壁心内膜炎. 心筋疾患. 新内科学大系 35巻A (山村雄一ほか監), p135-139, 中山書店, 1978.
 
4) Brockington IF, et al : Loffler's endocarditis and Davies' endomyocardial fibrosis. Am Heart J 85 : 308-322, 1973.
 
5) 岡田了三 : 特発性心筋症-本邦におけるLoffler心内膜炎について-. 循環器科 1 : 135-138, 1977.
 
6) Tai PC, et al : Deposits of eosinophil granule proteins in cardiac tissues of patients with eosinophilic endomyocardial disease. Lancet 1 : 643-647, 1987.
PubMed
7) Slungaard A, et al : Eosinophil cationic granule proteins impair thrombomodulin function. A potential mechanism for thromboembolism in hypereosinophilic heart disease. J Clin Invest 91 : 1721-1730, 1993.
PubMed
8) Weller PF, et al : The idiopathic hypereosinophilic syndrome. Blood 83 : 2759-2779, 1994.
PubMed
9) 大岩修太郎, ほか : 多発性脳梗塞にて発症し, 診断と治療効果の指標にPET-CTが有用であったLoffler心内膜心筋炎の1例. 心臓 49 : 253-259, 2017.
 
10) Kleinfeldt T, et al : Cardiac manifestation of the hypereosinophilic syndrome : new insights. Clin Res Cardiol 99 : 419-427, 2010.
PubMed
11) Kurokawa K, et al : Usefulness of Cardiac Magnetic Resonance in the Diagnosis of Loffler Endocarditis Secondary to Eosinophilic Granulomatosis with Polyangiitis. Intern Med 58 : 239-242, 2019.
PubMed
12) Gotlib J : World Health Organization-defined eosinophilic disorders : 2017 update on diagnosis, risk stratification, and management. Am J Hematol 92 : 1243-1259, 2017.
PubMed
13) Nakashima T, et al : Massive mobile thrombus in the left ventricle due to Loffler endocarditis complicated with dilated cardiomyopathy. Circ J 78 : 1992-1994, 2014.
PubMed
14) Metras D, et al : The surgical treatment of endomyocardial fibrosis : results in 55 patients. Circulation 72 (3 Pt 2) : II274-279, 1985.
 
15) Hii MW, et al : Obstructive prosthetic mitral valve thrombosis in idiopathic hypereosinophilic syndrome : a case report and review of the literature. J Heart Valve Dis 15 : 721-725, 2006.
PubMed
P.491 掲載の参考文献
1) Ziegler E : Ueber den Bau und die Entstehung der endocarditis chen Efflorescenzen. Ver Kong Inn Med 7 : 339-343, 1888.
 
2) Lopez JA, et al : Nonbacterial thrombotic endocarditis : a review. Am Heart J 113 : 773-784, 1987.
PubMed
3) Vlachostergios PJ, et al : Nonbacterial thrombotic (marantic) endocarditis in a patient with colorectal cancer. Onkologie 33 : 456-459, 2010.
 
4) Singh V, et al : Marantic endocarditis (NBTE) with systemic emboli and paraneoplastic cerebellar degeneration : uncommon presentation of ovarian cancer. J Neurooncol 83 : 81-83, 2007.
PubMed
5) Moyssakis I, et al : Libman-Sacks endocarditis in systemic lupus erythematosus : prevalence, associations, and evolution. Am J Med 120 : 636-642, 2007.
PubMed
6) Asopa S, et al : Non-bacterial thrombotic endocarditis. Eur J Cardiothorac Surg 32 : 696-701, 2007.
PubMed
7) Smeglin A, et al : Marantic endocarditis and disseminated intravascular coagulation with systemic emboli in presentation of pancreatic cancer. J Clin Oncol 26 : 1383-1385, 2008.
PubMed
8) Hojnik M, et al : Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation 93 : 1579-1587, 1996.
PubMed
9) el-Shami K, et al : Nonbacterial thrombotic endocarditis in cancer patients : pathogenesis, diagnosis, and treatment. Oncologist 12 : 518-523, 2007.
PubMed
10) Roldan CA, et al : Libman-Sacks endocarditis and embolic cerebrovascular disease. JACC Cardiovasc Imaging 6 : 973-983, 2013.
PubMed
11) Graus F, et al : Cerebrovascular complications in patients with cancer. Medicine (Baltimore) 64 : 16-35, 1985.
PubMed
12) Rogers LR, et al : Cerebral infarction from non-bacterial thrombotic endocarditis. Clinical and pathological study including the effects of anticoagulation. Am J Med 83 : 746-756, 1987.
PubMed
13) Joffe II, et al : Noninfective valvular masses : review of the literature with emphasis on imaging techniques and management. Am Heart J 131 : 1175-1183, 1996.
PubMed
14) Liu J, Frishman WH : Nonbacterial Thrombotic Endocarditis : Pathogenesis, Diagnosis, and Management. Cardiol Rev 24 : 244-247, 2016.
PubMed
15) Le Bot A, et al : [Non-infective endocarditis]. Rev Med Interne 39 : 782-791, 2018.
PubMed
P.494 掲載の参考文献
1) Libman E, Sacks B : A hitherto undescribed form of valvular and mural endocarditis. Arch Intern Med 33 : 701-737, 1924.
 
2) Deppisch LM, Fayemi AO : Non-bacterial thrombotic endocarditis : clinicopathologic correlations. Am Heart J 92 : 723-729, 1976.
PubMed
3) Gonzalez Quintela A, et al : Non-bacterial thrombotic endocarditis in cancer patients. Acta Cardiol 46 : 1-9, 1991.
PubMed
4) Hojnik M, et al : Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation 93 : 1579-1587, 1996.
PubMed
5) Roldan CA, et al : An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus. N Engl J Med 335 : 1424-1430, 1996.
PubMed
6) Moyssakis I, et al : Libman-Sacks endocarditis in systemic lupus erythematosus : prevalence, associations, and evolution. Am J Med 120 : 636-642, 2007.
PubMed
7) Lee JL, et al : Revisiting Libman-Sacks endocarditis : ahistorical review and update. Clin Rev Allergy Immunol 36 : 126-130, 2009.
 
8) Roldan CA, et al : Libman-Sacks Endocarditis : Detection, Characterization, and Clinical Correlates by Three-Dimensional Transesophageal Echocardiography. J Am Soc Echocardiogr 28 : 770-779, 2015.
PubMed
9) Roldan CA, et al : Libman-Sacks endocarditis and embolic cerebrovascular disease. JACC Cardiovasc Imaging 6 : 973-983, 2013.
PubMed
10) Chauvaud SM, et al : Systemic lupus erythematosus valvulitis : mitral valve replacement with a homograft. Ann Thorac Surg 60 : 1803-1805, 1995.
PubMed
11) Hakim Jp, et al : Mitral valve replacement and repair. Report of 5 patients with systemic lupus erythematosus. Tex Heart Inst J 28 : 47-52, 2001.
PubMed
12) Hachiya K, et al : Double-vaive replacement for mitral and aortic regurgitation in a Patient with Libman-Sacks endocarditis. Intern Med 53 : 1769-1773, 2014.
 
P.499 掲載の参考文献
1) Mocumbi AO, et al : A population study of endomyocardial fibrosis in a rural area of Mozambique. N Engl J Med 359 : 43-49, 2008.
 
2) Seth S, et al : Clinico-pathological evaluation of restrictive cardiomyopathy (endomyocardial fibrosis and idiopathic restrictive cardiomyopathy) in India. Eur J Heart Fail 6 : 723-729, 2004.
PubMed
3) Mocumbi AO, et al : Neglected tropical cardiomyopathies : II. Endomyocardial fibrosis : myocardial disease. Heart 94 : 384-390, 2008.
PubMed
4) Grimaldi A, et al. Tropical Endomyocardial Fibrosis : Natural History, Challenges, and Perspectives. Circulation 133 : 2503-2515, 2016.
PubMed
5) Perazzolo Marra M, et al : Cardiac magnetic resonance features of biopsy-proven endomyocardial diseases. JACC Cardiovasc Imaging 7 : 309-312, 2014.
PubMed
6) Salemi VM, et al : Late gadolinium enhancement magnetic resonance imaging in the diagnosis and prognosis of endomyocardial fibrosis patients. Circ Cardiovasc Imaging 4 : 304-311, 2011.
PubMed
7) Patel AK, et al : Familial cases of endomyocardial fibrosis in Uganda. Br Med J 4 : 331-334, 1971,
PubMed
8) Valiathan SM, Kartha CC : Endomyocardial fibrosis-the possible connexion with myocardial levels of magnesium and cerium. Int J Cardiol 28 : 1-5, 1990.
PubMed
9) Barretto AC, et al : Atrial fibrillation in endomyocardial fibrosis is a marker of worse prognosis. Int J Cardiol 67 : 19-25, 1998.
 
10) Shiraishi Y, et al : Endomyocardial fibrosis : missing tricuspid valve and Fontan-like circulation. Heart Vessels 31 : 1579-1582, 2016.
PubMed
11) Qureshi N, et al : MR imaging of endomyocardial fibrosis (EMF). Int J Cardiol 149 : e36-37, 2011.
PubMed
12) Smedema Jp, et al : Tropical endomyocardial fibrosis (Davies' disease) : case report demonstrating the role of magnetic resonance imaging. Int J Cardiovasc Imaging 20 : 517-522, 2004.
PubMed
13) Hassan WM, et al : Pitfalls in diagnosis and clinical, echocardiographic, and hemodynamic findings in endomyocardial fibrosis : a 25-year experience. Chest 128 : 3985-3992, 2005.
PubMed
14) Moraes F, et al : Surgery for endomyocardial fibrosis revisited. Eur J Cardiothorac Surg 15 : 309-312 ; discussion 312-313, 1999.
 
15) Gupta PN, et al : Clinical course of endomyocardial fibrosis. Br Heart J 62 : 450-454, 1989.
PubMed
P.504 掲載の参考文献
1) Lurie PR : Changing concepts of endocardial fibroelastosis. Cardiol Young 20 : 115-123, 2010.
PubMed
2) Ni J, et al : Viral infection of the myocardium in endocardial fibroelastosis. Molecular evidence for the role of mumps virus as an etiologic agent. Circulation 95 : 133-139, 1997.
PubMed
3) 西川俊郎, ほか : 原発性心内膜線維弾性症. 日本臨牀 58 : 171-175, 2000.
Medical*Online
4) 市田蕗子, ほか : 平成20年度稀少疾患サーベイランス調査結果. 日本小児循環器学会雑誌 25 : 746-748, 2009.
 
5) 河野靖子 : 剖検輯報による心筋疾患の30年間の病理統計. 順天堂医学 41 : 115-123, 1995.
 
6) 林憲一, 康井制洋 : 心内膜線維弾性症 ; 心内膜疾患. 別冊日本臨牀新領域別症候群シリーズ No. 5 循環器症候群 (第2版) II, p339-342, 日本臨牀社, 2007.
 
7) Puvabanditsin S, et al : Microdeletion of 16p11.2 associated with endocardial fibroelastosis. Am J Med Genet A 152A : 2383-2386, 2010.
PubMed
8) 柳川幸重 : 心内膜線維弾性症. 小児内科 34 (増刊号) : 327-329, 2002.
 
9) 姫野和家子, ほか : 心内膜線維弾性症の診断のポイント. 心エコー 2 : 842-845, 2001.
Medical*Online
10) Arya SO, et al : Primary endocardial fibroelastosis presenting in a young child as incessant ventricular tachycardia and dilated cardiomyopathy. Tex Heart Inst J 39 : 714-718, 2012.
 
11) Steger CM, et al : Endocardial fibroelastosis of the heart. Lancet 379 : 932, 2012.
PubMed
12) 西川俊郎 : 心内膜線維弾性症 ; 心筋疾患. 別冊日本臨牀新領域別症候群シリーズ No. 6 循環器症候群 (第2版) III, p 179-182, 日本臨牀社, 2008.
 
13) 廣野恵一, 市田蕗子 : 左室心筋緻密化障害をどのように診断するか. Heart View 20 : 121-131, 2016.
Medical*Online
14) 桃井伸緒 : Barth症候群. 日本小児循環器学会雑誌 32 : 409-416, 2016.
Medical*Online
15) 田原昌博 : 心内膜線維弾性症. 小児内科 46 (増刊号) : 428-431, 2014.
 

V 心膜疾患

P.509 掲載の参考文献
1) Friman G, Fohlman J : The epidemiology of viral heart disease. Scand J Infect Dis Suppl 88 : 7-10, 1993.
PubMed
2) Launbjerg J, et al : Long-term risk of death, cardiac events and recurrent chest pain in patients with acute chest pain of different origin. Cardiology 87 : 60-66, 1996.
PubMed
3) Troughton RW, et al : Pericarditis. Lancet 363 : 717-727, 2004.
PubMed
4) Imazio M, et al : Recurrent pericarditis. Rev Med Interne 38 : 307-311, 2017.
PubMed
5) Imazio M, et al : Risk of constrictive pericarditis after acute pericarditis. Circulation 124 : 1270-1275, 2011.
PubMed
6) Porta-Sanchez A, et al : Constrictive Pericarditis : Etiologic Spectrum, Patterns of Clinical Presentation, Prognostic Factors, and Long-term Follow-up. Rev Esp Cardiol (Engl Ed) 68 : 1092-1100, 2015.
PubMed
7) Cameron J, et al : The etiologic spectrum of constrictive pericarditis. Am Heart J 113 : 354-360, 1987.
PubMed
P.513 掲載の参考文献
1) Imazio M, et al : Myopericarditis versus viral or idiopathic acute pericarditis. Heart 94 : 498-501, 2008.
PubMed
2) Troughton RW, et al : Pericarditis. Lancet 363 : 717-727, 2004.
PubMed
3) Kyto V, et al : Clinical profile and influences on outcomes in patients hospitalized for acute pericarditis. Circulation 130 : 1601-1606, 2014.
PubMed
4) Adler Y, et al : 2015 ESC Guidelines for the diagnosis and management of pericardial diseases : The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by : The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 36 : 2921-2964, 2015.
 
5) Bonnefoy E, et al : Serum cardiac troponin I and ST-segment elevation in patients with acute pericarditis. Eur Heart J 21 : 832-836, 2000.
PubMed
6) Spodick DH : Pericardial rub. Prospective, Multiple observer investigation of pericardial friction in 100 patients. Am J Cardiol 35 : 357-362, 1975.
PubMed
7) Imazio M, Trinchero R : Triage and management of acute pericarditis. Int J Cardiol 118 : 286-294, 2007.
PubMed
8) Spodick DH : Acute cardiac tamponade. N Engl J Med 349 : 684-690, 2003.
PubMed
9) Imazio M, et al : A randomized trial of colchicine for acute pericarditis. N Engl J Med 369 : 1522-1528, 2013.
PubMed
10) Imazio M, et al : Indicators of poor prognosis of acute pericarditis. Circulation 115 : 2739-2744, 2007.
PubMed
11) Cremer PC, et al : Complicated Pericarditis : Understanding Risk Factors and Pathophysiology to Inform Imaging and Treatment. J Am Coll Cardiol 68 : 2311-2328, 2016.
PubMed
P.518 掲載の参考文献
1) Imazio M, et al : Evaluation and Treatment of Pericarditis : A Systematic Review. JAMA 314 : 1498-1506, 2015.
PubMed
2) Fowler NO : Tuberculous pericarditis. JAMA 266 : 99-103, 1991.
PubMed
3) Sagrista-Sauleda J, et al : Tuberculous pericarditis : ten year experience with a prospective protocol for diagnosis and treatment. J Am Coll Cardiol 11 : 724-728, 1988.
PubMed
4) Mayosi BM, et al : Mortality in patients treated for tuberculous pericarditis in sub-Saharan Africa. S Afr Med J g8 : 36-40, 2008.
 
5) Sagrista-Sauleda J, et al : Purulent pericarditis : review of a 20-year experience in a general hospital. J Am Coll Cardiol 22 : 1661-1665, 1993.
 
6) Parikh SV, et al : Purulent pericarditis : report of 2 cases and review of the literature. Medicine (Baltimore) 88 : 52-65, 2009.
PubMed
7) Chang SA : Tuberculous and Infectious Pericarditis. Cardiol Clin 35 : 615-622, 2017.
PubMed
8) Gooi HC, Smith JM : Tuberculous pericarditis in Birmingham. Thorax 33 : 94-96, 1978.
PubMed
9) Rooney JJ, et al : Tuberculous pericarditis. Ann Intern Med 72 : 73-81, 1970.
PubMed
10) Komsuoglu B, et al : The diagnostic and prognostic value of adenosine deaminase in tuberculous pericarditis. Eur Heart J 16 : 1126-1130, 1995.
PubMed
11) Aggeli C, et al : Relevance of adenosine deaminase and lysozyme measurements in the diagnosis of tuberculous pericarditis. Cardiology 94 : 81-85, 2000.
 
12) Burgess LJ, et al : The use of adenosine deaminase and interferon-gamma as diagnostic tools for tuberculous pericarditis. Chest 122 : 900-905, 2002.
PubMed
13) 竜美幸, ほか : 若年女性に発症した急性細菌性心膜炎の1例. 心臓 43 : 81-86, 2011.
Medical*Online
14) Mayosi BM, et al : Immunotherapy for tuberculous pericarditis. N Engl J Med 371 : 2534, 2014.
PubMed
15) 日本結核病学会治療委員会 : 「結核医療の基準」の改訂-2018年. 結核 93 : 61-68, 2018.
Medical*Online
P.522 掲載の参考文献
1) Picardi JL, et al : Pericarditis caused by Histoplasma capsulatum. Am J Cardiol 37 : 82-88, 1976.
PubMed
2) Adam RD, et al : The spectrum and presentation of disseminated coccidioidomycosis. Am J Med 122 : 770-777, 2009.
PubMed
3) Aliya N, et al : Histoplasmosis. In : Robbins and Cotran Pathologic Basis of Disease, 9th ed, Chapter 15, p669-726, WB Elsevier, Philadelphia, 2015.
 
4) Martin M, et al : Pericardial diseases. In : Braunwald's Heart Disease : A Textbook of Cardiovascular Medicine, 10th ed (ed by Mann DL, et al), p1636-1657, WB Saunders, Philadelphia, 2014.
 
5) Arsura EL, et al : Coccidioidal pericarditis : a case presentation and review of the literature. Int J Infect Dis 9 : 104-109, 2005.
PubMed
6) Rabinovici R, et al : Candida pericarditis : clinical profile and treatment. Ann Thorac Surg 63 : 1200-1204, 1997.
PubMed
7) Le Moing V, et al : Aspergillus pericarditis with tamponade : report of a successfully treated case and review. Clin Infect Dis 26 : 451-460, 1998.
PubMed
8) Makaryus AN, et al : A rare case of Actinomyces israelii presenting as pericarditis in a 75-year-old man. Cardiol Rev 13 : 125-127, 2005.
 
9) 竹末芳生 : 外科領域における深在性真菌症とその対策. 日本医真菌学会雑誌 45 : 217-221, 2004.
 
10) Masood Y, et al : Fungal pericarditis. In : Cardiology, 3rd ed (ed by Crawford M, et al), Chapter 82, p1125-1143, Mosby, Maryland, 2010.
 
11) Adler Y, et al : 2015 ESC Guidelines for the diagnosis and management of pericardial diseases : The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by : The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 36 : 2921-2964, 2015.
 
P.526 掲載の参考文献
1) Martin M, et al : Pericardial Diseases. In : Heart Disease, tenth ed (ed by Mann DL, et al), p1636-1657, WB Saunders, Philadelphia, 2014.
 
2) 特集 赤痢アメーバー症, JOHAC海外感染症通信, No. 2, p1-2, 1995.
 
3) Shamsuzzaman SM, et al : Thoracic amebiasis. Clin Chest Med 23 : 479-492, 2002.
PubMed
4) Dubey JP : Toxoplasmosis of Animals and Humans, 2nd ed, p65, CRC Press, Boca Raton, 2010.
 
5) 川中正憲 : エキノコックス症とは. IDWR, 第48号, 2001.
 
6) WHO Lymphatic filariasis, Fact sheet N°102, Updated March 2013.
 
7) 福島英雄 : フィラリア症の化学療法. 日本熱帯医学会雑誌 8 : 80-103, 1968.
 
8) 大前比呂思 : 充血吸虫症とは. IDWR, 第41号, 2006.
 
P.530 掲載の参考文献
1) Imazio M, et al : Risk of constrictive pericarditis after acute pericarditis. Circulation 124 : 1270-1275, 2011.
PubMed
2) Cervera R, et al : Morbidity and mortality in systemic lupus erythematosus during a 10-year period : a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82 : 299-308, 2003.
 
3) Ruiz-Irastorza G, Khamashta M : Cardiopulmonary disease in SLE. In : Dubois' Lupus Erythematosus and Related Syndromes, 8th ed (ed by Wallace DJ, Hahn BH), p352-362. Saunders, Elsevier, Philadelphia, 2013.
 
4) Gordon C, et al : The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults : Executive Summary. Rheumatology (Oxford) 57 : 14-18. 2018.
PubMed
5) Morel N, et al : Colchicine : a simple and effective treatment for pericarditis in systemic lupus erythematosus? A report of 10 cases. Lupus 24 : 1479-1485, 2015.
PubMed
6) Iwai A, et al : Short-term add-on tocilizumab and intravenous cyclophosphamide exhibited a remission-inducing effect in a patient with systemic lupus erythematosus with refractory multiorgan involvements including massive pericarditis and glomerulonephritis. Mod Rheumatol 27 : 529-532, 2017.
 
7) Follansbee WP, Marroquin OC : Cardiac involvement of systemic screlosis. In : Systemic Sclerosis, 2nd ed (ed by Clements PJ, Furst DE), p195-220, Lippincott Williams & Wilkins, New York, NY, USA, 2004.
 
8) McWhorter JE 4th, LeRoy EC : Pericardial disease in scleroderma (systemic sclerosis). Am J Med 57 : 566-575, 1974.
PubMed
9) Satoh M, et al : Massive pericardial effusion in scleroderma : a review of five cases. Br J Rheumatol 34 : 564-567, 1995.
PubMed
10) Naniwa T, et al : Pulmonary-renal syndrome in systemic sclerosis : a report of three cases and review of the literature. Mod Rheumatol 17 : 37-44, 2007.
PubMed
11) Hosoya H, Derk CT : Clinically Symptomatic Pericardial Effusions in Hospitalized Systemic Sclerosis Patients : Demographics and Management. Biomed Res Int 2018 : 6812082, 2018.
PubMed
12) Cavero T, et al : Eculizumab in secondary atypical haemolytic uraemic syndrome. Nephrol Dial Transplant 32 : 466-474, 2017.
PubMed
13) Theander L, et al : Severe Extraarticular Manifestations in a Community-based Cohort of Patients with Rheumatoid Arthritis : Risk Factors and Incidence in Relation to Treatment with Tumor Necrosis Factor Inhibitors. J Rheumatol 44 : 981-987, 2017.
 
14) Comarmond C, et al : Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) : clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 65 : 270-281, 2013.
 
15) Cantarini L, et al : Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis : results of a multicentre study. Clin Res Cardio1101 : 525-531, 2012.
PubMed
P.535 掲載の参考文献
1) McCanny P, Colreavy F : Echocardiographic approach to cardiac tamponade in critically ill patients. J Crit Care 39 : 271-277, 2017.
PubMed
2) Celik S, et al : Systemic chemotherapy in combination with pericardial window has better outcomes in malignant pericardial effusions. J Thorac Cardiovasc Surg 148 : 2288-2293, 2014.
PubMed
3) Maisch B, et al : Evaluation and management of pericardial effusion in patients with neoplastic disease. Prog Cardiovasc Dis 53 : 157-163, 2010.
PubMed
4) Lam KY, et al : Tumors of the heart. A 20-year experience with a review of 12,485 consecutive autopsies. Arch Pathol Lab Med 117 : 1027-1031, 1993.
 
5) Sogaard KK. et al : Pericarditis as a Marker of Occult Cancer and a Prognostic Factor for Cancer Mortality. Circulation 136 : 996-1006, 2017.
 
6) Little WC, Freeman GL : Pericardial disease. Circulation 113 : 1622-1632, 2006.
PubMed
7) Imazio M, et al : Indicators of poor prognosis of acute pericarditis. Circulation 115 : 2739-2744, 2007.
PubMed
8) Kushnir I, Wolf I : Nivolumab-Induced Pericardial Tamponade : ACase Report and Discussion. Cardiology 136 : 49-51, 2017.
 
9) Chen J, et al : Severe Cardiotoxicity in a Patient with Colorectal Cancer Treated with Bevacizumab. Anticancer Res 37 : 4557-4561, 2017.
 
10) Numico G, et al : Prolonged Drainage and Intrapericardial Bleomycin Administration for Cardiac Tamponade Secondary to Cancer-Related Pericardial Effusion. Medicine (Baltimore) 95 : e3273, 2016.
PubMed
11) El Haddad D, et al : Outcomes of Cancer Patients Undergoing Percutaneous Pericardiocentesis for Pericardial Effusion. J Am Coll Cardiol 66 : 1119-1128, 2015.
PubMed
12) Rousseau-Bussac G, et al : [Management of malignant pericardial effusion in lung cancer]. Rev Mal Respir 31 : 746-753, 2014.
PubMed
13) Hashimoto Y, et al : Pericardial biopsy revealed gastric signet-ring cell cancer. Case Rep Oncol 8 : 174-178, 2015.
PubMed
14) Maisch B, et al : Pericardioscopy and epi-and pericardial biopsy-anew window to the heart improving etiological diagnoses and permitting targeted intrapericardial therapy. Heart Fail Rev 18 : 317-328, 2013.
 
15) Apodaca-Cruz A, et al : Effectiveness and prognosis of initial pericardiocentesis in the primary management of malignant pericardial effusion. Interact Cardiovasc Thorac Surg 11 : 154-161, 2010.
PubMed
16) Jama GM, et al : Palliative treatment for symptomatic malignant pericardial effusion†. Interact Cardiovasc Thorac Surg 19 : 1019-1026, 2014.
 
P.540 掲載の参考文献
1) Kabadi UM, Kumar SP : Pericardial effusion in primary hypothyroidism. Am Heart J 120 : 1393-1395, 1990.
PubMed
2) Chahine J, et al : Pericardial diseases in patients with hypothyroidism. Heart 105 : 1027-1033, 2019.
PubMed
3) Yamanaka S, et al : Link between pericardial effusion and attenuation of QRS voltage in patients with hypothyroidism. Cardiology 116 : 32-36, 2010.
PubMed
4) Adler Y, et al : 2015 ESC Guidelines for the diagnosis and management of pericardial diseases : The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by : The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 36 : 2921-2964, 2015.
 
5) Ozmen B, et al : Serum N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) levels in hyperthyroidism and hypothyroidism. Endocr Res 32 : 1-8, 2007.
 
6) Taiwo AA, et al : Cardiac amyloidosis : A case report and review of literature. World J Clin Cases 7 : 742-752, 2019.
PubMed
7) Yuda S, et al : Pericardial Effusion and Multiple Organ Involvement Are Independent Predictors of Mortality in Patients with Systemic Light Chain Amyloidosis. Intern Med 54 : 1833-1840, 2015.
PubMed
8) Georgin-Lavialle S, et al : Isolated Pericardial Infiltration Without Myocardial Involvement in Light-Chain-Related Amyloidosis. Ann Thorac Surg 103 : e255-e257, 2017.
PubMed
9) Toyama K, et al : Primary systemic amyloidosis with bloody pericardial effusion. Intern Med 48 : 821-826, 2009.
PubMed
10) Singh V, et al : Primary systemic amyloidosis presenting as constrictive pericarditis. Cardiology 118 : 251-255, 2011.
PubMed
P.544 掲載の参考文献
1) Renfrew R, et al : Pericarditis and renal failure. Annu Rev Med 31 : 345-360, 1980.
PubMed
2) Kohara M, et al : Development of Acute Pericarditis Associated with New-onset Rheumatoid Arthritis in a Diabetic Patient with Renal Impairment : The Elusive Nature of Uremia. Intern Med 55 : 955-959, 2016.
 
3) Bright R : Tabular view of the morbid appearance in 100 cases connected with albuminous urine : with observations. Guys Hosp Rep 1 : 380-400, 1836.
 
4) Bentata Y, et al : Uremic pericarditis in patients with End Stage Renal Disease : Prevalence, symptoms and outcome in 2017. Am J Emerg Med 36 : 464-466, 2018.
PubMed
5) Wray TM, Stone WJ : Uremic pericarditis : a prospective echocardiographic and clinical study. Clin Nephrol 6 : 295-302, 1976.
PubMed
6) Luft FC, et al : Pericarditis in the patient with uremia : clinical and echocardiographic evaluation. Nephron 25 : 160-166, 1980.
PubMed
7) Meyer TW, Hostetter TH : Approaches to uremia. J Am Soc Nephrol 25 : 2151-2158, 2014.
PubMed
8) Twardowski ZJ, et al : Circulating immune complexes : possible toxins responsible for serositis (pericarditis, pleuritis, and peritonitis) in renal failure. Nephron 35 : 190-195, 1983.
PubMed
9) Maisch B, Kochsiek K : Humoral immune reactions in uremic pericarditis. Am J Nephrol 3 : 264-271, 1983.
PubMed
10) Yoshida K, et al : Uremic pericardial effusion : detection and evaluation of uremic pericardial effusion by echocardiography. Clin Nephrol 13 : 260-268, 1980.
PubMed
11) Hiraide A, et al : Cardiac tamponade secondary to hemorrhagic pericarditis during continuous hemofiltration for renal failure. The role of the anticoagulant. Ren Fail 16 : 299-301, 1994.
PubMed
12) Lindsay J Jr, et al : Chronic constrictive pericarditis following uremic hemopericardium. Am Heart J 79 : 390-395, 1970.
PubMed
13) Spodick DH : Frequency of arrhythmias in acute pericarditis determined by Holter monitoring. Am J Cardiol 53 : 842-845, 1984.
PubMed
14) Spodick DH : Acute cardiac tamponade. N Engl J Med 349 : 684-690, 2003.
PubMed
15) Queffeulou G, et al : Acute renal and hepatic failure : do not miss pericardial tamponade! Nephrol Dial Transplant 14 : 2260, 1999.
 
16) Sarnak MJ, et al : Kidney disease as a risk factor for development of cardiovascular disease : a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108 : 2154-2169, 2003.
PubMed
17) 木村眞規子, ほか : 血液透析導入期の潜在性結核に関する検討. 日本透析医学会雑誌 51 : 599-605, 2018.
 
18) Spector D, et al : A controlled study of the effect of indomethacin in uremic pericarditis. Kidney Int 24 : 663-669, 1983.
 
19) Leehey DJ, et al : Predicting need for surgical drainage of pericardial effusion in patients with end-stage renal disease. Int J Artif Organs 12 : 618-625, 1989.
PubMed
P.548 掲載の参考文献
1) Adler Y, et al : 2015 ESC Guidelines for the diagnosis and management of pericardial diseases : The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by : The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 36 : 2921-2964, 2015.
 
2) Imazio M, Gaita F : Diagnosis and treatment of pericarditis. Heart 101 : 1159-1168, 2015.
PubMed
3) Imazio M, et al : Evaluation and Treatment of Pericarditis : A Systematic Review. JAMA 314 : 1498-1506, 2015.
PubMed
4) Brucato A, et al : Recurrent pericarditis : still idiopathic? The pros and cons of a well-honoured term. Intern Emerg Med 13 : 839-844, 2018.
PubMed
5) Schoenwetter AH, Siber EN : Penicillin Hypersensitivity, Acute Pericarditis, and Eosinophilia. JAMA 191 : 672-673, 1965.
PubMed
6) Shabtaie SA, et al : Concurrent Sweet's syndrome and myopericarditis following mesalamine therapy. BMJ Case Rep 2018. pii : bcr-2017-223851, 2018.
 
7) Bernardo S, et al : Mesalamine-induced myopericarditis-A case report. Rev Esp Enferm Dig 108 : 753-756, 2016.
PubMed
8) Loizeau E : [Ulcerative colitis and pericarditis. The role of mesalazine hypersensitivity]. Rev Med Suisse Romande 115 : 935-938, 1995.
PubMed
9) Harbin AD, et al : Simulation of acute myopericarditis by constrictive pericardial disease with endomyocardial fibrosis due to methysergide therapy. J Am Coll Cardiol 4 : 196-199, 1984.
PubMed
10) Holmes DR, et al : Iatrogenic pericardial effusion and tamponade in the percutaneous intracardiac intervention era. JACC Cardiovasc Interv 2 : 705-717, 2009.
PubMed
11) Kodaira M, et al : Pathological Findings of Rivaroxaban-Associated Hemorrhagic Pericarditis. Circ J 82 : 2917-2918, 2018.
PubMed
12) Imazio M, et al : Myopericarditis versus viral or idiopathic acute pericarditis. Heart 94 : 498-501, 2008.
PubMed
13) Imazio M, et al : Indicators of poor prognosis of acute pericarditis. Circulation 115 : 2739-2744, 2007.
PubMed
14) Imazio M, et al : Recurrent pericarditis. Rev Med Interne 38 : 307-311, 2017.
PubMed
15) Imazio M, et al : Prevalence of C-reactive protein elevation and time course of normalization in acute pericarditis : implications for the diagnosis, therapy, and prognosis of pericarditis. Circulation 123 : 1092-1097, 2011.
PubMed
P.551 掲載の参考文献
1) Kataoka H : Pericardial and pleural effusions in decompensated chronic heart failure. Am Heart J 139 : 918-923, 2000.
PubMed
2) Maisch B : Pericardial diseases, with a focus on etiology, pathogenesis, pathophysiology, new diagnostic imaging methods, and treatment. Curr Opin Cardiol 9 : 379-388, 1994.
PubMed
3) Kessler KM, et al : Echocardiographic observations regarding pericardial effusions associated with cardiac disease. Chest 78 : 736-740, 1980.
PubMed
4) Benza RL, et al : Predicting survival in pulmonary arterial hypertension : insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 122 : 164-172, 2010.
PubMed
5) Natanzon A, Kronzon I : Pericardial and pleural effusions in congestive heart failure-anatomical, pathophysiologic, and clinical considerations. Am J Med Sci 338 : 211-216, 2009.
PubMed
6) Frohlich GM, et al : Haemodynamically irrelevant pericardial effusion is associated with increased mortality in patients with chronic heart failure. Eur Heart J 34 : 1414-1423, 2013.
PubMed
7) Yndestad A, et al : Systemic inflammation in heart failure-the whys and wherefores. Heart Fail Rev 11 : 83-92, 2006.
PubMed
8) Dixon DL, et al : Systemic inflammation and cell activation reflects morbidity in chronic heart failure. Cytokine 56 : 593-599, 2011.
PubMed
9) Hedayat M, et al : Proinflammatory cytokines in heart failure : double-edged swords. Heart Fail Rev 15 : 543-562, 2010.
PubMed
10) Imazio M, Adler Y : Management of pericardial effusion. Eur Heart J 34 : 1186-1197, 2013.
PubMed
11) Kearns MJ, Walley KR : Tamponade : Hemodynamic and Echocardiographic Diagnosis. Chest 153 : 1266-1275, 2018.
PubMed
12) Adler Y, et al : 2015 ESC Guidelines for the diagnosis and management of pericardial diseases : The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by : The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 36 : 2921-2964, 2015.
 
13) Kleinbongard P, et al : TNFalpha in atherosclerosis, myocardial ischernia/reperfusion and heart failure. Pharmacol Ther 127 : 295-314, 2010.
 
14) Sagrista-Sauleda J, et al : Long-term follow-up of idiopathic chronic pericardial effusion. N Engl J Med 341 : 2054-2059, 1999.
PubMed
15) Fenstad ER, et al : Pericardial effusions in pulmonary arterial hypertension : characteristics, prognosis, and role of drainage. Chest 144 : 1530-1538, 2013.
PubMed
P.556 掲載の参考文献
1) Oliva PB, Hammill SC : The clinical distinction between regional postinfarction pericarditis and other causes of postinfarction chest pain : ancillary observations regarding the effect of lytic therapy upon the frequency of postinfarction pericarditis, postinfarction angina, and reinfarction. Clin Cardiol 17 : 471-478, 1994.
PubMed
2) Cheitlin MD, et al : ACC/AHA guidelines for the clinical application of echocardiography : executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Clinical Application of Echocardiography). Developed in collaboration with the American Society of Echocardiography. J Am Coll Cardiol 29 : 862-879, 1997.
 
3) Correale E, et al : Comparison of frequency, diagnostic and prognostic significance of pericardial involvement in acute myocardial infarction treated with and without thrombolytics. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI). Am J Cardiol 71 : 1377-1381, 1993.
PubMed
4) Imazio M, et al : Frequency and prognostic significance of pericarditis following acute myocardial infarction treated by primary percutaneous coronary intervention. Am J Cardiol 103 : 1525-1529, 2009.
PubMed
5) Tanaka K, et al : Clinical course, timing of rupture and relationship with coronary recanalization therapy in 77 patients with ventricular free wall rupture following acute myocardial infarction. J Nippon Med Sch 69 : 481-488, 2002.
PubMed
6) 日本循環器学会, ほか : 循環器病の診断と治療に関するガイドライン (2012年度合同研究班報告). ST上昇型急性心筋梗塞の診療に関するガイドライン (2013年改訂版), 2013. [j-circ.or.jp/guideline/pdf/JCS2013_kimura_h.pdf] (2019年6月閲覧)
 
7) Dressler W : The post-myocardial-infarction syndrome : a report on forty-four cases. AMA Arch Intern Med 103 : 28-42, 1959.
PubMed
8) Kleinsorge H, Dornbusch S : [On the presence of a serum factor with auto-antibody features in heart infarct]. Klin Wochenschr 38 : 970-973, 1960.
PubMed
9) Thadani U, et al : Pericarditis after acute myocardial infarction. Br Med J 2 : 135-137, 1971.
PubMed
10) Tabatznik B, Isaacs Jp : Postpericardiotomy syndrome following traumatic hemopericardium. Am J Cardiol 7 : 83-96, 1961.
PubMed
11) Wessman DE, Stafforld CM : The postcardiac injury syndrome : case report and review of the literature. South Med J 99 : 309-314, 2006.
 
12) Khan AH : The postcardiac injury syndromes. Clin Cardiol 15 : 67-72, 1992.
PubMed
13) Northcote RJ, et al : Evidence for the continued existence of the postmyocardial infarction (Dressler's) syndrome. Am J Cardiol 53 : 1201-1202, 1984.
 
14) Shahar A, et al : Disappearance of a syndrome : Dressler's syndrome in the era of thrombolysis. Cardiology 85 : 255-258, 1994.
 
15) Bendjelid K, Pugin J : Is Dressler syndrome dead? Chest 126 : 1680-1682, 2004.
PubMed
P.559 掲載の参考文献
1) 原陽一, ほか : 放射線治療2年後に収縮性心膜炎をきたした1例. 心臓 29 : 909-913, 1997.
Medical*Online
2) Cohn KE. et al : Heart disease following radiation. Medicine (Baltimore) 46 : 281-298, 1967.
PubMed
3) Hikosaka Y, et al : Post-irradiation constrictive pericarditis following thymoma treatlnent : a report of two cases. Gen Thorac Cardiovasc Surg 63 : 413-415, 2015.
PubMed
4) Benoff LJ, et al : Radiation therapy-induced cardiac injury. Am Heart J 129 : 1193-1196, 1995.
PubMed
5) 高崎泉, ほか : 放射線照射17年後に発症した収縮性心膜炎の1例. 日本内科学会雑誌 77 : 54-58, 1988.
 
6) 日本循環器学会, ほか : 循環器病の診断と治療に関するガイドライン (2009年度合同研究班報告). 循環器超音波検査の適応と判読ガイドライン (2010年改訂版), 2010.
 
7) Seifert FC, et al : Surgical treatment of constrictive pericarditis : analysis of outcome and diagnostic error. Circulation 72 (3 Pt 2) : II264-273, 1985.
 
P.564 掲載の参考文献
1) Imazio M, et al : Risk of constrictive pericarditis after acute pericarditis. Circulation 124 : 1270-1275, 2011.
PubMed
2) Bertog SC, et al : Constrictive pericarditis : etiology and cause-specific survival after pericardiectomy. J Am Coll Cardiol 43 : 1445-1452, 2004.
PubMed
3) Szabo G, et al : Constrictive pericarditis : risks, aetiologies and outcomes after total pericardiectomy : 24 years of experience. Eur J Cardiothorac Surg 44 : 1023-1028 ; discussion 1028, 2013.
PubMed
4) 羽田勝征 : 新 心エコーの読み方, 考え方 [改訂4版], p332, 中外医学社, 2018.
 
5) Ha JW, et al : Annulus paradoxus : transmitral flow velocity to mitral annular velocity ratio is inversely proportional to pulmonary capillary wedge pressure in patients with constrictive pericarditis. Circulation 104 : 976-978, 2001.
PubMed
6) Rajagopalan N, et al : Comparison of new Doppler echocardiographic methods to differentiate constrictive pericardial heart disease and restrictive cardiomyopathy. Am J Cardiol 87 : 86-94, 2001.
PubMed
P.567 掲載の参考文献
1) Sagrista-Sauleda J, et al : Effusive-constrictive pericarditis. N Engl J Med 350 : 469-475, 2004.
PubMed
2) Adler Y, et al : 2015 ESC Guidelines for the diagnosis and management of pericardial diseases : The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by : The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 36 : 2921-2964, 2015,
 
3) Tokuda Y, et al : Outcome of pericardiectomy for constrictive pericarditis in Japan : a nationwide outcome study. Ann Thorac Surg 96 : 571-576, 2013.
PubMed
P.569 掲載の参考文献
1) Adler Y, et al : 2015 ESC Guidelines for the diagnosis and management of pericardial diseases : The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by : The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 36 : 2921-2964, 2015.
 
2) Bertog SC, et al : Constrictive pericarditis : etiology and cause-specific survival after pericardiectomy. J Am Coll Cardiol 43 : 1445-1452, 2004.
PubMed
3) Syed FF, et al : Constrictive pericarditis-a curable diastolic heart failure. Nat Rev Cardiol 11 : 530-544, 2014.
PubMed
4) Cimino JJ, Kogan AD : Constrictive pericarditis after cardiac surgery : report of three cases and review of the literature. Am Heart J 118 : 1292-1301, 1989.
PubMed
5) Killian DM, et al : Constrictive pericarditis after cardiac surgery. Am Heart J 118 : 563-568, 1989.
PubMed
6) Dardas P, et al : Constrictive pericarditis after coronary artery bypass surgery as a cause of unexplained dyspnea : a report of five cases. Clin Cardiol 21 : 691-694, 1998.
PubMed
7) Gaudino M, et al : Constrictive pericarditis after cardiac surgery. Ann Thorac Surg 95 : 731-736, 2013.
PubMed
8) Matsuyama K, et al : Clinical characteristics of patients with constrictive pericarditis after coronary bypass surgery. Jpn Circ J 65 : 480-482, 2001.
PubMed
9) Im E, et al : The incidence and clinical outcome of constrictive physiology after coronary artery bypass graft surgery. J Am Coll Cardiol 61 : 2110-2112, 2013.
PubMed
10) Talreja DR, et al : Constrictive pericarditis in 26 patients with histologically normal pericardial thickness. Circulation 108 : 1852-1857, 2003.
PubMed
11) Miranda WR, Oh JK : Constrictive Pericarditis : A Practical Clinical Approach. Prog Cardiovasc Dis 59 : 369-379, 2017.
PubMed
12) Nishimura S, et al : Long-Term Clinical Outcomes and Prognostic Factors After Pericardiectomy for Constrictive Pericarditis in a Japanese Population. Circ J 81 : 206-212, 2017.
 
13) Szabo G, et al : Constrictive pericarditis : risks, aetiologies and outcomes after total pericardiectomy : 24 years of experience. Eur J Cardiothorac Surg 44 : 1023-1028 ; discussion 1028, 2013.
PubMed
P.572 掲載の参考文献
1) Imazio M : The post-pericardiotomy syndrome. Curr Opin Pulm Med 18 : 366-374, 2012.
PubMed
2) Lehto J, et al : Incidence and risk factors of postpericardiotomy syndrome requiring medical attention : The Finland postpericardiotomy syndrome study. J Thorac Cardiovasc Surg 149 : 1324-1329, 2015.
PubMed
3) Imazio M, et al : Contemporary features, risk factors, and prognosis of the post-pericardiotomy syndrome. Am J Cardiol 108 : 1183-1187, 2011.
PubMed
4) Tamarappoo BK, et al : Post-pericardiotomy Syndrome. Curr Cardiol Rep 18 : 116, 2016.
PubMed
5) van Osch D, et al : Determinants of the postpericardiotomy syndrome : a systematic review. Eur J Clin Invest 47 : 456-467, 2017.
PubMed
6) Miller RH, et al : The epidemiology of the postpericardiotomy syndrome : a common complication of cardiac surgery. Am Heart J 116 (5 Pt 1) : 1323-1329, 1988.
 
7) Jaworska-Wilczyhska M, et al : Low interleukin-8 level predicts the occurrence of the postpericardiotomy syndrome. PLoS ONE 9 : e108822, 2014.
 
8) Lehto J, et al : Occurrence of Postpericardiotomy Syndrome : Association With Operation Type and Postoperative Mortality After Open-Heart Operations. J Am Heart Assoc 7 : e010269, 2018.
PubMed
9) Adler Y, et al : 2015 ESC Guidelines for the diagnosis and management of pericardial diseases : The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by : The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 36 : 2921-2964, 2015.
 
10) Imazio M, et al : COlchicine for the Prevention of the Post-pericardiotomy Syndrome (COPPS) : a multicentre, randomized, double-blind, placebo-controlled trial. Eur Heart J 31 : 2749-2754, 2010.
 
11) Imazio M, et al : Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation : the COPPS-2 randomized clinical trial. JAMA 312 : 1016-1023, 2014.
PubMed
12) Mott AR, et al : The effect of short-term prophylactic methylprednisolone on the incidence and severity of postpericardiotomy syndrome in children undergoing cardiac surgery with cardiopulmonary bypass. J Am Coll Cardiol 37 : 1700-1706, 2001.
PubMed
13) Bunge JJ, et al : Dexamethasone for the prevention of postpericardiotomy syndrome : A DExamethasone for Cardiac Surgery substudy. Am Heart J 168 : 126-131. e1, 2014.
 
14) Gill PJ, et al : The effect of short-term prophylactic acetylsalicylic acid on the incidence of postpericardiotomy syndrome after surgical closure of atrial septal defects. Pediatr Cardiol 30 : 1061-1067, 2009.
PubMed
15) van Osch D, et al : Risk factors and prognosis of postpericardiotomy syndrome in patients undergoing valve surgery. J Thorac Cardiovasc Surg 153 : 878-885. e1, 2017.
 
P.577 掲載の参考文献
1) Permanyer-Miralda G : Acute pericardial disease : approach to the aetiologic diagnosis. Heart 90 : 252-254, 2004.
 
2) Gilon D, et al : Characteristics and in-hospital outcomes of patients with cardiac tamponade complicating type A acute aortic dissection. Am J Cardiol 103 : 1029-1031, 2009.
PubMed
3) Hamaya R, et al : Management of cardiac tamponade in catheter ablation of atrial fibrillation : single-centre 15 year experience on 5222 procedures. Europace 20 : 1776-1782, 2018.
PubMed
4) Ristic AD, et al : Triage strategy for urgent management of cardiac tamponade : a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 35 : 2279-2284, 2014.
 
5) 日本循環器学会, ほか : 循環器病の診断と治療に関するガイドライン (2007-2008年度合同研究班報告). 循環器医のための心肺蘇生・心血管救急に関するガイドライン, 2009. [http://www.j-circ.or.jp/guideline/pdf/JCS2010kasanuki_h.pdf] (2019年6月閲覧)
 
6) Hamzaoui O, et al : Pulsus paradoxus. Eur Respir J 42 : 1696-1705, 2013.
PubMed
7) Sharp JT, et al : Hemodynamics during induced cardiac tamponade in man. Am J Med 29 : 640-646, 1960.
 
8) Spodick DH : Acute cardiac tamponade. N Engl J Med 349 : 684-690, 2003.
PubMed
9) Gillam LD, et al : Hydrodynamic compression of the right atrium : a new echocardiographic sign of cardiac tamponade. Circulation 68 : 294-301, 1983.
PubMed
10) Schiller NB, Botvinick EH : Right ventricular compression as a sign of cardiac tamponade : an analysis of echocardiographic ventricular dimensions and their clinical implications. Circulation 56 : 774-779, 1977.
PubMed
11) Klein AL, et al : American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease : endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr 26 : 965-1012. e15, 2013.
 
12) Tsang TS, et al : Consecutive 1127 therapeutic echocardiographically guided pericardiocenteses : clinical profile, practice patterns, and outcomes spanning 21 years. Mayo Clin Proc 77 : 429-436, 2002.
PubMed
13) Isselbacher EM, et al : Cardiac tamponade complicating proximal aortic dissection. Is pericardiocentesis harmful? Circulation 90 : 2375-2378, 1994.
PubMed
P.582 掲載の参考文献
1) Dib C, et al : Chylopericardium in adults : a literature review over the past decade (1996-2006). J Thorac Cardiovasc Surg 136 : 650-656, 2008.
PubMed
2) Kan CD, et al : Isolated chylopericardium after intrapericardial procedures : possible role of inadvertent right efferent lymphatic trunk injury. Tex Heart Inst J 34 : 82-87, 2007.
PubMed
3) Hattori H, et al : Primary chylopericardium treated by surgery : Report of two cases. J Cardiol Cases 3 : e106-e110, 2011.
 
4) Jensen GL, et al : Dietary modification of chyle composition in chylothorax. Gastroenterology 97 : 761-765, 1989.
PubMed
5) Nguyen DM, et al : The management of chylothorax/chylopericardium following pediatric cardiac surgery : a 10-year experience. J Card Surg 10 : 302-308, 1995.
PubMed
6) Szabados E, et al : Use of octreotide in the treatment of chylopericardium. Heart Lung 40 : 574-575, 2011.
PubMed
7) Akamatsu H, et al : Primary chylopericardium. Ann Thorac Surg 58 : 262-266, 1994.
PubMed
8) Furrer M, et al : Isolated primary chylopericardium : treatment by thoracoscopic thoracic duct ligation and pericardial fenestration. J Thorac Cardiovasc Surg 112 : 1120-1121, 1996.
PubMed
9) Wurnig PN, et al : Thoracoscopic direct clipping of the thoracic duct for chylopericardium and chylothorax. Ann Thorac Surg 70 : 1662-1665, 2000.
PubMed
10) Uchikawa T, et al : Constrictive Pericarditis and Worsening Mitral Annular Disjunction After Long-Term Chylopericardium. Circ Heart Fail 11 : e004698, 2018.
PubMed
11) Alexander JS : A Pericardial Effusion of "Gold-Paint" Appearance Due to the Presence of Cholesterin. Br Med J 2 : 463, 1919.
 
12) Brawley RK, et al : Cholesterol pericarditis. Considerations of its pathogenesis and treatment. Am J Med 41 : 235-248, 1966.
PubMed
13) Doherty JE, Jenkins BJ : Radiocarbon cholesterol turnover in cholesterol pericarditis. Am J Med 41 : 322-330, 1966.
PubMed
14) Roberts WC : Pericardial heart disease : its morphologic features and its causes. Proc (Bayl Univ Med Cent) 18 : 38-55, 2005. '
PubMed
15) Noiri E, Itoh T : Disorder of pericardial fluid cholesterol metabolism in cholesterol pericarditis. Jpn J Med 30 : 393, 1991.
PubMed
16) Fernandes F, et al : Cholesterol pericarditis. A specific but rare cause of pericardial disease. Arq Bras Cardiol 76 : 391-394, 2001.
PubMed
17) Setty NS, et al : Massive pericardial effusion and cardiac tamponade due to cholesterol pericarditis in a case of subclinical hypothyroidism : a rare event. J Am Coll Cardiol 63 : 1451, 2014.
 
18) Stanley RJ, et al : Cholesterol pericarditis terminating as constrictive calcific pericarditis. Follow-up study of patient with 40 year history of disease. Am J Cardiol 46 : 511-514, 1980.
PubMed
P.586 掲載の参考文献
1) Shimabukuro M : Cardiac adiposity and global cardiometabolic risk : new concept and clinical implication. Circ J 73 : 27-34, 2009.
PubMed
2) Packer M : Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium. J Am Coll Cardiol 71 : 2360-2372, 2018.
PubMed
3) Potz BA, et al : Novel molecular targets for coronary angiogenesis and ischemic heart disease. Coron Artery Dis 28 : 605-613, 2017.
PubMed
4) Nerlekar N, et al : Association of Epicardial Adipose Tissue and High-Risk Plaque Characteristics : ASystematic Review and Meta-Analysis. J Am Heart Assoc 6. pii : e006379, 2017.
 
5) Neeland IJ, et al : Cardiovascular and Metabolic Heterogeneity of Obesity : Clinical Challenges and Implications for Management. Circulation 137 : 1391-1406, 2018.
PubMed
6) Hirata Y, et al : Clinical Utility of Measuring Epicardial Adipose Tissue Thickness with Echocardiography Using a High-Frequency Linear Probe in Patients with Coronary Artery Disease. J Am Soc Echocardiogr 28 : 1240-1246. e1, 2015.
 
7) Maimaituxun G, et al : Local Thickness of Epicardial Adipose Tissue Surrounding the Left Anterior Descending Artery Is a Simple Predictor of Coronary Artery Disease-New Prediction Model in Combination With Framingham Risk Score. Circ J 82 : 1369-1378, 2018.
PubMed
8) Gaborit B, et al : Effects of bariatric surgery on cardiac ectopic fat : lesser decrease in epicardial fat compared to visceral fat loss and no change in myocardial triglyceride content. J Am Coll Cardiol 60 : 1381-1389, 2012.
 
9) Abdesselam I, et al : Time Course of Change in Ectopic Fat Stores After Bariatric Surgery. J Am Coll Cardiol 67 : 117-119, 2016.
PubMed
10) Rabkin SW, Campbell H : Comparison of reducing epicardial fat by exercise, diet or bariatric surgery weight loss strategies : a systematic review and meta-analysis. Obes Rev 16 : 406-415, 2015.
PubMed
11) Bouchi R, et al : Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes : a pilot study. Cardiovasc Diabetol 16 : 32, 2017.
PubMed
12) Fukuda T, et al : Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity : A Pilot Study. Diabetes Ther 8 : 851-861, 2017.
PubMed
13) Yagi S, et al : Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus. Diabetol Metab Syndr 9 : 78, 2017.
PubMed
P.590 掲載の参考文献
1) Adler Y, et al : 2015 ESC Guidelines for the diagnosis and management of pericardial diseases : The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by : The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 36 : 2921-2964, 2015.
 
2) Imazio M, et al : Controversial issues in the management of pericardial diseases. Circulation 121 : 916-928, 2010.
PubMed
3) Maisch B, et al : Guidelines on the diagnosis and management of pericardial diseases executive summary ; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. Eur Heart J 25 : 587-610, 2004.
 
4) 小村悟, ほか : 房室ブロックと治療抵抗性の感染症を契機に診断された心膜膿瘍の1症例. The Circulation Frontier 9 : 62-65, 2005.
 
5) Rubin RH, Moellering RC Jr : Clinical, microbiologic and therapeutic aspects of purulent pericarditis. Am J Med 59 : 68-78, 1975.
PubMed
6) Mitsuma W, et al : Pericardial abscess detected by Gallium-67 scintigraphy 40 years after cardiac surgery. Int Heart J 46 : 1119-1122, 2005.
PubMed
7) Brook I, Frazier EH : Microbiology of acute purulent pericarditis. A 12-year experience in a military hospital. Arch Intern Med 156 : 1857-1860, 1996.
 
8) Klacsmann PG, et al : The changed spectrum of purulent pericarditis : an 86 year autopsy experience in 200 patients. Am J Med 63 : 666-673, 1977.
PubMed
9) Goodman LJ : Purulent Pericarditis. Curr Treat Options Cardiovasc Med 2 : 343-350, 2000.
PubMed
10) Takashima A, et al : Purulent Pericarditis Accompanying Pericardial Abscess Induced by Nocardia in an Immunocompromised Patient. Circ J 80 : 2409-2411, 2016.
 
11) Gould K, et al : Purulent pericarditis in the antibiotic era. Arch Intern Med 134 : 923-927, 1974.
PubMed
12) Imazio M, et al : Medical therapy of pericardial diseases : part I : idiopathic and infectious pericarditis. J Cardiovasc Med (Hagerstown) 11 : 712-722, 2010.
PubMed
13) Sagrista-Sauleda J, et al : Purulent pericarditis : review of a 20-year experience in a general hospital. J Am Coll Cardiol 22 : 1661-1665, 1993.
 
14) Augustin P, et al : Clinical review : intrapericardial fibrinolysis in management of purulent pericarditis. Crit Care 15 : 220, 2011.
PubMed
P.594 掲載の参考文献
1) Jeung MY, et al : Imaging of cystic masses of the mediastinum. Radiographics 22 : S79-93, 2002.
PubMed
2) Kar SK, et al : Pericardial Cyst : A Review of Historical Perspective and Current Concept of Diagnosis and Management. Interventional Cardiology Journal 1 : 1-8, 2015.
 
3) De Roover P, et al : Congenital pleuropericardial cysts. Thorax 18 : 146-150, 1963.
PubMed
4) Alkharabsheh S, et al : Clinical Features, Natural History, and Management of Pericardial Cysts. Am J Cardiol 123 : 159-163, 2019.
PubMed
5) Nitu M, et al : Left Pleuropericardial Cyst. Curr Health Sci J 43 : 83-86, 2017.
PubMed
6) Lewis KM, et al : Mid-trimester prenatal sonographic diagnosis of a pericardial cyst. Prenat Diagn 16 : 549-553, 1996.
PubMed
7) Wang ZJ, et al : CT and MR imaging of. pericardial disease. Radiographics 23 : S167-180, 2003.
 
8) Tanoue Y, et al : Acute cardiac tamponade due to a bleeding pericardial cyst in a 3-year-old child. Ann Thorac Surg 84 : 282-284, 2007.
 
9) Butz T, et al : Images in cardiovascular medicine. Echocardiography-guided percutaneous aspiration of a Large Pericardial cyst. Circulation 116 : e505-507, 2017.
 
10) Kinoshita Y, et al : Ethanol sclerosis can be a safe and useful treatment for pericardial cyst. Clin Cardiol 19 : 833-835, 1996.
 
11) Sharma R, et al : Percutaneous aspiration of a pericardial cyst : an acceptable treatment for a rare disorder. Heart 93 : 22, 2007.
PubMed
P.598 掲載の参考文献
1) Atar S, et al : Bloody pericardial effusion in patients with cardiac tamponade : is the cause cancerous, tuberculous, or iatrogenic in the 1990s? Chest 116 : 1564-1569, 1999.
PubMed
2) Pawlak Cieslik A, et al : Diagnosis of malignant pericarditis : a single centre experience. Kardiol Pol 70 : 1147-1153, 2012.
PubMed
3) Imazio M, et al : Relation of acute pericardial disease to malignancy. Am J Cardiol 95 : 1393-1394, 2005.
PubMed
4) Vaitkus PT, et al : Treatment of malignant pericardial effusion. JAMA 272 : 59-64, 1994.
PubMed
5) Millaire A, et al : Malignant pericardial effusions : usefulness of pericardioscopy. Am Heart J 124 : 1030-1034, 1992.
PubMed
6) Mayosi BM, et al : Tuberculous pericarditis. Circulation 112 : 3608-3616, 2005.
PubMed
7) Reuter H, et al : Epidemiology of pericardial effusions at a large academic hospital in South Africa. Epidemiol Infect 133 : 393-399, 2005.
 
8) Adler Y, et al : 2015 ESC Guidelines for the diagnosis and management of pericardial diseases : The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by : The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 36 : 2921-2964, 2015.
 
9) Alpert MA, Ravenscraft MD : Pericardial involvement in end-stage renal disease. Am J Med Sci 325 : 228-236, 2003.
PubMed
10) 池内雅樹, ほか : 成因不明の心膜血腫を伴った滲出性収縮性心膜炎類縁の1症例. 心臓 50 : 1296-1300, 2018.
Medical*Online
11) Ohri SK, et al : Angiosarcoma of the heart causing cardiac rupture : a rare cause of hemopericardium. Ann Thorac Surg 55 : 525-528, 1993.
PubMed
12) Chou WH, et al : Metastatic breast cancer with right ventricular erosion. Eur J Cardiothorac Surg 49 : 1006-1007, 2016.
PubMed
13) Kimura S, et al : Cardiac tamponade due to spontaneous rupture of large coronary artery aneurysm. Asian Cardiovasc Thorac Ann 14 : 422-424, 2006.
PubMed
14) Bricheteau M : Ovservation d'hydro-pneumopericarde, accompagne d'un bruit de fluctuation perceptible a l'oreille. Arch Gen Med 4 : 334-339, 1844.
 
15) Cummings RG, et al : Pneumopericardium resulting in cardiac tamponade. Ann Thorac Surg 37 : 511-518, 1984.
PubMed

書評

最近チェックした商品履歴

Loading...